












Clostridia in medical, veterinary and food 
microbiology 













C. Duchesnes, P.E. Granum, M.G. Menozzi, M. Peck,  









Directorate-General for Research 
2006 Key Action 2 – Control of infectious diseases EUR 21463 EN 
Concerted Action QLK2-CT2001-01267 
 
This book was produced as part of an EU Concerted Action project: « Pathology and Ecology of the Genus 
Clostridium in Humans, Animals and Foodstuffs: Identification, Epidemiology and Prophylaxis (Genus 
Clostridium)”. This project is funded under the EU Quality of Life programme. 
 
Proceedings and scientific booklets have been published after each of the following meetings: 
1. Classification, molecular genetics and pathology of clostridia. 
2. Protein toxins of the genus Clostridium and vaccination. 
3. Diagnosis, epidemiology and antibiotic resistance of the genus Clostridium 
4. Food microbiology and sporulation of the genus Clostridium 
 












Europe Direct is a service to help you find answers  
to your questions about the European Union 
 
Freephone number: 




Neither the European Commission nor any person acting on behalf of the Commission is responsible for the 
use which might be made of the following information. 
The views expressed in this publication are the sole responsibility of the author and do not necessarily reflect 
the views of the European Commission. 
 
No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter 
of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions 
or ideas contained in the materials herein. 
 
Mention of any brand or firm names does not constitute an endorsement over others of a similar nature not 
mentioned 
 
A great deal of additional information on the European Union is available on the Internet. 
It can be accessed through the Europa server (http://europa.eu.int). 
 
Cataloguing data can be found at the end of this publication. 
 
Luxembourg: Office for Official Publications of the European Communities, 2006 
 
ISBN. 92-79-00422.EPS 
© European Communities, 2006 
Reproduction is authorised provided the source is acknowledged. 
 
Printed in Luxembourg 
 
PRINTED ON WHITE CHLORINE-FREE PAPER 
 3 




National Veterinary Institute – Bacteriology department – 751 89 Uppsala – Sweden 
Viveca.baverud@sva.se; Phone : +46-18-67-40-00 ; Fax : +46-18-67-40-93 
 
Eleftheria BOURTZI-HATZOPOULOU 
Aristotle University of Thessaloniki – Faculty of Veterinary Medicine – 
Microbiology and infectious diseases – University Campus – 54006 Thessaloniki – 
Greece 
bourtzi@vet.auth.gr; Phone: +30-2310-99-99-15 ; Fax: +30-2310-99-99-61 
 
Jean-Philippe CARLIER 
Institut Pasteur Paris - Centre National de Référence des Anaérobies - Toxines et 
Pathogénie Bactérienne - Rue du Dr Roux, 28 - 75724 Paris cedex 15 - France 
jcarlier@pasteur.fr; Phone : +33-1-45-68-83-10 ; Fax : +33-1-40-61-31-23 
 
Michel DELMEE 
Université catholique de Louvain – Microbiology Unit – Avenue Hippocrate 54.90 – 
1200 Bruxelles – Belgium 
Delmee@mblg.ucl.ac.be; Phone: +32-2-764-94-41; Fax: +32-2-764-94-40 
 
Piet DEPREZ 
University of Ghent – Faculty of Veterinary Medicine – Internal Medicine Large 
Animals – Salisburylaan, 133 – 9820 Merelbeke – Belgium 
Piet.deprez@ugent.ac.be; Phone: +32-9-264-75-80; Fax: +32-9-264-77-96 
 
Christiane DUCHESNES 
Université de Liège - Faculté de Médecine Vétérinaire - Bactériologie - Bât B43a - 
Sart Tilman - 4000 Liège - Belgium 
cduchesnes@ulg.ac.be; Phone: +32-4-366-40-52 ; Fax : +32-4-366-42-61 
 
Björn ENGSTROM 
National Veterinary Institute – Poultry department – 751 89 Uppsala – Sweden 
Bjorn.engstrom@sva.se; Phone : +46-18-67-40-00 ; Fax : +46-18-67-40-94 
 
Per Einar GRANUM 
The Norwegian Reference Laboratory - The Norwegian School of Veterinary 
Science - Food Hygiene - PO Box 8146 Dep - Ullevalsveien, 72 - 0033 Oslo - 
Norway 




National Veterinary Institute – Pathology department - PO Box 8156 Dep – 
Ullevalsveien, 68 - 0033 Oslo - Norway 
per.e.granum@veths.no; Phone: +47-23-21-64-38; Fax: +47-23-21-63-03 
 
Jacques MAINIL 
Université de Liège - Faculté de Médecine Vétérinaire - Bactériologie - Bât B43a - 
Sart Tilman - 4000 Liège - Belgium 
jg.mainil@ulg.ac.be; Phone: +32-4-366-40-50 ; Fax : +32-4-366-42-61 
 
Didier MARLIER 
Université de Liège – Faculté de Médecine Vétérinaire – Pathologie aviaire – Bât 
B42 – Sart Tilman – 4000 Liège – Belgium 
dmarlier@ulg.ac.be; Phone: +32-4-366-40-11 ; Fax : +32-4-366-40-12 
 
Maria Grazia MENOZZI 
University of Parma - Microbiology - Pathology and Laboratory Medicine – Via 
Gramsci, 14 – 43100 Parma - Italy 
mariagrazia.menozzi@unipr.it; Phone: +39-0521-98-88-85; Fax: +39-0521-99-36-20 
 
Anastasios MINAS 
Technological institute of Larisa – Microbiology – 51 223 – Greece 
mhnas@ram.gr; Phone: +30-2410-611-069 ; Fax: +30-2410-611-070 
 
Michael PECK 
Institute of Food Research - Food Safety Science Division - Norwich Research Park - 
Colney -  NR4 7UA Norwich - England - United Kingdom 
mike.peck@bbsrc.ac.uk; Phone: +44-1603-25-52-51; Fax: +44-1603-50-77-23 
 
Karl PEDERSEN 
Danish Institute for Food and Veterinary Research – Department of Poultry, Fish and 
Fur Animals – Hangovej, 2 – 8200 Aarhus – Denmark 
kpe@dfvf.dk; Phone: +45-72-34-68-93; Fax: +45-72-34-69-01 
  
Sinikka PELKONEN 
National Veterinary and Food Research Institute - Kuopio Regional Laboratory – PO 
Box 92 Neulaniementie, 4 - 70701 Kuopio - Finland 
sinikka.pelkonen@eela.fi; Phone: +358-17-20-14-50; Fax: +358-17-20-14-58 
 
Evanthia PETRIDOU 
Aristotle University of Thessaloniki – Faculty of Veterinary Medicine – 
Microbiology and infectious diseases – University Campus – 54006 Thessaloniki – 
Greece 




Institut Pasteur Paris - Centre National de Référence des Anaérobies - Toxines et 
Pathogénie Bactérienne - Rue du Dr Roux, 28 - 75724 Paris cedex 15 - France 
mpopoff@pasteur.fr; Phone : +33-1-45-68-83-10 ; Fax : +33-1-40-61-31-23 
 
Christine RHODE 
DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH - 
Molecular Systematics and Ecology - Mascheroder Weg, 1b - 38124 Braunschweig - 
Germany 
chr@dsmz.de; Phone: +49-531-261-62-20; Fax: +49-531-261-64-18 
 
Glenn SONGER  
University of Arizona – Veterinary Science and Microbiology – 1117 east Lowell 
Street – 85721 Tucson – Arizona – USA 
gsonger@u.arizona.edu; Phone: +1-520-621-2962; Fax: +1-520-621-6366 
 
Erko STACKEBRANDT 
DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH - 
Molecular Systematics and Ecology - Mascheroder Weg, 1b - 38124 Braunschweig - 
Germany 
erko@dsmz.de; Phone: +49-531-261-63-52; Fax: +49-531-261-64-18 
 
David TAYLOR 
University of Glasgow – Veterinary School – Bearsden Road – Bearsden G61 1QH – 
Glasgow – United Kingdom 
d.taylor@vet.gla.ac.uk; Phone: +44-141-330-5396; Fax: +44-141-330-5602 
 
Richard TITBALL 
Defence Science and Technology Laboratory - CBD Porton Down – Porton Down - 
Salisbury - Wiltshire - SP4 0JQ - England - United Kingdom 






The purpose of the Concerted Action of the 5th Framework programme 
QLK2-CT2001-01267 ‘Pathology and Ecology of the Genus Clostridium in Humans, 
Animals, and Foodstuffs. Identification, Epidemiology and Prophylaxis’ was to 
exchange across Europe scientific knowledge and technical know-how about the 
genus Clostridium. This Concerted Action brought together leading laboratories in 
the field with collaboration between human, veterinary and food microbiology 
laboratories. 
Four workshops were initially planned with different themes. The first, 
entitled “Molecular genetics, classification, pathology and ecology of the genus 
Clostridium” was organised in Liège (Belgium) in January 2002; the second, entitled 
“Protein toxins of the genus Clostridium and vaccination”, in Salisbury (England, 
UK) in November 2002; the third, entitled “Diagnosis, epidemiology and antibiotic 
resistance of the genus Clostridium” in Parma (Italy) in October 2003 and the fourth 
and final workshop, entitled “Food microbiology and sporulation of the genus 
Clostridium” in Oslo (Norway) in June 2004. In addition to the proceedings, a 
scientific booklet relating to the general theme of the workshop was edited after each 
meeting. These booklets are available in hard copy and on the website of the 
Concerted Action : http://www.genusclostridium.net. 
These workshops, proceedings and scientific booklets have assisted and 
continue to assist in the exchange of scientific knowledge regarding clostridia, not 
only across Europe but also, it is hoped, on a worldwide scale. 
Exchange of technical know-how will be achieved through the publication 
of this book ‘Clostridia in Medical, Veterinary and Food Microbiology : Diagnosis 
and Typing’. The purpose of the book is to propose as much an overview as a 
summary of technical approaches in the following : clinical and necropsy diagnosis 
of clostridial diseases, collection of appropriate specimens for routine diagnostic 
laboratories, classical and molecular identification and toxintyping of clostridia, 
confirmation of problems of food spoilage by different clostridial species and 
specific food poisonings caused by C. botulinum and C. perfringens in humans. This 
book should be of considerable relevance to technical, medical and scientific staff 
members of laboratories working in the fields of clostridial diseases of animals and 
humans and of clostridial food microbiology. 
 
Dr Isabel Mínguez Tudela 
Directorate-General for Research 
Biotechnology, Agriculture and Food Research 




Molecular tools have induced new insight into the classification of the 
bacteria and their complexity is well exemplified by the taxonomy of the genus 
Clostridium. Since the description of Clostridium butyricum, the type species, in 
1880 by Prazmowski1, many bacterial species have been included in the genus 
Clostridium, while others have been reclassified in other genera. The genus 
Clostridium comprises nowadays up to 200 species of Gram-Positive spore-forming 
anaerobic rods, which are distributed worldwide. Fortunately most of the species are 
harmless non-pathogenic bacteria living in the environment, on plants, on the skin 
and on the mucosa of animals and humans (especially in the intestinal tract). Some of 
these species contaminate and grow on foods of vegetable and animal origins, 
causing food spoilage. 
For several reasons, including their specific growth requirements, the 
diagnosis of infections and food contamination caused by clostridia still presents 
much difficulty at the clinical, bacteriological and molecular levels. Between 40 and 
50 species are associated with clinical conditions in domestic animals and in humans. 
About 30 of them are considered to be minor pathogens. Fifteen species are major 
pathogens. Two of the major pathogens are also responsible for specific food 
poisoning in humans. The major pathogenic species produce several toxins that are 
responsible for the development of lesions and clinical signs. Those toxins are 
amongst the most potent in the microbial world and are still a basis for identification 
of several major pathogenic species.  
The main purpose of this book is to present an overview of the parameters 
of the diagnosis of Clostridium in animals, humans and foodstuffs. In each chapter, 
an extended bibliography is given, to allow the reader to find additional and more 
detailed information on specific items. 
Part I summarises necessary data for the clinical and necropsy diagnosis of 
the infections caused by clostridia. 
Part II focuses on the growth conditions of the clostridial major pathogenic 
species, on their morphological and genetic identification and on the identification by 
various means of their virulence factors (toxintyping). 
Part III presents information, scientific and legal, dealing with the specific 
problems of food microbiology: sampling, growth conditions, identification and 
typing procedures. 




                                                 
1
 Prazmowski A. (1880) Untersuchung uber die Entwickelungsgeschichte und 
Fermentwirking einiger Bacterien-Arten. Inaug. Hugo Voigt, Leipzig. 
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1. Tetanus and botulism in humans 
 
M.W. Peck and C. Duchesnes 
 
1.1. Introduction 
Tetanus and botulism are two severe neurological diseases. Tetanus is 
characterised by a spastic paralysis, while botulism causes a flaccid paralysis. Both 
diseases are due to neurotoxins produced by clostridia. In tetanus, Clostridium tetani 
is responsible for formation of the toxin. Seven different types of botulinum toxins 
(A through to G) are produced by six different clostridia (C. botulinum Group I, C. 




1.2.1. Aetiology and epidemiology 
Spores of C. tetani are found worldwide in the uppermost layers of the soil 
and in the digestive system of humans and of various animals. They are more 
frequently found in highly manipulated soils and are therefore more widespread in 
densely populated cities and in cultivated regions. The bacterium grows best at 37°C 
and is therefore rarely found in polar regions or at altitude. The spore is very resistant 
to antiseptics and heating. Killing of spores requires boiling for at least 4 hours or 
autoclaving for 12 minutes at 121°C (Bartlett, 2000b).  
Tetanus in humans is divided into localised, generalised and neonatal forms. 
It is realistic to estimate that about 106 cases of tetanus occur per year worldwide, 
although most are not officially reported (Bleck, 2000a). Tetanus is of a great 
concern for to the WHO, and the WHO is developing a programme of vaccination, 
targeting the regions of Africa and Asia where neonatal tetanus is still common. The 
WHO states that the number of cases of neonatal tetanus was 500,000 in 2002 
(http://www.who.int/vaccines-surveillance/ and http://www.who.int/vaccines/). 
Tetanus occurs mainly in the developing countries because of poor sanitary 
conditions at birth, and a lack of maternal immunisation  (Vandelaer et al., 2003).  
 
In developed countries, the number of tetanus cases is significantly lower 
because of widespread vaccine protection. The most susceptible persons are the 
elderly (Hyslop and Leach, 1998; Bleck, 2000a), as a result of a decrease in 
immunity with age. Injection intravenous drug users have recently become an 
important risk group because of a lack of asepsis and contamination of the drugs. 
 
1.2.2. Pathogenesis 
C. tetani is a non-invasive bacterium. Therefore, spores or bacteria must 
penetrate into the human (or other animal) through a disruption of the body’s natural 
barrier. Besides obvious wounds, cases have been reported after puncture, laceration, 
 20
surgery, burn, medial otitis, dental infections, pregnancy and abortion. It should be 
noted that 20% of the cases occur without any recognised portal of entry. Neonatal 
tetanus is mostly due to poor sanitary conditions at birth and to the traditional septic 
practice of umbilical stump sealing with earth, principally in Africa. 
In the tissues, spores germinate in tissues and, in anaerobic conditions, the 
bacterium will produce the neurotoxin (TeNT). Anaerobic conditions develop in deep 
wounds, in tissue necrosis and following simultaneous infection with other bacteria. 
The toxin binds to specific receptors of the motorneuron at the 
neuromuscular junction. Tetanus toxin reaches the central nervous system after 
retrograde transport through the local peripheral motor nerve ends. 
Because the amount of toxin produced is low (and the toxin is very highly 
potent), tetanus does not induce immunisation and, therefore, vaccination is required 
even after the disease (Bleck, 2000a). 
  
1.2.3. Clinical signs 
1.2.3.1. Generalised form 
The incubation time between wound and the appearance of symptoms is 
highly variable (2 to 56 days), but is commonly reported to be less less than 14 days. 
A shorter incubation time corresponds to a more severe disease (Bleck, 2000a). 
The first symptoms are restlessness, irritability, muscular pain, excessive 
sweating, dysphagia with hydrophobia and drooling and difficulty in opening the 
mouth.  The first clinical signs are the spasms of the jaw muscle, leading to the well-
known sign of lockjaw (trismus) and giving the typical aspect of the face (risus 
sardonicus). This is reported in 50 to 75% of  cases (Bartlett, 2000b). Harmful 
spasms will progress to the muscles of the neck, back and abdomen before reaching 
the extremities. Opisthotonos results from spasms of the spinal muscles. Flexion and 
adduction of the arms with clenched fists and extension of the legs with plantar 
flexion of the toes is a typical attitude. These spastic waves are so powerful that bone 
fractures have been reported. 
The autonomic nervous system is usually involved with an excessive 
adrenergic activity leading to tachyarrhythmia, fluctuating arterial blood pressure, 
laryngeal spasm, profound sweating and urinary retention (Hyslop and Leach, 1998). 
Consciousness, awareness and perception are not affected, but pain is very severe. 
Complications are due to the direct effect of the toxin: hypoxia, atelectasia, 
pneumonia due to spasms of the respiratory muscles, laryngeal spasm and fractures 
due to simultaneous spasms of agonists and antagonists. Secondary lesions, such as  
bedsores, thrombophlebitis and pulmonary embolism are due to the effects of 
prolonged confinement to bed, and also stress ulcers due to the intensity of the pain. 
 
1.2.3.2. Localised and cephalic forms 
This form is usually observed in partially immunised patients (Hyslop and 
Leach, 1998). Various levels of severity are recorded. Cephalic wound or medial 
otitis are the main  portals of entry. In these particular cases, because the local 
concentration of toxin is high, a significant amount of it remains bound to the nerve 
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terminals at the neuromuscular junction in the infected site. This interferes with 
acetylcholine release by means indistinguishable from botulinal toxins, and first leads 
to paralysis of the muscles closest to the site, before spasticity occurs (Hyslop and 
Leach, 1998). A wound at a limb will usually first induce weakness, followed by 
localised spasms. There is considerable variation in severity in these localised forms 
but usually the prognosis for survival is excellent (Bartlett, 2000b). 
 
1.2.3.3. Neonatal tetanus 
This form is separated from the others mainly for epidemiological purposes, 
although the symptoms are the same as those of the generalised form. However, it 
affects newborns (in Africa) within the first ten days of life and is due to the 
contamination of the umbilical stump. It is fatal in more than 90% of the cases 
because of a lack of intensive care facilities. Neonatal tetanus is the most common 
form of tetanus across the globe. 
 
1.2.4. Diagnosis 
Diagnosis is usually made based on clinical observations. Organisms are 
rarely recovered from material removed from wounds (Bartlett, 2000b). According to 
Bleck (2000a), attempts to culture C. tetani from wounds are not useful in diagnosis 
since a)- cultures are frequently negative; b-) the organism might not contain the 
toxin-producing plasmid; c)- a positive culture may be present without disease in 
immunised patients. 
In many countries, a single national laboratory is responsible for 
investigating cases of tetanus and for isolating and characterising implicated 
clostridia. Toxin detection, isolation and identification of the organisms require 
specialised techniques. Detection of the tetanus neurotoxin relies upon the use of a 
mouse bioassay. Identification of C. tetani organisms requires detection of the 
production of neurotoxins in culture supernatant, using the mouse bioassay. 
This is a field in which new methods continue to be developed. For 
example, in vitro methods that detect biologically active toxin are being developed. 
Organisms which contain toxin gene fragments can be detected by PCR. For 
example, in response to an increase in cases of tetanus associated with heroin abuse 
in the UK in 2004, the Health Protection Agency has developed a more rapid 
laboratory test to examine samples of heroin for C. tetani. In trials so far, the new test 
has enabled detection of C. tetani in heroin samples within hours after enrichment 
culture. This is substantially quicker than with conventional laboratory methods 
(Akbulut et al., 2004a).  
 
1.3. Botulism 
1.3.1. Aetiology and epidemiology 
Botulinum toxin  is produced by C. botulinum Group I (proteolytic C. 
botulinum), C. botulinum Group II (non-proteolytic C. botulinum), C. botulinum 
Group III and C. argentinense, and also by neurotoxigenic strains of C. baratii and 
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C. butyricum (Lund and Peck, 2000). C. botulinum is the term used for a complex of 
four species that are physiologically and phylogenetically distinct from each other, 
and they should be considered distinct species. Individual strains are capable of 
producing one or two of the seven antigenically distinct toxins types (A through to 
G). C. botulinum Group IV has been reclassified as a new species, C. argentinense 
(Suen et al., 1988). Some strains of C. baratii and C. butyricum also produce 
botulinum toxins (Hall et al., 1985; Aureli et al., 1986). Of the seven toxin types, 
only four (types A, B, E and, F) produce human disease. As little as 30 ng of 
botulinum neurotoxin can be fatal (Peck, 2004). 
The six species that produce botulinum neurotoxin are found worldwide in 
fresh water, salt water, soil and in lake and marine sediments. They are also found in 
the digestive system of animals and can therefore contaminate meat products in the 
slaughterhouse. 
Botulism is very rare in Europe, although some EU countries have up to 100 
cases of foodborne botulism each year (Peck, 2004). In the USA, since 1973, the 
median number of yearly reported cases is 71 for infant botulism, 24 for foodborne 
botulism and 3 for wound botulism. The case fatality rate has decreased 
progressively, with the development of intensive care facilities, from 60 to 
approximately 10 %. The progress of the disease is dependent on the age of the 
patient and promptness of treatment (Bleck, 2000b). 
 
1.3.2. Pathogenesis 
Various forms of botulism are distinguished and take account of the route of 
contamination (whether an infection or intoxication). These forms are: foodborne, 
wound, infant botulism and others. 
Foodborne botulism is the well-known form, due to the ingestion of food 
containing preformed toxin. Food is contaminated by bacteria (in slaughterhouse) or 
more likely by spores (dust, unclean water), which can germinate if the conditions 
are appropriate. The vegetative forms will produce the toxin. Poor heating, 
inadequate refrigeration, and a neutral pH of the food may all contribute to the 
production of toxin. Sometimes, food will smell because of proteolysis due to the 
bacteria. But for non-proteolytic C. botulinum, there may be no odour and therefore 
the consumer may not be aware of the hazard. The toxin is absorbed through the 
intestinal wall and is carried by the blood stream before reaching peripheral 
cholinergic synapses, where it blocks acetylcholine release.  
Infant botulism occurs in children up to one year of age, where the gut is 
contaminated by ingested spores. An underdeveloped intestinal flora will allow 
vegetative growth and formation of toxin. Soil and honey are the most common 
sources of spores. Honey consumption is therefore discouraged before the age of one 
year.  
Wound botulism is, like tetanus, due to contamination of wounds by spores. 
As with tetanus, wounds presenting anaerobic conditions allow spore germination 
and production of toxin. Cases of botulism in intravenous drug users are increasing in 
many EU countries. 
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Other reported cases in adults have their origin in gut colonisation by C. 
botulinum. Achlorydia and altered commensal flora (e.g. as a result of antibiotic 
treatment or chemotherapy) or enteric lesions (surgery, inflammatory diseases) allow 
settlement of C. botulinum and in situ production of toxin (Bleck, 2000b).  
 
1.3.3. Clinical signs 
The incubation time for botulism is variable (3 hours to 14 days), but is 
commonly reported to be between 12 and 36 hours for foodborne botulism. A shorter 
incubation time corresponds to a more severe disease. The severity of the disease 
also depends on the type of toxin. 
The first symptoms include blurred vision, dysphagia with dry mouth, 
weakness, nausea and apathy. The first clinical signs are associated with the eyes and 
facial muscles, which are more sensitive to any form of neuromuscular blockage than 
are skeletal muscles. Subsequent signs are: diplopia, inability to focus, dysphonia, 
dysarthria, eyelid ptosis, medial rectus paresis and abnormal pupillary reflex. 
Muscular weakness, and then paralysis, progresses from head to the neck and then to 
other parts of the body. Paralysis of the respiratory muscles is usually the cause of 
death (Bartlett, 2000a). 
The cholinergic autonomic nervous system is usually involved, leading to 
dry mouth with decreased production of saliva, ileus or diarrhoea, urinary retention 
and alteration of heart rate. Specific features of botulism include: the lack of effect on 
consciousness, awareness and perception, fever is absent, paralysis is bilateral and/or 
symmetrical and there is no hypotension. Blurred vision is the only sensory deficit 




Laboratory confirmation of a clinical diagnosis of botulism requires the 
detection of neurotoxin in a clinical specimen (serum, faeces, gastric contents and or 
food). Organisms may also be isolated from faeces, food and wound tissue. Isolation 
of C. botulinum organisms from a faecal specimen alone, without detection of toxin 
in a clinical specimen from that patient, does not confirm a clinical diagnosis of 
botulism. This is because the organisms are spore formers and are widespread in the 
environment. Moreover, neither does the failure to detect toxin and recover C. 
botulinum exclude the diagnosis.  
In infants, however, the recommendation is to test stools for culture and 
toxin; two negative specimens obtained during the acute phase of disease will 
generally rule out this diagnosis (Bartlett, 2000a). 
As with tetanus, in many countries, a single national laboratory is 
responsible for detecting botulism neurotoxins and for isolating and characterising 
implicated clostridia. Toxin detection, isolation and identification of the organisms 
require specialised techniques. 
Detection of botulinum neurotoxins relies upon the use of a mouse bioassay 
and upon neutralisation of botulism symptoms with specific antisera. Isolation of C. 
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botulinum organisms requires enrichment, sometimes for up to 14 days. The 
organisms are very diverse, and there is no simple biochemical test(s) that will 
identify organisms as C. botulinum. Identification of C. botulinum organisms requires 
detection of the production of neurotoxins in culture supernatant, using the mouse 
bioassay. In addition, cases of botulism in humans have been caused by organisms 
that have been unequivocally identified as C. baratii or C. butyricum, but which 
produced botulinum neurotoxin. New and more rapid methods continue to be 
developed. In vitro methods that detect biologically active toxin are being developed 
(Lund and Peck, 2000). Organisms that contain toxin gene fragments can be detected 
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At first glance, tetanus and botulism are completely different diseases, since 
the main clinical symptoms are opposite, being paralysis in botulism and tetany in 
tetanus. There are, however, several common aspects to these two diseases, such as 
their worldwide distribution, their broad range of target species, their toxins and their 
high mortality rate in animals. Both syndromes have been known for centuries, but 
only modern bacteriology and biotechnology have been able to unravel the 
epidemiology and pathogenesis of these two diseases. Diagnosis, however, remains 
largely based on clinical symptoms. 
 
2.2. Tetanus  
2.2.1. Aetiology and affected species 
Tetanus is caused by toxins produced by Clostridium tetani. This spore-
forming anaerobe has a worldwide distribution and can be demonstrated in more than 
50% of soil samples, especially in those from cultivated soils. The spread of spores 
by stools from healthy individuals may be an explanation for this higher occurrence 
in cultivated soil. Spores are not confined to the outdoor environment; they have 
been recovered from household dust and even in operating theatres. Lambs and 
horses seem to be the animals most vulnerable to developing tetanus. Adult 
ruminants and carnivores, especially scavengers, such as hyenas, seem to be less 
susceptible, probably due to the acquisition of a certain level of active immunity 
during their life (Smith, 2002 a). Lambs and horses, especially, suffer the generalised 
clinical form of tetanus, while carnivores more often develop a localised clinical 
form. Birds are much less susceptible than mammals. 
 
2.2.2. Pathogenesis 
The usual portal of entry of spores and bacilli is a deep and narrow wound 
(such as a nail wound at hoof level in horses) or a larger wound with necrotic tissues 
(after unclean castration of piglets and lambs) or through difficult and injurious 
farrowing in cows and bitches. 
Spores germinate, C. tetani multiply and tetanus toxin is produced as soon 
as local oxygen tension is sufficiently low, as is common in such wounds. 
Nevertheless, the development of appropriate conditions may take so long that the 
original injury may have healed by the time the toxin has been produced. 
The toxin reaches the local peripheral motorneuron trunk at the 
neuromuscular junction and is transported along the axon into the central nervous 
system. In highly susceptible species (horses), the tetanus toxin is distributed via the 
bloodstream to the motorneuron trunks in the whole body. 
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In some cases in herbivores, the spores may be ingested and the gut appears 
to be the site of  toxin production. The toxin subsequently crosses the intestinal wall 
and is transported by the bloodstream to the motorneuron ends. 
 
2.2.3. Clinical signs 
The incubation period of tetanus may vary between 1 and 4 weeks and 
depends on factors, such as the localisation of the portal of entry, local tissue 
conditions, the number of bacteria that have entered the body and the level of specific 
antibodies in the host. The first signs can be subtle; signs of colic in horses and bloat 
and constipation in ruminants have been reported. Lameness or stiffness in one limb 
is observed in some animals and this may reflect the localised form of tetanus as 
described in humans. In most cases, initial symptoms evolve within 24 hours into the 
typical form of tetanus, with generalised stiffness to spasticity and an extended head 
posture. Symptoms are dominated by hypertonia of the antigravity muscles, resulting 
in hyperextension of all limbs in animals, while in humans the arms are typically 
flexed with clenched fists. The posture of animals with tetanus is often described as a 
“sawhorse stance”. 
At the head, ears and lips may be retracted (risus sardonicus) and the jaw 
firmly fixed (lockjaw). Protrusion and rapid movement of the third eyelid is present, 
especially in horses, when the head is raised or when a menacing gesture is made. 
Difficulties in swallowing are often present, resulting in accumulation of saliva in the 
mouth and the presence of frothy saliva at the lip commissures. These difficulties in 
swallowing may lead to aspiration pneumonia. In a further stage, animals may 
become recumbent and, even with support in a sling, be unable to remain standing. 
The muscular spasms are tonic, but can become more pronounced and convulsive 
after auditory, visual or tactile stimulation. Increased muscular tonus and attempts to 
rise usually induce hypothermia in affected animals and profuse sweating in horses. 
When the respiratory muscles become affected, hypoxia may develop. Evolution of 
the disease may be fast, over the course of just a few days. However, especially in 
less affected animals, progression may be observed for up to 2 weeks after initial 
symptoms, due to the slow transport of the toxin in the axons. Tetanus can lead to 
death for several reasons, such as hypoxia, heart failure, autonomic dysfunction or 
secondary pathologies, including aspiration pneumonia and exhaustion (Smith, 
2002a; Stöber, 2002a).  
 
2.2.4. Diagnosis 
2.2.4.1. Clinical diagnosis 
Diagnosis of tetanus is almost exclusively based on typical clinical 
symptoms. In adult animals, a history of a wound 1 to 2 weeks before the onset of 
symptoms and the absence of active immunisation, may further support the 
presumptive diagnosis. In neonates, the absence of maternal immunisation may 
support the inclusion of tetanus in the differential diagnosis of tetanic conditions. 
Exclusion of other conditions that may resemble tetanus, such as (in horses) 
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hypocalcemic tetany, strychnine poisoning, meningitis, rhabdomyolysis or laminitis, 
can help in establishing a diagnosis (Smith, 2002a; Bartlett, 2000a).  
 
2.2.4.2. Pathological lesions 
On post-mortem examination, no characteristic lesions are present, apart 
from secondary lesions, such as those of aspiration pneumonia or, occasionally, bone 
fractures as a result of muscular spasms. Special attention should be paid to the 
presence of wounds (Stöber, 2002a). 
  
2.2.4.3. Laboratory diagnosis 
Bacteriological examination of wounds is occasionally performed, but 
recovery of the organism is infrequent. Swabs from wounds in anaerobic transport 
media may be submitted to a laboratory. Direct smears from wound fluid or tissue 
may show Gram-Positive rods, but polybacterial presence is common in 
contaminated wounds. Currently, there is no routine diagnostic method available for 
the identification of the toxin, except for the mouse bioassay (Bartlett, 2000a).  
 
2.3. Botulism 
2.3.1. Aetiology and affected species 
Botulism is classically described as a disease caused by toxins produced by 
Clostridium botulinum. Since several species and groups of clostridia seem to be 
involved, it is more accurate to describe botulism as being a result of toxins from 
botulinum neurotoxin (BoNT)-producing clostridia (Johnson and Bradshaw, 2001). 
When suitable conditions are present, spores of BoNT-producing clostridia 
develop into vegetative forms and may produce one of seven antigenically distinct 
neurotoxins (A, B, C1, D, E, F or G). Suitable growth conditions can be defined, in 
general, as anaerobic conditions with a protein source, sufficient temperature and 
moisture. For animals, these conditions can, for example, be found in decomposing 
cadavers, in insufficiently acidified ensiled feed or in decomposing vegetation in 
ponds. Botulinum neurotoxins have some species specificity: in horses botulism 
caused by types A, B and C is most common; from cattle, types B, C or D are mostly 
recovered; fur animals, such as ferrets and mink, are notoriously susceptible to 
botulism type C and, to a lesser degree, to types A and B; birds are sensitive to type 
A, very sensitive to types C and E but may harbour type D-producing strains in their 
gut without showing symptoms; fish seem especially vulnerable to type E (Bartlett, 
2000b; Smith, 2002b).  
 
2.3.2. Pathogenesis 
The route of contamination in animals is primarily the ingestion of 
preformed toxins in food, water or carrion.  
In some cases, as in shaker foal syndrome, spores of C. botulinum are 
ingested and are present in the gut. After germination of the spores, toxin is produced 
directly in the gut. (This is called toxicoinfection.) 
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The botulinum toxin subsequently crosses the stomach and intestinal wall 
and reaches the neuromuscular junctions via the bloodstream. 
 
2.3.3. Clinical signs 
2.3.3.1. Incubation period 
In monogastric animals, the incubation period of foodborne botulism is 
usually short (an average of 18 to 36 hours), with a wide variation from a few hours 
to 8 days, depending on the amount of ingested toxin. In ruminants, the incubation 
period is usually somewhat longer and, after ingestion of smaller amounts of toxin, 
symptoms may be absent for over a week. This implies that, even after withdrawal of 
suspected feed, new cases may still appear after seven to ten days. For wound 
botulism and shaker foal syndrome, the incubation period is longer and an indicative 
period of 4 to 14 days is suggested in the literature (Smith, 2002b). 
 
2.3.3.2. Clinical signs in farm animals (horses, cattle and pigs) 
Depending on the amount of ingested toxin, initial symptoms may be subtle 
or overt in large domestic animals. Animals may be found dead or may die within a 
few hours, showing symptoms of lateral recumbency, paddling movements and 
progressively worsening dyspnoea. 
In less acute cases, mild gastrointestinal symptoms, such as firm faeces and 
decreased rumen contractions in cattle, or mild abdominal discomfort in horses, can 
be the initial signs. These are quickly followed by decreased muscle tone and/or 
dysphagia. Decreased muscle tone in cattle may mimic the symptoms of milk fever, 
i.e. weakness and incoordination, evolving into recumbency. In horses, a shuffling 
gait with toe-dragging and muscle tremors are the initial signs, eventually leading to 
recumbency and increasing difficulty in rising. Lifting the head into the physiological 
position may become increasingly difficult for horses infected with botulism and this 
low head carriage can lead to both oedema of the head and difficulty in breathing.  
Physical activity may have a negative effect on clinical evolution: it is 
believed that such activity results in further depletion of acetylcholine reserves and 
worsening of symptoms. Recumbent animals may remain sternally or become 
laterally recumbent in more advanced stages. For large animals, lateral recumbency 
is a poor prognostic sign and is often accompanied by symptoms of respiratory 
failure (due to paralysis of respiratory muscles) and by paddling movements in the 
terminal stages. Prolonged recumbency without respiratory failure remains 
prognostically poor because of complications associated with recumbency in heavy 
animals.  
Dysphagia is present in most, but not all, cases of botulism in horses and 
cattle. Decreased masseter tone, decreased tongue strength and pharyngeal paresis or 
paralysis (bulbar paresis) may contribute to dysphagia each in variable degree. 
Dysphagia can express itself as an abnormally long time to consume a small amount 
of food, as a loss of saliva and/or food from the mouth, or as chewing for hours on a 
cud of hay or straw without swallowing. Testing tongue strength (tongue stress test) 
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by manually pulling the tongue from the mouth, testing masseter tonus by moving 
the mandible laterally and timing the uptake of a small amount of food are simple 
tests that should be done during the initial evaluation of animals suspected of having 
botulism. These tests may not be pathognomonic, but are at least indicative for 
botulism.  
Due to the effects of toxin at the cholinergic nerve endings in the gastro-
intestinal tract, constipation and signs of colic may be present early in the course of 
the disease. Moderate mydriasis and a poor pupillary response to light are additional 
clinical symptoms of botulism in large animals. The course of the disease depends 
largely on the initial evolution; mildly affected animals may show early signs of 
recovery after 7 to 14 days (Galey, 2001; Smith, 2002b; Stöber, 2002b). 
Symptoms of shaker foal syndrome are comparable to botulism in adult 
horses, but evolution is usually slower. The foal will initially lie down more often 
than normal and will exhibit muscle tremors when forced to stand up. After suckling, 
the foal will lose milk from the mouth and tongue strength will be reduced. Mild 
pupillary dilation, ptosis, constipation and ileus may be present. As the disease 
progresses, the foal may become more and more lethargic and weak, develop 
secondary pathologies, such as aspiration pneumonia, and, when respiratory failure 
ensues, death may follow (Wilkins and Palmer, 2003).  
Recently, a clinical syndrome in cattle, characterised by increased animal 
losses, reduced performance, a high incidence of lame, ataxic and paretic cattle and 
various digestive problems, has been suggested as the consequence of intestinal 
proliferation of toxigenic Clostridium botulinum (“visceral” botulism) (Böhnel et al., 
2001, Holzhauer, 2004). 
In horses, there is increasing evidence that toxicoinfection with Clostridium 
botulinum type C may be linked to Grass Sickness. Neurotoxin has been detected in 
the gastro-intestinal contents of a significantly higher number of affected horses than 
in control horses. Moreover, antibodies against Clostridium botulinum type C and 
BoNT type C are lower in affected horses (Hunter et al., 1999; Hunter and Poxton, 
2001).  
Pigs seem relatively resistant to botulism, at least our domestic and 
commercially raised pigs. Muscle paralysis, vomiting, feed and drink refusal and 
mydriasis are reported as symptoms. 
 
2.3.3.3. Clinical signs in carnivores 
There are very few reports on botulism in pets. Cats seem resistant to 
botulism, while a few case reports exist on botulism in dogs, mainly involving type C 
toxin. Symptoms of progressive flaccid paralysis dominate, starting with skeletal 
muscles and involving head musculature at a later stage (Borst et al., 1986).  
Other small mammals that eat meat and meat products, such as mink, ferrets 
and foxes, seem more prone to botulism. Toxin type C and, to a lesser degree, types 
A and B, have been reported. Large scale outbreaks in industrially raised fur animals 
are common and symptoms include the same clinical signs as those in large domestic 
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animals, i.e. some animals are found dead and others present varying degrees of 
flaccid paralysis and dyspnoea (Phaneuf et al., 1972).   
 
2.3.3.4. Clinical signs in birds 
Flaccid paralysis is the main symptom of botulism in birds. First, the ability 
to fly and walk disappears and then the birds become unable to lift their neck. This 
inability to erect the neck is a typical symptom described as “limber neck”. Paralysis 
of the inner eyelid is another characteristic symptom at this stage of the disease. 
Without treatment, birds will die because of drowning (in the case of waterfowl), 
emaciation or respiratory failure. A toxicoinfectious form of botulism has been 
described in broilers, which causes the same symptoms, eventually  followed by 
diarrhoea with excess urates (Wobeser, 1997).  
 
2.3.3.5. Clinical signs in fish 
Regarding botulism in fish, mostly reported in farmed trout or salmon, the 
first observed symptom will be increased mortality. Individual fish may initially 
show agitation, followed by progressive paralysis of the fins, the tail fin being the 
last to become paralysed. Fish will, therefore, lose the ability to swim in a 
coordinated way and tend to sink to the bottom, tail fin first (Eklund et al., 2004). 
 
2.3.4. Diagnosis 
2.3.4.1. Clinical diagnosis 
Clinical symptoms of botulism are strongly indicative but not specific. Other 
causes of sudden death and nervous system disorders causing weakness and 
dysphagia must be included in differential diagnosis. These include milk fever or 
listeriosis in cows, herpes virus encephalomyelitis in horses, intoxication and 
autoimmune diseases (myasthenia gravis). Therefore, the diagnostic work-up will 
include elimination of other disease entities through clinical, biochemical and other 
diagnostic procedures and the positive identification of botulism as the primary cause 
of the symptoms (Smith, 2002b; Stöber, 2002b).  
 
2.3.4.2. Pathological lesions 
Necropsy findings are usually unremarkable, although in more protracted 
cases, secondary pathologies, such as aspiration pneumonia or lung congestion, may 
be present. These negative post-mortem results can be used as a diagnostic tool per 
exclusionem. 
In cattle, congestion and haemorrhagic lesions can sometimes be observed 
in the proximal jejunum, and histological examination reveals local intestinal 
necrosis. These lesions are similar to those of clostridial enterotoxaemia in cattle and 
it is suggested that this may be the result of enterotoxins, such as C2, being locally 
produced by ingested clostridia (Martel, 2003). 
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2.3.4.3. Laboratory diagnosis 
Diagnosis of botulism can be made by demonstrating 1) toxin in the patient 
(serum, gastro-intestinal contents, liver, wound), 2) Clostridium botulinum spores in 
the patient (gastro-intestinal contents, liver, wound), 3) toxin or spores in the feed or 
close environment of the patient or 4) an antibody response in a recovered patient 
(Smith, 2002b).  
 
2.3.4.3.1. Sampling procedure and transport to the laboratory 
Samples of serum (10 ml), ruminal or gastro-intestinal contents (200 g), 
faecal material and tissue samples (liver) for the detection of toxin should be taken as 
soon as possible after the onset of symptoms, or after death. The toxin is sensitive to 
heat (destruction after 20 minutes at 50 °C), but is stable for weeks when frozen. 
Transport on cold packs (4 to 8 °C) and in air- tight containers is preferred when it is 
possible for the sample to arrive at the laboratory within 24 hours.  
Samples for bacteriology (tissue samples, ruminal or gastro-intestinal 
contents, faecal material, food, carcasses) should preferably be shipped on cold packs 
in air-tight and leak- proof containers, as freezing may reduce the recovery of 
bacteria on subsequent culture. 
All containers should be clearly marked as possibly holding BoNT (Böhnel 
and Gessler, 2003). 
 
2.3.4.3.2. Laboratory procedures 
Toxin assay is available only in a small number of reference laboratories. 
Currently, the most sensitive test is the mouse bioassay. Serum or extracts of other 
submitted material is intraperitoneally injected into mice. The animals are then 
observed for 4 days for the development of clinical symptoms (wasp waist) or death. 
The injection of unneutralised samples and samples neutralised with specific antisera 
further confirms the presence and serotype of the toxin. ELISA techniques are 
currently being developed to reduce the use of laboratory animals and possibly to 
enhance the sensitivity of the test, but they are not yet approved as a reference test 
(Galey, 2001; Moeller et al. 2003; Ferreira et al., 2004, Gessler and Böhnel, 2004). 
 
Bacteriological examination of clinical samples or suspected food is carried 
out by anaerobic culture on appropriate media (for example egg yolk agar plates) and 
subsequent inoculation of suspected colonies takes place on broth media (Glasby and 
Hatheway, 1985; Shone and Tranter, 1995). The supernatant of those media can then 
be tested for the presence of toxin. Classic bacteriology will be combined in the near 
future with PCR assays for the demonstration of toxinogenic clostridia in clinical and 
environmental samples (Szabo et al., 1992; Galey, 2001, Lindström et al., 2001).  
 
2.3.4.3.3. Interpretation of laboratory results 
Although demonstration of toxin in the patient is the most valuable 
diagnostic technique, it remains difficult to achieve. This is because the mouse 
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lethality test will only be positive when there is still a significant amount of free toxin 
present in serum, tissue or gastro-intestinal contents. This test will, therefore, 
probably only be positive when samples are taken early in the course of the disease 
and/or when the patient has ingested a large amount of toxin. Preferred samples in 
the diagnosis of botulism in cattle are gastro-intestinal contents or those taken from 
the liver. In foals with shaker foal syndrome, intestinal contents may yield up to 20% 
positive results in toxin assay (Smith, 2002b). In birds, toxin can be demonstrated at 
a fairly constant rate in serum, intestinal contents or tissue samples. The low 
diagnostic sensitivity of mouse bioassay implies that multiple samples have to be 
examined before discarding botulism as a possible cause of symptoms. Anecdotal 
evidence suggests that even an extensive search for toxin may remain negative when 
all other symptoms indicate botulism as the cause of the disease (Heider et al., 2001; 
Cobb et al., 2002). Recent work has shown that one explanation for frequent negative 
diagnostic results when using the mouse lethality test in cattle may be their higher 
sensitivity to botulinum toxin in comparison with mice (Moeller et al., 2003).  
Demonstration of spores in gastro-intestinal contents or tissues of animals 
with symptoms indicative of botulism, supports the diagnosis. Spores are normally 
rarely detected in faecal samples from foals or horses, but in cases suspected of 
botulism on clinical grounds, spores can be detected in 34% of faeces from adult 
horses and in 70% of foal faeces (Smith, 2002b).  
Demonstration of spores or toxin in feed of animals showing symptoms of 
botulism may also help in diagnosis. This demonstrates that the animals are at risk 
and may help to identify the source of the toxin in order to prevent further fatalities. 
The presence of toxin in feed, in particular, is regarded as diagnostic evidence; the 
presence of spores is more indicative than diagnostic (Kelch et al., 2000). 
Where a test is available, demonstration of neutralising antibodies may 
allow a retrospective diagnosis in recovered animals (Smith, 2002b; Holzhauer, 
2004). 
Diagnosis of botulism, certainly when few animals are affected, can be 
difficult for several reasons: the small amount of toxin needed to kill an animal, the 
rapid disappearance of toxin from the circulation and the usually focal distribution of 
toxin in feed. Diagnosis is based, therefore, on exclusion of other causes, rather than 
on positive identification. The cost of repeated attempts to identify the bacterium or 
toxin may further limit diagnostic possibilities in veterinary medicine. 
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The first stage of clostridial soft tissue infection in animals is the deposit of 
spores in the tissues: wound, derm and subcutaneous tissue, internal organs. 
Following the development of anaerobiosis, often after tissue necrosis, the spores 
will germinate; clostridia will multiply and produce their toxins. These toxins will act 
locally, digesting and lysing the tissue (gangrene, necrosis and abscedation), 
sometimes with gas production, and generally, after resorption in the bloodstream 
and distribution throughout the whole body (erythrolysis, lethal effect).  
Soft tissue infections in animals are various (Songer, 1997, 2002, 2004). 
Their diagnosis can be performed clinically, bacteriologically or even molecularly on 
clinical specimens. 
 
3.2. Clinical and necropsy diagnosis 
Clostridial soft tissue infections in animals can be subdivided into specific 
and non-specific pathologies. All specific diseases can be suspected, or even in some 
cases diagnosed, based on criteria such as the target host species, clinical signs and 
lesions at necropsy (Table 3.1): 
• necrotic and haemorrhagic myositis caused by Clostridium chauvoei in 
ruminants (blackleg) or by Clostridium septicum in any animal species (false 
blackleg, by extension of gas gangrene or of non-traumatic origin); 
• necrotic hepatitis in ruminants caused by Clostridium novyi type B 
(black disease) or Clostridium haemolyticum (bacillary haemoglobinuria); 
• hepatitis, myocarditis and enteritis in laboratory animals and young 
mammals caused by Clostridium piliforme (Tyzzer’s disease); 
• (gas) gangrene in subcutaneous or submucosal tissues and/or internal 
organs caused by a variety of clostridia: Clostridium septicum, C. novyi type 
A, C. sordellii, C. chauvoei, and, more rarely, C. perfringens type A; 
• necrotic dermatitis in poultry caused by Clostridium septicum; 
• enteritis and hepatitis in birds caused by Clostridium colinum (Quail 
disease). 
 
Non-specific pathologies of soft tissue caused by clostridia are 
osteomyelitis, mastitis, meningo-encephalitis, external otitis, subcutaneous and 




3.3. Bacteriological diagnosis 
Bacteriological diagnosis is often necessary for confirmation, but results are 
reliable only if lesions have been appropriately sampled and those samples 
appropriately transported. In some cases, growth of bacteria will not be necessary, 
because a diagnosis can be performed based on careful examination of Gram and 
Ziehl-Neelsen-stained smears from tissue samples sent to the laboratory. It is also 
possible to perform immuno-fluorescence or immuno-cytochemical assays on smears 
using clostridial species-specific whole cell immune sera and, in some cases, PCR 
assays. When growth of clostridia is necessary, the laboratory procedure targets one 
or more clostridial species, depending on the pathology suspected.   
 
3.3.1. Sampling and transport  
Quite often the laboratory receives the whole animal body for necropsy and, 
subsequently, bacterial analysis of suspect lesions (Table 3.2). Sometimes the dead 
animal will be necropsied directly by the practitioner. Reliable bacterial analysis can 
be effectively performed only if the body is sampled soon after death, especially if 
the outdoor temperature is high. Otherwise multiplication of clostridia originating 
from the gut will overwhelm any pathogenic species, even in the internal organs. 
This is particularly true for infections with gangrene-producing clostridia, since 
putrefaction starts even before death.  
Tissue samples should be large enough (at least 4 cm3) to include lesion 
area(s) and be stored in a jar with a catalyst, if not immediately introduced into an 
anaerobic cabinet. Fluids should be transported in air-free containers. All samples 
should be refrigerated and brought in, rather than sent, to the laboratory. If sent by 
post, they should be wrapped in two layers of leak-proof plastic bags. In the few 
cases where a cotton swab is taken, the transport medium must be appropriate for 
anaerobes. However, toxin detection is not possible in the case of cotton swabs.  
 
3.3.2. Gram and Ziehl-Neelsen-stained smears  
Gram and Ziehl-Neelsen stainings can be performed on smears prepared 
directly from clinical samples at the site of lesions (Table 3.2). The former gives 
information on the morphology of the bacteria; the latter on the spores, if any. Also a 
stained smear can reveal the presence of multiple bacterial species in the case of 
samples taken quite late after death. But all species become Gram-Negative in old 
cultures and when the cells are sporulating. Moreover, Clostridium piliforme always 
gives a negative reaction at Gram staining, and Giemsa staining must be used in 




Table 3.1: Main criteria for clinical diagnosis of specific clostridial soft tissue 
infections (Mainil and Duchesnes, 2002; Mainil et al., 2002; Songer, 2004) 
Pathology Clostridium Host species Clinical sign(s) Lesion(s) 
Blackleg chauvoei Cattle, sheep 
>2 years 





necrosis in the muscles 
   Sudden death (mainly of the 
hindlimbs), 
    rancid butter odour 
False blackleg septicum Ruminants + 
others 
See gas gangrene See gas gangrene of 
muscles 
(Gas) gangrene septicum, novyi A, 
sordellii, chauvoei,  
Ruminants (C. 
novyi A,  
C. septicum, 
C. sordellii,  
C. chauvoei,  
Warm, then cold, 
tumefaction, 




and necrosis, gas in the  
subcutaneous and 
submucosal 




tissues and in internal 
organs 




(liver, muscles), rapid 
  Pigs (C. 
septicum) 






Black disease novyi B Small (large) 
ruminants 
None specific Subcutaneous venous 
congestion, 
   Sudden death focal hepatic venous 
infarcts, 







Large hepatic venous 
infarct(s), 
  (>1 year) jaundice anaemia, red urine in 
the bladder 
    fluke infection 





Necrotic foci on the 
liver, heart, 







Necrotic dermatitis septicum Chickens Incoordination, red 
skin, 
Oedema, necrosis and 
gas 
   subcutaneous 
swelling 
in the subcutaneous 
tissue 






  poultry  hepatitis and splenitis 
1
 and several minor pathogens  
2
 For rabbits see Chapter 10  
3
 For Quail disease caused by Clostridium colinum see Chapter 11
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3.3.3. Immunoassays  
Though the morphology of clostridial rods is indicative of their identity, 
accurate identification can be obtained only through biotyping or toxintyping. 
Because this procedure is difficult and time-consuming, especially in ill-equipped 
laboratories, it would be advantageous to obtain a good indication of clostridial 
identity without growing the bacteria.  
Identification is possible using specific whole cell polyclonal immune 
serums in immuno-fluorescent reactions on smears prepared from tissue samples 
(Table 3.2). Fluorescent-labelled antiserums to C. chauvoei, C. haemolyticum, C. 
novyi, C. piliforme, C. septicum and C. sordellii are available.  
Detection of C. chauvoei and C. haemolyticum has also been reported with 
the peroxydase-antiperoxydase (PAP) technique on formalin-fixed paraffin-
embedded tissue sections (Giraudo Conesa et al., 1995; Uzal et al., 1992).  
 
3.3.4. PCR on clinical specimens 
Different PCRs (Polymerase Chain Reactions) have been developed for 
identification of clostridia (see Chapter 16). Some have been tested on clinical 
samples to detect and differentiate myositis and gas gangrene-associated clostridia: 
C. chauvoei, C. novyi, C. septicum, C. sordellii (Uzal et al., 2003; Sasaki et al., 2001, 
2000a  and b; Kojima et al., 2001; Kuhnert et al., 1997) and C. piliforme in intestinal 
specimens and faeces (Furukawa et al., 2002; Ikegami et al., 1999).  However, PCRs 
are not yet used in routine diagnostic laboratories on clinical samples. 
 
3.3.5. Demonstration of toxin production in vivo  
With the exception of C. colinum and C. piliforme so far, major pathogenic 
clostridia produce toxins during infection (Titball et al., 2003). The following toxins 
can be detected (Table 3.2) in tissue samples, exsudates and serosal effusions: α 
toxin of C. perfringens type A; α and/or β toxins of C. novyi types A, B and those of 
C. haemolyticum. Tests for these are immuno-chemical or animal assays (lethality in 
mice, dermonecrosis in guinea pigs). It must be emphasised that neutralising immune 
sera are not available for the α and β toxins of C. novyi and C. haemolyticum. Other 
toxins are not routinely detected.  
 
3.3.6. Growth media and conditions 
Though clostridia are anaerobes by definition, anaerobic requirements can 
vary between species. Amongst the species listed in this chapter, three are very strict 
in their requirement for anaerobiosis (C. chauvoei, C. haemolyticum and C. novyi). C. 
haemolyticum and C. novyi die within minutes of exposure to air. It is not always 
possible to obtain their growth in anaerobic jars and use of an anaerobic cabinet is 
recommended when possible. On the other hand, a species like C. perfringens can 
grow even if traces of oxygen are still present; it is therefore very easy to grow in any 
basically equipped laboratory. In addition, several species require the presence of 
blood and some enrichment in specific components (C. chauvoei, for example).  
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Table 3.2: Sampling and routine direct diagnostic procedures (Titball et al., 2003; 
Mainil et al., 2004; Popoff, 2004). 
 
Pathology Clostridium Samples Gram 
stain 
Immunoassays In vivo toxin 
demonstration 
Myositis chauvoei Muscle 
lesions 
Yes IFA1, PAP2 No 





Yes IFA No 
 novyi A organs 
(muscles, 
 IFA Yes 
 sordellii liver, 
spleen…), 
 IFA No 
 chauvoei wound swab  IFA No 
 perfringens A   No Yes 
Hepatitis3 novyi B Liver lesions Yes  IFA Yes 
 haemolyticum  Yes IFA, PAP Yes 
 colinum  Yes No No toxin 
identified 
 piliforme (also faeces) No 
(Giemsa)4 
IFA No toxin 
identified 
Dermatitis septicum Skin,  
subcutaneous 
tissue 
Yes No No 
 
1
 IFA = Immuno-Fluorescence Assay 
2
 PAP = Peroxydase-Antiperoxydase technique 
3
 For Quail disease caused by Clostridium colinum 
4
 Intracellular bundles of bacilli by Giemsa stain 
 
3.4. Interpretation criteria 
In general, the results of bacteriological analysis must be interpreted with 
care. Some clostridia originating from the gut (e.g. C. septicum, C. perfringens) will 
invade the body very rapidly after death, even during the agonic period, and 
overgrow other pathogenic species present in the internal tissue. Conversely, several 
clostridia are extremely O2 sensitive and will die rapidly when exposed to air.  
There are no general rules; each case is unique. Interpretation criteria must 
therefore include clinical signs and lesions, the delay between death and sampling, 
the outdoor temperature, the quality of sampling, transport conditions and the purity 
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Table 4.1: Clostridia causing abomasitis in domestic ruminants   
Clostridium species Abomasitis in: 
perfringens type A neonatal and older calves, young lambs 
perfringens type C neonatal calves, young lambs (uncommon), 
older lambs (pine) 
septicum neonatal and older calves, young lambs 
 
4.1. Clostridium perfringens 
Clostridium perfringens is common in the environment and in the intestinal 
tracts of humans and domestic and wild animals. Infecting organisms may be from an 
exogenous source, but are often endogenous. It is perhaps the most frequently-
isolated pathogenic bacterium; it is undeniably the most important cause of clostridial 
disease in domestic animals. The widely known typing system allows division of the 
species into 5 toxin phenotypes or genotypes. Truly non-toxigenic strains of C. 
perfringens (not producing any of the 4 major toxins) are rare. 
There is considerable syndromic overlap between abomasitis (regardless of 
species) and enteritis/enterotoxaemia. The latter frequently involves abomasal 
damage as well. 
Information about distribution of C. perfringens genotypes is accumulating 
as more diagnostic and research laboratories adopt PCR-based methods for toxin 
gene detection. There is evident disparity in prevalence of the various genotypes by 
geographic region, although type A remains the most commonly-isolated type 
overall. In North America, type A predominates, although types C (mainly from 
neonatal enteritis cases), D  (mainly from ovine or caprine enterotoxaemia) and E  
(from bovine neonatal hemorrhagic enteritis) are not uncommon. In various studies, 
nearly 97% of isolates from various sources in Belgium were of non-enterotoxigenic 
type A, including all of those from cattle and horses with enterotoxaemia. Type C 
was limited to swine, type D was isolated from small ruminants with enterotoxaemia, 
and types B and E were not found. Types C and E were detected in Poland, while in 
Austria, type A was most common in sheep and type D in goats. Enterotoxaemia in 
goats, reindeer, and blackbuck were caused by type E. Type C was found only in 
swine. In Northern Greece, type B is apparently most prevalent in lambs (nearly 50% 
of cases of lamb dysentery), although type C accounted for 20% and type D 28% of 
all isolates. Types A and E were not found.  
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4.1.1. C. perfringens type A (α toxin) 
4.1.1.1. Abomasitis in lambs and kids 
Lamb enterotoxaemia (yellow lamb disease) and a similar condition in kids 
occurs sporadically in wet springs in the north-western US. Depression, anaemia, 
icterus and haemoglobinuria are common, and affected lambs die after a 6–12 h 
clinical course. Lesions begin in the abomasum and progress through the small 
intestine, with haemorrhagic necrosis throughout. Elevated numbers of C. 
perfringens (up to 107 colony-forming units per gram) are found in affected mucosa 
and intestinal contents. It is often difficult to distinguish yellow lamb disease from 
lamb dysentery, although type B infections (see below) are rare-to-non- existent in 
the US geographical range of yellow lamb disease. 
 
4.1.1.2. Abomasitis in calves 
Type A-associated abomasitis is more common in beef and dairy calves than 
in lambs, including calves raised for veal, but is similar in many respects to the 
disease in lambs. Infection may originate in contaminated colostrum, and the method 
of administration has associated risk factors; icy colostrum in large volumes is 
associated with development of disease.   
Bloating is common, and the clinical syndrome ranges from severe 
diarrhoea, with a brief clinical course, to sudden death without premonitory signs. 
Gross lesions consist typically of haemorrhagic gastroenteritis. The abomasum is 
often grossly dilated, haemorrhagic and ulcerated, with thickened, emphysematous 
walls and folds. Microscopic lesions include severe necrosis and haemorrhage, with 
micro-colonies of large rod-shaped bacteria observed in the mucosa and submucosa. 
Rapid autolysis may obscure enteric lesions. Veal calves may experience similar 
infections at times of significant dietary change, not uncommonly as late as 4 months 
of age. 
 
4.1.2. C. perfringens type C (α and β toxins) 
Newborn animals are typically most susceptible to type C infection, likely 
following rapid gut colonisation in the absence of well established normal intestinal 
flora. Sudden dietary changes can alter flora and incite type C infection in older 
animals. Type C, shed in small numbers by dams, may be selectively enriched in the 
neonatal gut. 
  
4.1.2.1. Abomasitis in neonatal calves, lambs, and kids 
Robust, vigorous calves, often less than 10 days old, display signs of severe 
abdominal pain, sometimes with central nervous system signs including tetany and 
opisthotonos. Death may be peracute, occasionally without other clinical signs, but 
typically follows a clinical course of hours to days. Gross lesions include 
haemorrhagic, necrotic abomasitis and enteritis, and are similar to, though usually 
more severe than, type A infections. 
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Type C abomasitis in lambs resembles lamb dysentery, although colonic 
involvement, if any, is usually limited to the distal portion. Attack rates are often as 
high as 20%, and case fatality rates of 100% are not unusual. In these animals, and 
others affected by type C, β toxin is the virulence factor of note, and immunity is 
mainly antitoxic. 
 
4.1.2.2. Abomasitis in adult sheep (struck)  
Adult sheep (typically young ewes) in specific locales (e.g., Wales and the 
Romney Marsh areas of England), can be affected by an often peracute form of 
clostridial abomasitis and enteritis. Rapid death, which gives the impression of 
lightning strike, has resulted in application of the picturesque name “struck”. Damage 
to gastrointestinal mucosa, caused perhaps by poor quality or frozen feed, encourages 
multiplication of type C in abomasal and small intestinal walls, resulting in mucosal 
necrosis, usually without dysentery or diarrhoea. Accumulation of fluid in the 
peritoneum and thoracic cavity, as well as central nervous system signs (including 
peracute death), suggest a role for β toxaemia, and rare cases have no gross lesions in 
the gut.   
 
4.1.3. C. perfringens type B (α, β and ε toxins)  
The natural history of lamb dysentery is much the same as for other forms of 
clostridial abomasitis and enteritis affecting neonates. Type B organisms, originating 
with the dam, multiply in the neonatal gut, resulting in abomasitis, as well as 
extensive haemorrhage and ulceration of the small intestine. Death is often peracute, 
but may be preceded by inappetence, abdominal pain, haemorrhagic diarrhoea, 
recumbency and coma. Older lambs may develop a chronic condition called “pine,” 
in which infection of the abomasum and intestine manifests as chronic abdominal 
pain without diarrhoea. 
 
4.2. Clostridium septicum 
Clostridium septicum is commonly found in soil, and has also been isolated 
from the faeces of domestic animals and humans. It is frequently a post-mortem 
invader from the gut. 
 
4.2.1. Abomasitis in sheep and calves (braxy) 
In lambs or older sheep, the organism interacts with damaged abomasal 
epithelium and produces braxy or bradsot. It is responsible for large numbers of 
deaths in sheep in Great Britain, Ireland, Norway, Iceland and the Faroe Islands and 
has been reported in Europe, Australia, the United States and elsewhere. The 
invasion mechanism has not been characterised experimentally, but ingestion of 
coarse or frozen feed is associated with development of disease in both sheep and 
dairy calves. Impaired mucosal function may allow entry of the organism, followed 
by local multiplication and dissemination of toxins throughout the body, producing 
local lesions and toxaemia. The clinical course is often fulminant, with sudden death 
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of affected animals. Those not dying peracutely may exhibit lassitude and abdominal 
pain, and may occasionally produce haemorrhagic stools. Gross lesions include 
haemorrhagic, necrotic abomasitis, with diffuse suppurative inflammation; abomasal 
and proximal small intestinal walls are oedematous, haemorrhagic, necrotic, and 
emphysematous. Accumulation of fluid in body cavities, and other signs of 
bacteraemia and toxaemia, are common. Disease in calves is much the same, but 
occurs most commonly in neonates fed large volumes of barely-thawed, pooled 
colostrum. 
α toxin is the key factor in pathogenesis of abomasitis, and antitoxic 
immunity protects against infection.  
 
4.3. Diagnosis 
Diagnosis can be based upon clinical signs, gross and microscopic findings 
at necropsy, Gram- and fluorescent antibody staining of direct smears, bacteriologic 
culture, and, in the case of C. perfringens, typing of isolates. 
 
4.3.1. Clinical and necropsy findings 
Clinical signs have much in common from organism to organism and host to 
host. Animals with peracute disease may simply be found dead, without premonitory 
signs. Those with acute disease will usually show evidence of depression, 
inappetence, abdominal pain and diarrhoea with blood, sometimes progressing to 
central nervous system signs, including opisthotonos. Subacute or chronic cases are 
more likely to experience haemorrhagic diarrhoea, although chronicity is rare. 
Necropsy findings are dominated by extensive haemorrhagic necrosis of the 
abomasal epithelium and underlying tissues, often with a marked suppurative 
component. Signs suggestive of toxaemia are common in C. septicum- and C. 
perfringens type C-induced disease, and there is good evidence for systemic effects 
of their α and β toxins, respectively. Bacteraemia is a recognised component of C. 
septicum enteric infections in domestic animals and humans, and may also occur, at 
least terminally, in C. perfringens type A or type C infections. 
It is common for similar lesions to extend into the small intestine and not 
uncommon for the colon to be affected as well. 
 
4.3.2. Sampling procedures 
Tissues should be preserved in buffered formalin for histopathologic 
examination. A portion of affected abomasum should be collected fresh for direct 
examination and bacteriologic culture. Contents, especially in the small intestine, can 
be preserved in a separate, sterile container or ca 15 cm of intestine can be ligated at 
each end for transport to the laboratory. 
Due to the proclivity of these organisms for post-mortem invasion, 
euthanasia and necropsy is much preferable to examination of cadavers, especially if 




Fresh tissues should be transported to the laboratory as rapidly as possible, 
and may be shipped on wet ice. Freezing may reduce the titre of organisms and toxin 
present, but is an acceptable alternative if shipping must be delayed for more than 24 
hours. 
 
4.3.4. Laboratory aspects of diagnosis 
4.3.4.1. Direct smears 
Gram-staining of direct smears from affected tissues is often useful in 
providing an indication of clostridial activity in a case. Comparison of organisms 
visualised with organisms isolated by bacteriologic culture is useful in determining 
the effectiveness of the latter. 
Cells of C. perfringens stain as Gram-Positive-to-Gram-variable, short, 
plump rods with blunt ends ("box cars"). Staining of C. septicum may be uneven, 
regardless of the age of the culture. Cells are straight-to-curved rods, occurring singly 
or in pairs, but may also be pleomorphic, especially in lesions. Spores are oval, 
subterminal, and swell the cell. 
The fluorescent antibody test is a useful direct, rapid differential aid for 
diagnosis of abomasitis. Conjugates are specific for myonecrosis agents, including C. 
chauvoei, C. novyi, C. septicum, and C. sordellii, but unfortunately none are routinely 
available for detection of C. perfringens. Nonetheless, a positive fluorescence assay 
for C. septicum in tissues from a freshly-necropsied clinical case is strongly 
suggestive of aetiology. 
 
4.3.4.2. Toxin detection 
Culture supernatant fluids or eluates from gut contents (trypsin-treated or 
untreated, neat or mixed with antiserum) may be examined for C. perfringens toxins, 
either in mice (injected IV) for lethality or guinea pigs (injected ID) for 
dermonecrosis. Toxin detection strongly suggests the existence of disease, but 
lability of these proteins, especially β toxin, may cause false negatives.  
However, demonstration of toxins by in vivo assay has become less 
common, due to expense, variability of results and humanitarian concerns. 
Immunoassays have been developed for detection of toxins produced by C. 
perfringens, and the most common of these are enzyme immunoassays. These 
commercially available assays are quite helpful in establishing a diagnosis. 
Detection of C. septicum α toxin is not a routine part of the diagnostic 
protocol. 
 
4.3.4.3. Bacterial quantitation 
Bacterial quantitation may be useful in establishing a diagnosis, but relative 
numbers (relative to “normal” animals or animals affected by other syndromes), 
rather than actual counts, are usually sufficient. This is more likely to provide 
practical information in, for example, type A enteritis in piglets (where lesions are 
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minimal) than in cases (bovine or ovine abomasitis) dominated by severe clinical 
signs and lesions.   
 
4.3.4.4. Isolation and identification 
Methods for isolation of enteric clostridia are as diverse as the veterinary 
microbiologists themselves. However, many would inoculate a pre-reduced, non-
selective, blood-based agar medium. Increasing the agar content to 2% and 
supplementing with phenyl-ethanol help prevent swarming. Incubation is at 37 °C in 
an oxygen-free atmosphere, usually with hydrogen, nitrogen, and carbon dioxide. 
Presumptive identification of C. perfringens on this medium can often be made from 
its colony morphology (circular-to-stellate and smooth) and from the presence of a 
distinctive double zone of haemolysis. The inner zone of complete β-haemolysis is 
not always present, in that about 2% of isolates do not produce θ toxin, but strains 
failing to produce the outer zone of incomplete haemolysis (an effect of α toxin) are 
rare-to-non-existent. Growth of C. perfringens on egg yolk agar is characterised by 
lecithinase and lipase activity. 
Clostridium perfringens and Clostridium septicum are likely to be aetiologic 
agents if they predominate in specimens obtained soon after death or euthanasia. 
Colonies of C. septicum are circular, 1–5 mm in diameter, and have rhizoid-to-
irregular margins. They are slightly raised, translucent, grey, glossy and β-
haemolytic. Many strains cultivated on media without phenyl-ethanol produce an 
almost invisible film over the entire agar surface due to swarming. 
PCR genotyping can be a useful diagnostic tool in C. perfringens infections. 
Genes for α, β, ε, ι, and β2 toxins, as well as enterotoxin, can be detected in a 
multiplex assay; the correlation between major toxin phenotype and genotype 
approaches 100%, although silent enterotoxin and β2 toxin (apparently) genes have 
been reported.  
If isolates of genotype C are obtained from animals with typical lesions in 
non- vaccinated herds, diagnosis is unequivocal. Diagnosis of genotype A infections 
is more complex, but if clinical signs and lesions are compatible and, if other 
aetiologies are ruled out by concurrent microbiologic examination, a diagnosis of 
type A enteritis should be considered. 
 
4.3.4.5. Interpretation criteria for lab results 
The major stumbling block in diagnosis of clostridial abomasitis is 
answering the question of aetiologic agent versus post-mortem invader. This is 
especially an issue with C. septicum. Thus, diagnostic data should be interpreted 
soberly, allowing for the possibility of alternative aetiologies and isolation of 
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It is challenging to separate bovine enteritis and enterotoxaemia into distinct 
syndromes, although the latter term seems to be reserved for cases in which sudden 
death is the hallmark.   
 
Table 5.1: Clostridium and intestinal diseases in cattle 
 
Species Clinical entity Host 
perfringens 
type A 
















Enteritis, with or without 





Haemorrhagic enteritis and sudden death 
 
Young calves 
septicum Haemorrhagic enteritis Neonates and 
young calves 
sordellii Possible involvement in enteritis and 
sudden death 
Any age 
difficile Possible involvement in mild enteritis Neonates and 
young calves 
 
5.1. Clostridium perfringens 
Enteritis and enterotoxaemia can be produced in calves by all C. perfringens 
toxin types (Table 5.1). Nevertheless, incidence of each toxin type can vary widely 
geographically (even within Europe) and some regions can be free of some of them. 
Cattle breed sensibility  variations may also exist. 
Information about distribution of C. perfringens genotypes is accumulating 
as more diagnostic and research laboratories adopt PCR-based methods for toxin 
gene detection.  There is evident disparity in prevalence of the various genotypes by 
geographic region, although type A remains the most commonly-isolated type 
overall. In North America, type A predominates, although types C (mainly from 
neonatal enteritis cases), D (mainly from ovine or caprine enterotoxaemia) and Erom 
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bovine neonatal hemorrhagic enteritis) are not uncommon. Nearly 97% of isolates 
from various sources in Belgium were non- enterotoxigenic type A, including all of 
those from cattle and horses with enterotoxaemia. Type C was limited to swine, type 
D was isolated from small ruminants with enterotoxaemia, and types B and E were 
not found. Types C and E were detected in Poland, while in Austria, type A was most 
common in sheep and type D in goats. Enterotoxaemia in goats, reindeer, and 
blackbuck were caused by type E. Type C was found only in swine. In Northern 
Greece, type B is apparently most prevalent in lambs (nearly 50% of cases of lamb 
dysentery), although type C accounted for 20% and type D 28% of all isolates. Types 
A and E were not found.  
 
5.1.1. C. perfringens type A (α toxin) 
Toxins produced by type A strains (e.g., α and θ toxins) are systemically 
lethal under experimental conditions, and it is tempting to speculate as to a systemic 
role for these toxins in intestinal infection. However, unlike disease caused by types 
B, C, and D, there is little or no direct evidence that toxaemia occurs in animals 
experiencing sudden death due to type A infection.   
Type A-associated enteritis is more common in beef and dairy calves, 
including those raised for veal, than in lambs. Feeding of icy colostrum in large 
volumes is a risk factor, especially if contaminated. Many affected calves are 
tympanic, depressed and lack appetite. The clinical course is seldom more than 12 
hours and gross lesions consist typically of haemorrhagic gastroenteritis. The 
abomasum is often dilated and has emphysematous walls and folds. Haemorrhagic 
lesions may extend from abomasum into caecum and proximal colon. Microscopic 
examination reveals severe necrosis and haemorrhage, with micro-colonies of Gram-
Positive rod-shaped bacteria and emphysema in mucosa and submucosa. As in the 
disease in lambs, this syndrome seems to be centred in the small intestine, which 
yields heavy growth of C. perfringens upon bacteriologic culture.  
Enterotoxaemia is more common in small ruminants than in cattle. 
Nevertheless, Belgian Blue calves seem particularly prone to the “enterotoxémie” 
form of the disease, and > 10,000 die annually in Belgium. Affected animals 
experience haemorrhagic enteritis, with a high case fatality rate, and sudden death is 
common. Lesions may extend into the colon. Microscopic examination of affected 
tissues reveals necrosis of the villous tips, enterocytes, and the vascular axis of villi.  
Type A C. perfringens aetiology of this form of enterotoxaemia has not been 
confirmed by fulfilment of Koch’s postulates, although inoculation of calves with 
pure cultures inconsistently reproduces enteritis. Numbers of C. perfringens in 
affected tissues (107–108 colony-forming units per gram of mucosa) is significantly 
higher in typically affected calves than in controls, although there may be no useful 
difference in counts on individual animals. When lesions are localised, numbers are 
substantially higher in lesions than in adjacent normal tissue. Thus, it may be that C. 
perfringens, normally present in small numbers in the small intestine, multiplies to 
higher numbers when conditions allow. Alteration of flora by sudden dietary change 
may also be an inciting factor. 
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5.1.2. C. perfringens type B (α, β and ε toxins) 
Type B is best-known as the cause of lamb dysentery, but it also infects 
calves. They develop inappetence, abdominal pain, and bloody diarrhoea, and 
become recumbent and comatose. This is a true enterotoxaemia, and both β and ε 
toxins are demonstrable in the gut and in effusions throughout the body. Case fatality 
rates approach 100% and sudden deaths are common. Gross lesions include extensive 
haemorrhage and ulceration of the small intestine, and devastating haemorrhagic 
necrosis is observed microscopically.  
Older lambs may develop a chronic condition called “pine,” in which 
infection of the abomasum and intestine manifests as chronic abdominal pain without 
diarrhoea. This is apparently quite rare in calves. 
 
5.1.3. C. perfringens type C (α, β toxins) 
Newborn animals are typically most susceptible to infections by C. 
perfringens type C, perhaps due to ready colonisation of the gut in the absence of 
established normal intestinal flora. Alteration of flora by sudden dietary change may 
also be an inciting factor.  
Infection of calves by type C may be sporadic, affecting only occasional 
calves in vaccinated herds. However, morbidity rates can reach 50%, with case 
fatality rates of 100% in non-vaccinated herds. This is perhaps most common in very 
young calves, where lack of normal flora provides unoccupied niches for 
multiplication of type C and production of β toxin. These animals often experience 
peracute disease, with diarrhoea and dysentery. Calves infected near the end of the 
neonatal period or later may have a longer clinical course and lower mortality rate, 
but seldom recover to normal production. Intestinal lesions are extensive and severe, 
but death may be due ultimately to β toxaemia. Tetany and opisthotonos are not 
uncommon. As in type B disease, hallmark signs are haemorrhagic necrosis affecting  
mucosa, submucosa, and muscularis mucosa of jejunum and ileum, and emphysema 
is also commonly observed in these tissues. The proximal colon may be affected in 
some cases. 
 
5.1.4. C. perfringens type D (α, ε toxins)  
Enterotoxaemia in suckling calves often follows dietary change. If a calf is 
denied access to the dam and then overfeeds when access is re-established, 
undigested nutrients entering the small intestine can stimulate rapid growth of type 
D. ε toxin has permease-like activity, facilitating its own absorption, and producing 
toxaemia, often with minimal enteritic lesions. Effects of ε toxin on the CNS and 
other tissues cause sudden death, preceded in some cases by clinical signs such as 
opisthotonos and convulsions. Focal encephalomalacia, which is apparently a chronic 
manifestation of enterotoxaemia in sheep, is uncommon in calves. Disease occurs 
rarely in adult cattle.  
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5.1.5. C. perfringens type E (α, ι toxins)  
Dogma has held that type E enterotoxaemia in calves is rare. However, 
strains of type E comprise 3–5% of isolates from domestic animals with enteritis, and 
perhaps as many as 50% of isolates from calves experiencing haemorrhagic enteritis 
and sudden death in North America. Lesions are very similar to those produced by 
types A, B, and C in calves. 
Strains of type E produce ι toxin, the A component of which is ADP-
ribosylates actin. Little is known about pathogenesis, but ι toxin is assumed to play 
an important role. The enterotoxin gene, cpe, is detected routinely in type E isolates, 
but is silent.  
 
5.1.6. Enterotoxigenic C. perfringens 
Enterotoxigenic strains of C. perfringens have been detected in many 
species of animals, including cattle, but there is no direct evidence of a role for 
enterotoxin in bovine enteric disease. 
 
5.2. Clostridium sordellii and Clostridium difficile 
5.2.1. Clostridium sordellii 
Clostridium sordellii is a common intestinal organism in cattle, and is not 
uncommonly a cause of myositis and sudden death. Large numbers of urease-
negative strains have been found (in the company of large numbers of C. perfringens 
type A) in the intestines of 20% of Belgian Blue calves experiencing “sudden death 
syndrome”. Curiously, these strains were non-toxigenic (lacking major toxin genes). 
Enteritis has been experimentally produced with toxigenic strains of the organism. 
Two toxins, one haemolytic and one lethal, are antigenically and 
pathophysiologically similar to C. difficile toxins A and B, respectively. Like those 
toxins, Clostridium sordellii lethal toxin (TcsL) glucosylates Rac and Ral. But this 
toxin differs from other large clostridial toxins in its glucosylation of Ras. 
 It is assumed that these toxins play a role in pathogenesis. 
 
5.2.2. Clostridium difficile 
Clostridium difficile has been isolated from calves with diarrhoea, and 
inoculation with either purified toxins or spores results in mild diarrhoea. However, 
there is insufficient information at present to suggest that infection by this organism 
is an important cause of neonatal enteritis in calves. 
 
5.3. Diagnosis 
Diagnosis can be based upon clinical signs, gross and microscopic findings 
at necropsy, Gram- and fluorescent antibody staining of direct smears, bacteriologic 
culture, and, in the case of C. perfringens, typing of isolates. 
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5.3.1. Clinical and necropsy findings 
5.3.1.1. Infection by Clostridium perfringens types A, B, C, and E 
Affected animals may experience peracute death, or may have a brief 
clinical course with abdominal pain, hemorrhagic diarrhoea, and central nervous 
system signs. At necropsy, lesions may be seen in the abomasum, but the most 
dramatic are haemorrhagic necrosis, emphysema, and oedema in the small intestine. 
These may extend into the proximal colon. 
 
5.3.1.2. Infection by Clostridium perfringens type D 
Type D enterotoxaemia may or may not be accompanied by haemorrhagic 
enteritis. It is not unusual for calves to experience sudden death, or central nervous 
system signs such as opisthotonos, and have no remarkable changes in the small 
intestine. In others, the clinical picture is more like that in goats, with chronic 
fibrinous or haemorrhagic diarrhoea. In either case, if lesions are present at necropsy, 
they resemble those in infections by types A, B, C, and E. 
 
5.3.1.3. Infection by Clostridium sordellii and C. difficile 
Experimental infection with C. sordellii results in passage of soft faeces 
containing blood and mucus within a week after inoculation. Mild inflammatory 
changes have been reported. Culture filtrate produces similar clinical and 
pathological changes, with mild congestion and inflammation in jejunal and ileal 
mucosa and dilation of crypts and capillaries in colonic mucosa. 
Gross lesions are apparently absent in C. difficile infection in calves. 
Animals infected experimentally or exposed to toxins A or B experience diarrhoea, 
but with only very mild inflammatory change in the small intestine and colon. 
 
5.3.2. Sampling procedures 
Tissues should be preserved in buffered formalin for histopathologic 
examination. A portion of affected intestine should be collected fresh for direct 
examination and bacteriologic culture. Contents, especially in the small intestine, can 
be preserved in a separate, sterile container or ca 15 cm of intestine can be ligated at 
each end for transport to the laboratory. 
Due to the proclivity of these organisms for post-mortem invasion, 
euthanasia and necropsy is much preferable to examination of cadavers, especially if 
the interval since death is > 4 h. 
 
5.3.3. Transport 
Fresh tissues should be transported to the laboratory as rapidly as possible 
and may be shipped on wet ice. Freezing may reduce the titre of organisms and toxin 




5.3.4. Laboratory aspects of diagnosis 
5.3.4.1. Direct smears 
Gram-staining of direct smears from affected tissues is often useful in 
providing an indication of clostridial involvement. Comparison of organisms 
visualised with organisms isolated by bacteriologic culture is useful in determining 
the effectiveness of the latter. 
Cells of C. perfringens stain as Gram-Positive-to-Gram-variable, short, 
plump rods with blunt ends ("box cars"). Cells are straight-to-curved rods, occurring 
singly or in pairs, but may also be pleomorphic, especially in lesions. Spores are 
oval, subterminal, and swell the cell. 
 
5.3.4.2. Toxin detection 
Culture supernatant fluids or eluates from gut contents (trypsin-treated or 
untreated, neat or mixed with antiserum) may be examined for C. perfringens toxins, 
either in mice (intravenously injected) for lethality or guinea pigs (intradermically 
injected) for dermonecrosis. Toxin detection strongly suggests the existence of 
disease, but lability of these proteins, especially β toxin, may cause false negatives.  
However, demonstration of toxins by in vivo assay has become less 
common, due to expense, variability of results, and humanitarian concerns. Enzyme-
immunoassays have been developed for detection of toxins produced by C. 
perfringens. 
Detection of C. difficile toxins is also possible by immunoassays and 
detection of toxins in rectal swab samples or colonic contents is suggestive of toxin 
action in the gut. Tests for detection of C. sordellii toxins are not in routine 
diagnostic use. 
 
5.3.4.3. Bacterial quantitation 
Bacterial quantitation in the small intestine may be useful in establishing a 
diagnosis, but numbers (relative to “normal” animals or animals affected by other 
syndromes), rather than actual counts, are usually sufficient. This is more likely to 
provide practical information in, for example, type A enteritis in piglets (where 
lesions are minimal) than in calf disease, which is dominated by severe clinical signs 
and lesions.   
 
5.3.4.4. Isolation and identification 
Methods for isolation of enteric clostridia are as diverse as the veterinary 
microbiologists themselves. However, many would inoculate a pre-reduced, non-
selective, blood-based agar medium. Increasing the agar content to 2% and 
supplementing with phenyl-ethanol both help prevent swarming. Incubation is at 
37°C in an oxygen-free atmosphere, usually with hydrogen, nitrogen, and carbon 
dioxide. Presumptive identification of C. perfringens on this medium can often be 
made from its colony morphology (circular-to-stellate and smooth) and from the 
presence of a distinctive double zone of haemolysis.  
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The inner zone of complete β-haemolysis is not always present, in that about 
2% of isolates do not produce θ toxin, but strains failing to produce the outer zone of 
incomplete haemolysis (an effect of α toxin) are rare-to-non-existent. Growth of C. 
perfringens on egg yolk agar is characterised by lecithinase and lipase activity. 
Isolation of C. difficile is less likely to be meaningful, in that it is often found in the 
absence of disease. 
 
5.3.4.5. Interpretation criteria for lab results 
The major stumbling block in diagnosis of clostridial abomasitis is 
answering the question of aetiologic agent versus post-mortem invader. Thus, 
diagnostic data should be interpreted soberly, allowing for the possibility of 
alternative aetiologies and isolation of clostridia as a red herring. 
Diagnosis of infection by C. sordellii or C. difficile in cattle is equivocal at 
best. Isolation of C. sordellii raises the possibility of infection, given the 
experimental infection of calves with this organism. However, it is important to note 
that isolates from the bovine intestine are often incapable of producing the large 
clostridial toxins, and might not be expected to be virulent.   
Clostridium difficile-associated disease has not been produced 
experimentally in calves. Thus, detection of the organism has relatively little 
meaning. Toxin detection is the gold standard for diagnosis and, since inoculation 
with purified toxins produces an effect in the calf gut, one might expect toxin 
positivity to indicate toxin action in the gut. This will require further study by both 
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6. Enteritis and enterotoxaemia in small ruminants 
 
E. Bourtzi-Hatzopoulou, E. Petridou and A. Minas 
 
6.1. Introduction 
Clostridial enterotoxaemia is an acute, highly fatal infectious disease in 
animals. The clostridial group of diseases is caused by various toxin types of C. 
perfringens. In parts of Europe, especially in some Mediterranean countries, 
enterotoxaemia is the most common clostridial disease affecting sheep. Types B, C 
and D are of major importance to sheep and goats, while the role of type A 
enterotoxaemia in small ruminants is not clear. In small ruminants, C. perfringens 
types B, C and D cause lamb dysentery, struck and pulpy kidney disease 
respectively, while type E is not implicated. 
 
6.2. Type A enterotoxaemia 
Type A, which only produces the α toxin, is distributed worldwide and is 
well adapted to survive in the soil, as well as in the alimentary tract of animals and 
humans (Aiello, 1998). It is commonly found as part of the normal intestinal 
microflora of lambs and kids (Songer, 1996). Regarding the involvement of type A in 
small ruminant enterotoxaemia, some researchers believe that it is occasionally 
pathogenic, while its role in disease production is considered doubtful by others 
(Niilo, 1980). Recently, a survey investigating lamb dysentery in Greece revealed 
that C. perfringens type A was not isolated to diseased lambs, but was also present in 
the intestinal tract of healthy animals (Gkiourtzidis et al., 2001). It is well known that 
this toxigenic type is responsible for haemolytic disease in enterotoxaemic lambs, 
“yellow lamb disease”, which has been described in the USA (Songer, 1998), but is 
unknown in most parts of the world.  
 
6.3. Lamb dysentery 
C. perfringens type B causes dysentery in lambs and kids. The disease is a 
severe and often fatal haemorrhagic enteritis, affecting these animals during the first 
3–4 days of their life, although it may also affect older lambs and kids up to 2–3 
weeks old. Because of the age of the affected animals, the assumption is that the 
micro-organism is usually acquired at birth from contaminated udder teats or from 
the hands of the farm labourer who looks after the animals (Martin and Aitken, 
1999). The mixture of ingested virulent bacteria and large amounts of milk in the 
stomach favours multiplication of bacteria, which adhere to the small intestinal 
mucosa and produce large quantities of β toxin. The high susceptibility of this age 
group may be explained by the absence of microbial competition, low proteolytic 
activity in the neonatal intestine and low levels of pancreatic secretion (Biberstein 
and Hirsh, 1999). It is well known that β toxin is highly sensitive to the presence of 
proteolytic enzymes (trypsin) and this susceptibility partly explains why the disease 
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targets newborns. In the absence of trypsin (colostrum contains antitrypsin 
substances), β toxin retains its potency and leads to the onset of the disease 
(Radostits et al., 2000).  
Outbreaks occur mainly towards the end of the lambing and kidding period. 
Sudden death without symptoms is the most frequent appearance of the disease in 1–
4 day old, strong, well-fed lambs and kids. In acute cases, cessation of feeding and 
severe abdominal pain is accompanied by bloody diarrhoea, with recumbency, coma 
and death (Swift et al., 1988). Incidence may be as high as 30%. Kids are more 
susceptible than lambs and their mortality can reach 100%. Death usually occurs 2–
12 hours after the onset of symptoms.  
In post-mortem examination, severe haemorrhagic enteritis affecting parts of 
the ileum, with blood-tinged fluid in the peritoneal cavity and pericardial sac are the 
major findings. Ulceration of congested intestinal mucosa may also be present. The 
stomach contains clotted milk, while petechiae can be found in the stomach mucosa 
(Timoney et al., 1988).   
In older lambs and kids, aged 2–3 weeks, the disease is characterised by 
listlessness, unwillingness to suckle and abdominal pain followed by foetid 
diarrhoea. The most prominent lesions are those of extensive haemorrhagic enteritis. 
The intestinal mucosa is congested and ulceration and necrosis may be present in the 
intestinal walls. The intestinal lumen and peritoneal cavity often contain 
haemorrhagic fluid. These animals survive for a longer period, 2–3 days (Swift et al., 
1988). 
C. perfringens type C causes haemorrhagic enteritis in newborn lambs and 
kids worldwide. Beta toxin is also the major pathogenic factor here. Under 
favourable conditions, clostridia proliferate in the intestinal tract, leading to 
production of large quantities of toxin. Outbreaks are sporadic, affecting mostly 
strong, well-nourished lambs and kids younger than 3 weeks of age. Symptoms and 
lesions resemble those seen in type B lamb dysentery (Biberstein and Hirsh, 1999). 
Death occurs within hours of onset of the disease. Sudden death may occur without 
the observance of bloody diarrhoea or other symptoms. At necropsy, generalised 
haemorrhagic enteritis is present, but lesions are commonly confined to the jejunum 
and ileum. Distinct necrotic ulcers are not a feature. In severe cases, free blood may 
be present in the lumen of the intestine. Mesenteric lymph nodes are oedematous and 
sometimes haemorrhagic (Martin and Aitken, 1999 
 
6.4. Struck 
The disease in adult sheep, caused by C. perfringens type C, is known as 
“struck” because of the rapid and sudden death of the affected animals. Struck is well 
known in defined regions in different countries and usually occurs in adult sheep and 
goats at pasture, especially during the spring. Bacteria are ingested from the soil or 
may be present in small numbers in the intestinal tract of normal animals. 
Predisposing factors, such as a sudden dietary change, influence rapid multiplication 
of the micro-organism in the intestinal tract and lead to production of large quantities 
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of  toxin. Βeta toxin plays a major role in the pathogenesis of the disease. As with 
other enterotoxaemiae, animals in good condition are most likely to be affected. The 
peracute form of struck manifests as sudden death, although some animals may be 
found in terminal convulsions. If found alive and suffering from the acute form, 
sheep are dull, reluctant to be moved and lame. Losses are usually sporadic 
(Radostits et al., 2000).  
Post-mortem findings are often absent. Haemorrhagic enteritis affects the 
jejunum and ileum, but few ulcers are present. Most often, patchy hyperaemia in the 
small intestine, and pericardial and thoracic effusion are present. Accumulation of 
fluid in the peritoneal cavity, along with congestion of peritoneal vessels and local 
haemorrhages, may be found (Kimberling, 1988).  
 
6.5. Pulpy kidney disease 
Type D enterotoxaemia (pulpy kidney disease) represents the most common 
appearance of enterotoxaemia in sheep and goats and has a worldwide distribution. 
Affected animals are usually in very good condition and well-nourished. Pulpy 
kidney disease occurs in all breeds and in either sex, but is usually encountered in 4–
10 week old lambs and/or in lambs older than 6 months. Adults may be affected 
sporadically, but losses can be high. In most areas of Greece, pulpy kidney disease is 
the most commonly diagnosed type of clostridial disease (Papadopoulos, 2000).  
The vast majority of cases of enterotoxaemiae appear when animals change 
their nutritional pattern. Pulpy kidney disease may occur during any season, but the 
highest incidence comes during the months following weaning, when fattening takes 
place. In some countries, most cases of the disease are diagnosed during the summer 
when sheep are grazing in harvested wheat fields. During this period, animals 
consume wheat straw and a large amount of wheat grain, which favours the 
multiplication of clostridia and produces high levels of  protoxin. This process 
requires activation by trypsin. The high concentration of  toxin slows intestinal 
motility, increases the permeability of the intestinal wall to toxins and aids the 
passage of toxin into the blood. Once in the blood, the toxin produces generalised 
toxaemia and leads to development of clinical signs (Quinn et al., 2002).     
In most cases, the disease is peracute and the animals are found dead. Some 
individuals, in subacute cases, may exhibit neurological signs, such as ataxia, 
blindness or convulsions just prior to death. Hyperglycaemia, together with 
glucosuria, is a typical finding of the disease. Gross lesions are variable but, in 
peracute cases, may be absent (Timoney et al., 1988). These animals often have the 
rumen and abomasum filled with concentrated feed. The only post-mortem finding 
may be scattered hyperaemic areas in the intestines, especially in the ileum. The 
pericardial sac is often distended, with pale yellow or straw-coloured fluid. In 
addition, pulmonary oedema is common. Both pericardial and endocardial 
haemorrhage are present. ε toxin contributes to rapid autolysis of the kidneys, which 
is often the only reliable indication of the disease in animals necropsied within a few 
hours of death. Diagnosis can be established by histology of the brain, where focal 
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symmetrical encephalomalacia and symmetrical haemorrhagic lesions in the basal 
ganglia and midbrain may be present (Buxton et al., 1978).  
 Pulpy kidney disease is more frequent and severe in sheep than in goats 
because of their differing nutritional habits. The onset of neurological signs, followed 
by sudden death, is more common in sheep. Goats are commonly affected with 
haemorrhagic enterocolitis. The chronic form of pulpy kidney disease occurs more 
often in goats, and these animals are more likely to show signs of diarrhoea before 
death (Uzal and Kelly, 1996). 
 
6.6. Diagnosis 
In most veterinary laboratories, routine diagnosis of lamb dysentery and 
enterotoxaemia in small ruminants is based on evaluation and interpretation of the 
following: clinical signs, gross and microscopic lesions, microbiological examination 
of appropriate specimens and the detection of toxin in gut content and/or in the 
bloodstream. 
 
6.6.1. Clinical and necropsy findings 
The criteria for clinical and necropsy diagnosis of the disease have already 
been described. In most cases, farmers are alarmed by the sudden death of newborn 
or adult animals. In order to avoid post-mortem invasion, liver, spleen and small 
intestine specimens (duodenum) are taken rapidly from those recently dead or 
euthanised animals exhibiting clinical symptoms of the disease. 10–20 ml of gut 
content is collected in a universal container (to which 1–2 drops of chloroform may 
be added), and is submitted to a laboratory where an ELISA or mouse neutralisation 
test can be performed (Matthews, 1999).  
 
6.6.2. Laboratory aspects of diagnosis 
The results of bacteriological culture must be interpreted with caution 
because C. perfringens strains are present in the gut of apparently healthy animals 
and can penetrate tissues of cadavers within a few hours of death (Quinn et al, 1994). 
Enumeration of C. perfringens from small intestine mucosa or content (the presence 
of an average of 10–12 bacteria per optical immersion field is a significant finding), 
can be an indicator of the presence of disease (Gkiourtzidis et al., 2001). 
Enumeration is achieved by smears with direct microscopy and/or culture in selective 
media, or by serial ten-fold dilutions of gut content from recently dead animals. 
Detection of one of the major toxins of C. perfringens can be a useful diagnostic 
finding, but does not necessary confirm the existence of disease, since toxins can be 
found in small quantities in the gut of apparently healthy adult animals.  
The traditional mouse or guinea pig toxin neutralisation test is sensitive for 
the detection of α, β and ε toxins, but β may be destroyed if there is a delay with 
small intestinal contents reaching the laboratory. Failure to demonstrate the presence 
of toxin in the intestinal centrifuged supernatant (ileal) does not necessarily exclude a 
diagnosis of clostridial enterotoxaemia. Until recently, the mouse or guinea pig test 
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was widely used to demonstrate and identify major toxins in the small intestine, in 
the bloodstream and/or in the supernatant of C. perfringens culture. This method still 
remains the most valuable, but has now become less common on grounds of animal 
welfare, variability of results and high cost (Songer, 1996).  
ELISAs can be used as an alternative to in vivo assays for demonstrating 
toxin in the same fluids. The sensitivity and specificity of ELISA for detection of C. 
perfringens toxins almost match those of mouse or guinea pig neutralisation 
methods. Failure to demonstrate toxins by ELISA may be as significant as by in vivo 
assay because of the lability of these toxins in the presence of proteases (Biberstein 
and Hirsh, 1999).  
Polymerase chain reaction (PCR) can be employed to detect gene coding for 
the four major toxins (α, β, ε and ι toxins), for the recently described β2 toxin 
(Gkiourtzidis et al., 2001), and for enterotoxin. 
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Clostridia can cause enteric disease in pigs which is recognisable from 
clinical or pathological observations by the veterinarian and the farmer. Clostridial 
enteritis and enterotoxaemia occur principally in the sucking pig as recognisable 
syndromes, but these organisms can cause disease in older pigs, where the clinical 
signs are less easily identifiable. In addition to the specific syndromes described 
below, the existence of clostridia in the gut flora throughout life means that the 
organisms can respond rapidly to any change in enteric environment, colonise an 
enteric lesion and contribute to the clinical signs and pathology. Conditions in which 
clostridia colonise lesions are difficult to diagnose from clinical signs or pathology 
alone as they depend on the initiating disease and the presence of the organisms is 
usually confirmed by laboratory means such as histopathology and bacterial 
isolation. Finally, there is a group of conditions in the older weaned pig and in adults 
where sudden death occurs, associated with the presence of inflamed intestines. The 
frequent presence of clostridia in the intestinal contents of these animals may be 
related to the cause, but the sudden onset and rapid post-mortem change make their 
involvement subject to speculation. Experimental reproduction of this type of 
syndrome is difficult and, until it can be done repeatedly, the role of clostridia in 
these syndromes remains a matter of debate.   
 
7.2. Defined syndromes in the sucking pig 
 
Syndromes caused by Clostridum perfringens type A, type C and/or type B  
and C. difficile can be distinguished in the sucking pig. In all cases the identification 
of the syndrome on the ground is based on a combination of time of occurrence in the 
life of the pig, clinical signs and pathology. Confirmation is by demonstration of the 
agent and its toxins and is not considered here. Of these syndromes, C. perfringens 
type C is the most easily diagnosed on the ground. The presence of β2 toxin genes in 
C. perfringens strains involved in diarrhoea cannot yet be associated with any 
specific syndrome. 
 
7.2.1. Clostridium perfringens type C enterotoxaemia 
Clostridium perfringens type C produces a fatal necrotic and haemorrhagic 
enteritis in piglets under 7 days of age and may cause chronic infection in older 
piglets (Mackinnon, 1989). It occurs in most pig-keeping countries. Outbreaks often 
follow the introduction of infected breeding stock and disease persists in herds for up 
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to 2 months, but, where new stock is constantly introduced, outbreaks may continue 
for up to 15 months. Farrowing houses or areas may become heavily contaminated. 
Transmission of vegetative organisms occurs through faeces. Other animal species 
may be infected and may theoretically represent a source of infection for pigs.  
Typically, three or four litters or part of a litter in a herd may be affected by 
severe disease but up to 50 litters have been reported to be affected in some 
outbreaks. Herds may be infected with the organism but typical disease may be 
absent. In some cases this results from early treatment with antimicrobials as 
treatment or prevention, but most commonly it results from the increasing practice of 
including C. perfringens type C toxoid in vaccines given to sows to prevent piglet 
diarrhoea (Bergeland, 1972; Ripley and Gush, 1983). Where protective antibody is 
present in the colostrum at adequate levels, no disease will be seen. Where levels are 
inadequate or intake is insufficient, the clinical signs may develop slightly later and 
be mild and difficult to recognise. When individual pigs have not been protected and 
develop the disease, its occurrence in these isolated animals may not be noticed. 
  
7.2.1.1. Clinical signs 
Affected pigs are normal at birth and may sicken on the first, or usually, the 
second day of life (36 hours after birth) and usually die within 12-24 hours of the 
onset of clinical signs. High mortality rates and the passage of reddish faeces are 
always suggestive of the presence of C. perfringens type C enterotoxaemia. A 
dramatic, profuse diarrhoea occurs and rapidly becomes claret-coloured. The 
hindquarters may be soiled with bloody faeces, but in some cases, the heat of creep 
lamps dries the faeces and the presence of diarrhoea may be overlooked. Affected 
piglets become weak, collapse and die. Piglets about to die may have greenish 
discolouration of the abdomen, subnormal temperatures or severe blood-stained 
diarrhoea. Some may be found dead without clinical signs being observed. Where 
acute disease is present, all members of the litter usually die. 
In more chronic cases, shreds of necrotic material may appear in the 
reddish-brown watery faeces and chronically-affected animals become very thin and 
pale before death. Depression of growth rate may be a feature in chronically-infected 




Piglets which have died suddenly from C. perfringens type C 
enterotoxaemia are often in good condition and there may be no obvious presence of 
faeces on the perineum. Insertion of a probe or gentle pressure may allow faeces to 
be extruded. There are usually diarrhoeic and reddish in colour. There may be 
greenish discolouration of the abdomen, but the most obvious post-mortem finding is 
haemorrhagic enteritis in the jejunum.. The jejunum of affected piglets is swollen 
with an angry purplish-red colour and if death has been sudden, is usually full of 
pasty, blood-stained contents. In more chronic cases, the serosa of the intestine may 
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be pale and unevenly swollen. A diptheritic layer is present on the mucosa and the 
contents are watery with diphtheritic material.   
 
7.2.1.3. Laboratory 
Samples for further investigations should include unopened affected small 
intestine for bacteriology and fixed bowel wall for histopathology (Arbuckle, 1972). 
Laboratory examination is necessary to confirm the identity of the organism 
present, as C. perfringens type B may also be found in this syndrome and it is not 
possible to distinguish clinically or pathologically between the two. 
 
7.2.2. Clostridium perfringens type A enteritis and enterotoxaemia 
C. perfringens type A causes, in piglets, a syndrome resembling that caused 
by C. perfringens type C but much less severe (Estrada Correa and Taylor, 1986; 
Nabuurs et al., 1983; Songer and Glock, 1998; Taylor and Olubunmi, 1982). The 
disease appears to be present in many countries and to be fairly common where it is 
recognised. As the organism is ubiquitous, being present in soil, intestinal contents  
and faeces, the disease could occur at any time, but is most commonly seen affecting 
some of the piglets in several litters on the same farm.  
  
7.2.2.1. Clinical signs 
C. perfringens type A may cause sudden death within 48 hours of infection 
or birth in non-immune piglets but more commonly causes diarrhoea. The main 
clinical signs are a pasty diarrhoea, loss of condition, lack of fever and low mortality 
beginning at 36-48 hours after birth. Affected diarrhoeic sucking piglets appear dull 
with sunken flanks and evidence of loss of condition. The perineal area is heavily 
pasted with yellowish faeces. The faeces present on the pen floor frequently contain 
some mucus but are often creamy or pasty containing flecks of fresh blood or of a 
pinkish tinge. Marked depression of growth occurs. A transient watery diarrhoea may 
be seen on some occasions with no mortality. Affected piglets rarely die, but those 
approaching death have low rectal temperatures and discoloured abdomens. 
 
7.2.2.2. Pathology 
The small intestine of dead piglets is often congested and its contents 
creamy or watery, but not blood-filled. Necrotic areas may be seen on the mucosal 
surface of the jejunal and ileal mucosa with a dissecting microscope and villous 
atrophy is obvious. The post-mortem findings do not prove that this is a case of C. 
perfringens type A enteritis.  They do, however, distinguish the condition from that 
caused by Types C and B, as affected animals do not have the intensely reddened 
small intestine. Few changes, apart from congestion and darkening of the carcase are 
seen outside the gut. Similar findings may be made in chronically infected piglets. C. 
perfringens may contribute, by these changes, to syndromes initiated by other agents. 
C. perfringens type A may be isolated in profuse culture from the small intestines of 
animals with enteritis caused by a number of agents such as transmissible 
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gastroenteritis (T.G.E.), virus, rotavirus, coccidial and cryptosporidial infections. The 
lesions seen are those of the most important contributor to the syndrome present, but 
C. perfringens type A may contribute villous atrophy and the presence of diphtheritic 
material to the final lesions.  
 
7.2.2.3. Laboratory 
Samples of small intestine should be taken for laboratory diagnosis. 
Successful therapy with a penicillin suggests that a Clostridium is involved, 
but confirmation requires the demonstration of C. perfringens type A by direct 
culture or immunofluorescence and the elimination of other causes of similar piglet 
disease such as Type C disease and coccidial infections.   
 
7.2.3. Clostridium difficile typhlocolitis 
C. difficile has occasionally been isolated from the intestines of individual 
pigs with chronic or haemorrhagic diarrhoea, but large-scale outbreaks in piglets in 
Canada, the USA and France confirm that the organism can cause disease. These 
outbreaks have enabled the disease to be distinguished clinically and pathologically 
following post-mortem examination (Songer et al., 2000; Waters et al., 1998; Waters 
et al., 2003). It is not clear to what extent the condition follows routine treatment of 
neonatal pigs with antimicrobials, but their use could contribute to the development 
of this disease.  
 
7.2.3.1. Clinical Signs 
The onset of this disease is anywhere between 1 and 7 days after birth. 
Affected piglets develop dyspnoea, emaciation, mild abdominal distension and 
scrotal oedema. The presence of abdominal distension and scrotal oedema are 
unusual and may suggest C. difficile disease. Diarrhoea may develop and affected 
animals may appear dehydrated with sunken eyes and have perineal faecal staining. It 
can cause preweaning losses of up to 90%, but mortality is usually less than 50%. 
High mortality rates would also be suspicious, particularly if routine treatments with 
antimicrobials had been given early in life. 
 
7.2.3.2. Pathology 
Piglets which have died from C. difficile infection may be dehydrated and 
have perineal faecal staining. There may be distension of the abdomen. The findings 
include ascites, with more than 50 ml of fluid being present in the peritoneal cavity, 
oedema of the mesocolon, hydrothorax and urate deposits in the kidneys. There may 
be scrotal oedema. Affected piglets have full stomachs. The mesocolic oedema is 
accompanied by large intestinal lesions including necrosis of the mucosa. There is 
local exudation of mucus, fibrin and neutrophils into the lumen of the colon and 
caecum and deep ulcers may give rise to transmural necrosis. 
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The post-mortem findings provide reinforcement of the provisional 
diagnosis as ascites, mesocolic oedema and colitis without major small intestinal 
involvement are unusual in piglets of this age group.  
 
7.2.3.3. Laboratory 
Final confirmation of the condition as C. difficile infection comes from 
laboratory demonstration of the organism, its toxin or toxin genes in the large 
intestine. 
The organism can be demonstrated in direct smears of the colonic wall, by 
isolation on difficile agar and its preformed toxins can be demonstrated in colonic 
contents by Reverse Passive Agglutination Tests or ELISA and the presence of the 
B toxin-encoding gene can be detected by PCR. The samples required for this 
condition are portions of the large intestine rather than the small intestine as in the 
other conditions.  
 
7.3. Defined syndromes in the weaned pig 
The identification of clostridial enteritis and enterotoxaemia in weaned pigs 
is difficult, but one condition may be suspected on clinical grounds. The occurrence 
of sudden death associated with volvulus and haemorrhagic enteritis has been 
mentioned above, but the syndrome associated with C. perfringens type A is 
described here. It is a diarrhoea and loss of condition occurring from weaning 
onwards for a variable length of time and at different times in animals of the same 
group. This diarrhoea forms part of the ‘colitis’ complex of diarrhoeas and enteritides 
of weaned pigs and its development can be affected by the composition of the ration 
(Jestin et al., 1985), the presence of antimicrobial therapy or growth promoters in the 
feed and the use of products such as zinc oxide which affect the microbial flora. The 
recent ban on the use of high concentrations of copper and the forthcoming ban on 
the use of antimicrobial growth promoters in the European Union are likely to 
increase the amount of clostridial enteritis and enterotoxaemia in weaned pigs. 
 
7.3.1. C. perfringens type A enterotoxaemia in weaned pigs 
C. perfringens type A is a potential cause of and contributor to the ‘colitis’ 
complex of diarrhoeas. These are diarrhoeas of weaned pigs of any age from weaning 
to slaughter (but particularly from weaning to 40kg), the cause of which is not 
immediately apparent and which may result in loss of performance. Experimental 
infection of weaned pigs with enterotoxigenic strains of C. perfringens of porcine 
origin has resulted in a mild, featureless diarrhoea resembling that from which the 
organisms were isolated. The condition is rarely identified on the ground, largely 
because the majority of diarrhoeas of this type can be attributed to other agents such 
as Brachyspira pilosicoli or Salmonella. The role of C. perfringens type A in these 
diarrhoeas was first identified by Jestin et al. (1985) and confirmed by Estrada 
Correa and Taylor (1988). 
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The condition is present within individual farms, and transfer from farm to 
farm may occur with breeding stock. It is more common under unhygienic 
conditions. There may be an association with feed type and especially with the 
absence of antimicrobial growth promoters (Taylor and Estrada Correa, 1988) such 
as avilamycin. The syndrome of colitis has been identified in a number of countries 
including the UK, France, Belgium, Denmark, The Netherlands, Canada, the U.S. 
and Eire. 
 
7.3.1.1. Clinical signs  
Uncomplicated C. perfringens type A disease can be suspected from the 
clinical signs of greyish diarrhoea or soft motions, and loss of condition in weaned 
pigs from weaning until about 40 kg in weight. The syndrome is most common in the 
8-10 week age group, but can occur later. In weaned pigs immunity is common but 
non-sporulating strains can induce transient nervous signs and minor faecal changes, 
sometimes accompanied by loss of condition in experimental infection. Sporulating 
strains cause a greyish, sometimes mucoid diarrhoea lasting 3-7 days or more after 
the onset of clinical signs. The faeces may froth and bubble immediately after being 
taken from the rectum. Inappetance and reduction in weight-gain occur. Loss of 
condition and faecal staining of the perineum and coat are common. Affected pigs 
appear hollow-flanked, dirty and restless. Growth rates may be depressed and feed 




The pathology of this condition is only clear when affected animals are 
killed. Because they rarely die, post-mortem examination is rarely carried out. 
Affected pigs may be hairy, in poor condition and covered with faeces. In classic 
'colitis' only the large intestine is affected, but in this condition the posterior small 
intestine may be flaccid and contain mucous and bubbles of gas and the large 
intestines are flaccid and their contents are uniform, fluid, and filled with tiny 
bubbles and sometimes have an oily sheen. In early cases the mucosa appears to be 
normal even on histological examination, as it also does with electron microscopy 
scanning. Local loss of microvilli from colonic epithelial cells may occur. In some 
cases there may be more obvious colonic lesions and inflammation, with some 
epithelial cell shedding, may occur as the disease progresses.  
  
7.3.1.3. Laboratory  
Samples of ileum and its contents and large intestine and its contents are 
required for confirmation of the presence of enterotoxin and sporulating C. 
perfringens type A (Moller and Ahrens, 1996) as well as to rule out the presence of 
other agents. Samples of the wall of both regions should be taken for histological 
examination. 
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The presence of enterotoxin in faecal filtrates can be confirmed using 
commercial Reversed Passive Latex Agglutination tests, counter 
immunoelectrophoresis, ELISA and Vero cells toxicity. Sporulating strains may be 
isolated by dilution of faeces in ethanol for 1 hour or by heating at 80oC for 10 
minutes and then culturing anaerobically. The genes for the toxins concerned can be 
detected by PCR, but only confirm the involvement of the organism. Other causes of 
the ‘colitis’ syndrome such as the presence of B. pilosicoli, Salmonella enterica, 
Yersinia enterocolitica and Eimeria sp should be sought to confirm that C. 
perfringens type A is the cause of a particular outbreak.  
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This chapter will focus on 2 clostridial species implicated in enteritis and 
enterotoxaemia in humans: Clostridium difficile and Clostridium perfringens. 
Clostridium difficile is the main aetiological agent of pseudomembranous 
colitis. Most of the time, this pathology is linked to antimicrobial therapy that 
disturbs the normal intestinal flora, allows C. difficile to develop when present, and 
causes disease. There is a wide range of symptoms from simple self-limiting 
diarrhoea to severe colitis.  
Clostridium perfringens is often implicated in food poisoning, as are other 
micro-organisms, such as Staphylococcus aureus and Bacillus cereus. In these cases, 
enterotoxins produced in large amounts by bacterial growth in food cause intestinal 
disease when ingested. 
 
8.1. Pseudomembranous colitis and antibiotic-associated diarrhoea 
caused by C. difficile 
 
8.1.1. Clinical signs 
C. difficile-associated disease (CDAD) should be suspected in every case of 
diarrhoea occurring after antimicrobial therapy. In some rare cases, colitis is induced 
by chemotherapy. 
Diarrhoea may appear during treatment or after it has been discontinued. In 
the most severe cases, typical pseudomembranes can been seen at the surface of 
colonic mucosa by rectoscopy or colonoscopy. However, due to the difficulty of 
performing this type of examination and the lack of sensitivity, diagnosis is mostly 
obtained by laboratory tests on faecal specimens. 
 
8.1.2. Laboratory diagnosis 
Laboratory diagnosis of CDAD is based both on isolation of the pathogen in 
stool specimens by culture and on toxin detection. The latter can be performed either 
by detection of a cytopathic effect of a stool filtrate on cell lines or by direct enzyme 
immunoassay. Cytotoxin detection is advocated by many authors, especially in the 
USA, as the gold standard for diagnosis, but both culture and toxin detection are 
necessary to achieve an optimal result (Delmée, 2001). 
Other indirect tests have been proposed in the past, such as gas liquid 
chromatography (GLC) performed on stool specimens, latex agglutination and CT-
scans. However, these approaches do not reach sufficient sensitivity and specificity 
to be acceptable, unless used in addition to the other tests. 
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For optimal bacteriological diagnosis, only liquid stools should be accepted, 
except in the case of epidemiological investigation. Due to a rapid loss of cytotoxin 
activity, only freshly taken specimens should be processed and they should be stored 
at 4 °C, or less in cases where tests cannot be performed rapidly. Complete 
inactivation of cytotoxin has been demonstrated in about 20% of samples sent 
through the post (Brazier, 1993). On the other hand, cultures of C. difficile remain 
unaffected by ambient storage, due to sporulation. Repeated samples within 7 days of 
initial request seem to give little useful information (Renshaw et al., 1996). 
 
8.1.2.1. Culture 
Just after the discovery of the pathogenic role of C. difficile, George et al. 
proposed a selective agar plate called CCFA (cycloserine cefoxitin fructose agar) for 
its isolation from stool specimens (George et al., 1979). This medium is still in use in 
most laboratories.  
Colonies of C. difficile are easily recognised on culture plates, due to their 
typical morphology (ground glass appearance) when observed with binoculars. GLC 
of an agar plot around a suspected colony is the best and easiest method for 
confirming identification (see also Chapter 13). Such a device, however, is not 
available in many laboratories. Individual biochemical tests or anaerobic panels may 
also be used, as well as a somatic antigen latex kit. Cross-reactions, however, have 
been documented with this latter reagent.  
Enzyme-linked immunosorbent assays (ELISAs) have been developed to 
detect toxin A or both toxins A and B. They may be used on culture or directly on 
faeces (see below), but, of course, will only recognise toxigenic isolates. Production 
of proline-aminopeptidase by disc test has recently been proposed as a means of 
rapid identification of C. difficile, when used in conjunction with the typical 
morphology of colonies (Fedorko and Williams, 1997). 
 
8.1.2.2. Toxin detection 
 
8.1.2.2.1. Cytotoxicity assays 
This method consists of inoculating a filtrate of stool suspension into a cell 
culture and observing a cytopathic effect as a consequence of disruption of the cell 
cytoskeleton; this results in cell rounding in many cell lines. The effect is mainly due 
to toxin B, which is a thousand times more cytotoxic than toxin A. 
Almost all cell lines commonly used in clinical microbiology laboratories 
can be used to detect faecal cytotoxin. Vero, HEp2, fibroblast, CHO and HeLa cells 
are the most common. Vero cell lines are considered by many to be the most 
sensitive. Confirmation of specificity is obtained by repeating the test with the 
addition of a specific antiserum directed against C. difficile or against C. sordellii 
toxins, which share the same antigens. 
The cytotoxicity assay method has many advantages. It is sensitive and 
specific and it can also detect other clostridial toxins. On the other hand, it is 
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relatively slow in comparison with ELISA. In addition, a specific cytopathic effect 
(not neutralised by antiserum) can be observed in about two percent of cases, 
rendering impossible any interpretation. Having to maintain cell lines, which is both 
time consuming and expensive, especially if only a small number of specimens are 
processed, is another drawback. 
 
8.1.2.2.2. Immunological assays 
Many ELISAs have become commercialised over the last 10 years. 
Establishing a complete list is difficult, since not all are available in every country. 
Most use monoclonal anti-toxin A antibodies, although a few of them are designed to 
detect both toxins A and B. The reason why kits detecting both toxins have been 
developed is mainly because some isolates from clinical cases have been shown to 
produce only toxin B (Alfa et al., 2000). In our experience, such strains are very 
rarely observed. However, in England, they account for 3% of the strains referred to 
the reference laboratory for typing (Brazier, 1998) and outbreaks with A-negative, B-
positive strains have also been described in Canada (al-Barrak et al., 1999). 
Finally, in one of the latest kits, the detection of toxin A is coupled with the 
detection of a glutamate dehydrogenase (GDH), a C. difficile-specific enzyme found 
in toxigenic as well as non-toxigenic isolates. Although the sensitivity of toxin A 
detection is within the same range as other kits (79.4%), the addition of the GDH test 
allows us to obtain an excellent negative predictive value of infection by C. difficile 
(Landry et al., 2001; Barbut et al., 2000). A negative result for both tests at the same 
time means that the presence of a toxigenic strain of C. difficile can be excluded, with 
a reliability factor of 99.6 % (Barbut et al., 2000). This latest kit may be used as a 
rapid screening test to decide which stools need to be processed further. 
There are numerous publications regarding the performance of different kits. 
When compared to faecal cytotoxin detection on cell lines, different ELISAs show a 
slightly lower sensitivity. In our experiments, serial two-fold dilutions of a positive 
faecal sample could be detected at a dilution of 1/64 with the cytotoxicity test, 
whereas this was the case only at ½ dilution for most ELISAs (unpublished results). 
The same observations have been made in clinical studies (Barbut et al., 1993; 
Barbut et al., 1997; Bentley et al., 1998; Fedorko et al., 1999; Jacobs et al., 1996; 
Vanpoucke et al., 2001).  
Although less sensitive, ELISAs can be used as a screening test and may be 
useful in laboratories without tissue-culture facilities. Some kits are presented as 
individual panels, others as 96-well micro-plates. One of the main advantages of 
these kits is their rapidity, since results can be obtained within 20 minutes with some 
of them. 
ELISA tests should always be combined with culture and, when negative 
with a positive culture, should be repeated by testing the strain isolated on the plate. 
In several studies, toxigenic culture has been demonstrated as the most 
sensitive and specific technique for the diagnosis of CDAD (Barbut et al., 1993; 
Delmée et al., 2005; Fedorko et al., 1999; Lozniewski et al., 2001; Staneck et al., 
1996). In this approach, culture of faecal specimens on CCFA is followed by in vitro 
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determination of the toxigenicity of positive colonies by cytotoxin test or by ELISA. 
Most comparisons of ELISA kits against toxigenic culture have demonstrated lower 
performance on the part of ELISAs. 
 
8.1.2.2.3. Genetic assays 
Compared to other infectious diseases, molecular methods for the diagnosis 
of CDAD have been far less studied. This is probably due to the relatively 
satisfactory results obtained with classical methods, as described above, as well as to 
the difficulty of applying such methods to faecal specimens. This is known often to 
interfere with amplification procedures.  
Direct detection of C. difficile genes in faecal specimens has also been 
tested. Oligonucleotide probes designed to detect toxin B have been used by Green 
(Green et al., 1994), with sensitivity and specificity in the same range as ELISAs. 
PCRs using sets of primers designed to detect toxin A or B have also been tested on 
stools by several authors (Kato et al., 1993; Gumerlock et al., 1993; Arzese et al., 
1995; Wolfhagen et al., 1994). Procedures usually comprise a preliminary step to 
avoid inhibitory substances. So far, they have been tested on a small series of 
specimens and the results have not shown any significant improvement in 
comparison with classical methods.  
 
Table 8.1:Proposed scheme for bacteriological diagnosis of CDAD 
 
initial tests on stools   
culture faecal toxin additional test conclusion 
- -  no CDAD 
+ +  CDAD 
+ - 
strain in vitro 
toxigenicity  
  + probable CDAD 
  - 
carriage of non-toxigenic C. 
difficile 
- + 
repeated culture on 
CCFA + taurocholate probable CDAD 
 
8.2. Food poisoning due to Clostridium perfringens 
8.2.1. Clinical signs 
Acute liquid diarrhoea occurs rapidly (within 6 to 24 hours, most often 8 to 
12 hours) after ingestion of contaminated food. It is often preceded by abdominal 
cramps. Fever or vomiting are more rare. Usually symptoms do not last for more than 
24 hours. They are mainly caused by C. perfringens belonging to type A and 
producing the enterotoxin. 
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Necrotising enterocolitis has been described only in very rare cases. This is 
caused by C. perfringens type C. 
 
8.2.2. Laboratory diagnosis 
Diagnosis can be obtained by culturing either the patient’s stool or the 
suspected food. The difficulty lies in the fact that C. perfringens may be present in 
normal stools as well as in non-implicated foods. However the number of bacteria 
differs: the usual count in normal stools is 103 to 104 cells per g, but from 0 to 103 in 
food.  
The Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) 
currently accept (Olsen et al., 2000) several laboratory criteria for confirming the 
occurrence of a C. perfringens type A food poisoning outbreak: (a) demonstrating the 
presence of 105 C. perfringens organisms/g of stool from two or more persons (b) 
demonstrating the presence of 105 C. perfringens organisms/g of epidemiologically 
implicated food, or (c) demonstrating the presence of cpe gene in the faeces of 
several people involved in a food poisoning outbreak.  
 
8.2.2.1. Culturing procedures for sporulation and enterotoxin 
production 
In order to determine the enterotoxigenicity of C. perfringens from food or 
faeces, it is necessary to induce sporulation of the organism. Isolates are first 
subcultured in fluid thioglycollate broth and subsequently in one of the numerous 
proposed sporulation media (Peck et al., 2004). The two recommended here are the 
modified AEA medium of Taniguti (Taniguti, 1969) and the modified (Harmon and 
Kautter, 1986a) medium of Duncan and Strong (Duncan and Strong, 1969; Labbe 
and Rey, 1979). 
The resulting culture is checked for spores by using a phase-contrast 
microscope or by examining stained smears. Fewer than 5 spores per microscopic 
field is not considered adequate sporulation. A portion of the sporulated culture is 
then centrifuged for 15 mins at 10,000 x g and the cell-free culture supernatant tested 
for enterotoxin. 
 
8.2.2.2. Rapid methods for detecting C. perfringens enterotoxin 
A number of immunological assays have been reported for the rapid 
detection of enterotoxin. The most rapid methods available are the afore mentioned 
enzyme-linked immunosorbent assays (ELISAs) and Reverse Passive Latex 
Agglutination (RPLA) (Harmon and Kautter, 1986b). A rapid and inexpensive slide 
latex agglutination assay has also been reported (McClane and Snyder, 1987), which 
requires special test reagents and equipment not generally available. 
A hydrophobic grid membrane filter-colony hybridisation method for the 
enumeration and isolation of cpe gene-carrying C. perfringens spores from faeces has 
been described (Heikinheimo et al., 2004). First results seem promising and this may 
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be an aid in the investigation of faecal samples from patients suffering from food 
poisoning or other diseases caused by cpe-positive C. perfringens 
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Acute colitis in adult horses is a very severe disease with high mortality and 
often unknown aetiology (Cohen and Woods, 1999; Murray, 1992; Palmer, 1992). 
Some colitis cases result from infection with clostridia. Clostridial colitis in horses 
may be caused by toxigenic isolates of Clostridium difficile or Clostridium 
perfringens (Divers, 2002). 
 
9.1. Clostridium difficile diarrhoea 
C. difficile is a well known nosocomial pathogen in humans with antibiotic-
associated diarrhoea. The bacterium can produce an enterotoxin, A and a cytotoxin, 
B. C. difficile has recently been reported as a pathogen in horses developing acute 
colitis when treated with antibiotics for problems other than gastrointestinal disorders 
(Båverud, 2002a, 2004; Båverud et al., 1997, 2003, 2004; Beier et al., 1994; 
Cosmetatos et al., 1994; Gustafsson et al., 1997, 2004; Madewell et al., 1995; 
Magdesian et al., 1997; Perrin et al., 1993). Often, horses had been treated with 
antibiotics for some days when diarrhoea developed, and the majority of them had 
also been hospitalised (Båverud et al., 1997, 2003; Gustafsson et al., 1997).  
C. difficile has also been isolated from diarrhoeic horses not treated with 
antibiotics (Båverud et al., 2003; Beier et al., 1994; Cosmetatos et al., 1994; 
Magdesian et al., 1997). This is also the case in other horse studies where there is no 
information as to whether or not the animals have been treated (Donaldson and 
Palmer, 1999; Weese et al., 2000). Furthermore, C. difficile has been associated with 
acute colitis in mares when their foals have been treated orally with erythromycin 
and rifampicin for Rhodococcus equi pneumonia (Båverud et al., 1998). In faecal 
samples from healthy adult horses, C. difficile is rarely found (isolation rate 0–1%) 
(Al Saif and Brazier, 1996; Båverud et al., 1997, 2003; Jones et al., 1987; Weese et 
al., 2001). Healthy young foals less than 2 weeks old and non-diarrhoeic foals treated 
with antibiotics are often carriers of C. difficile (Båverud et al., 2003). Other authors 
have reported on C. difficile being isolated from foals with diarrhoea (Jones et al., 
1987, 1988a, 1988b; Magdesian et al., 1999, 2002; Weese et al., 2001). 
In an experimental infection after oral inoculation with C. difficile in mature 
horses, penicillin treatment was demonstrated to be a risk factor for establishment of 
C. difficile in the intestine (Gustafsson et al., 2004). Infection control measures to 
limit susceptibility of hospitalised horses and to decrease exposure to C. difficile may 
play a role in the control of C. difficile-associated disease. To prevent C. difficile 
diarrhoea in hospitalised horses judicious use of antimicrobials is important and also 
to minimise different stress factors at the clinic. Isolation of infected horses, cleaning 




9.1.1. Clinical signs  
C. difficile diarrhoea should be diagnosed if an adult horse develops 
diarrhoea during or after antibiotic treatment, if it is or has recently been hospitalised 
and if toxin A and/or B is identified in faeces. The clinical signs of a horse with 
antibiotic-associated diarrhoea caused by C. difficile cannot be differentiated from 
those of a horse suffering from diarrhoea caused by C. perfringens (Divers, 2002). 
 
9.1.2. Laboratory procedures 
9.1.2.1. Sampling and transport 
A faecal sample (20–30 g) should be directly submitted to the laboratory for 
investigation (Weese et al., 2000). If there is a delay in transport and/or in laboratory 
investigation, samples should be stored at −70°C (Jones, 2000). Multiple faecal 
samples should be taken on several consecutive days, as cytotoxin B is demonstrated 
one day later than a positive culture and also intermittently (Gustafsson et al., 1997). 
C. difficile shows poor survival when faeces are exposed to air (Weese et al., 2000). 
However, faeces may contain spores of C. difficile (Båverud et al., 2003).  
 
9.1.2.2. Culture 
Faecal samples are cultured for C. difficile on a selective agar medium 
containing cycloserine (250 mg/L), cefoxitin (8 or 16 mg/L) and fructose (CCFA) 
(George et al., 1979; Levett, 1985; Båverud, 2002b). Addition of bile salts, such as 
taurocholate, to a medium enhances germination of spores (Buggy et al., 1983; 
Wilson et al., 1982). Selective agar plates are available commercially. Isolates may 
be tested for antimicrobial susceptibility (Båverud et al., 2003, 2004; Jang et al., 
1997; Weese et al., 2001) and subtyped using molecular methods (Jang et al., 1997; 
Madewell et al., 1995; Magdesian et al., 2002; reviewed by Brazier 1998; 2001). 
 
9.1.2.3. Detection of toxin A and/or B 
Cytotoxin B of C. difficile in faecal specimens may be investigated by tissue 
culture, e.g. on human diploid fibroblast cells or MRC-5 cells (Båverud et al., 1997). 
Other cell lines may also be used (Delmée, 2001). Positive toxin samples should be 
confirmed by neutralisation with C. difficile antitoxin B (Båverud et al., 1997). 
Toxin A and/or B may be tested in faecal samples by using enzyme 
immunoassays. Commercial products are available for rapid detection of C. difficile 
toxins (O’Connor et al., 2001; Turgeon et al., 2003). Tests have been performed on 
faecal samples from horses, but not yet validated (Donaldson and Palmer, 1999; 
Weese et al., 2001; Gustafsson et al., 2004).  
Isolates may be tested for the possession of toxin A and B genes by PCR 
(Båverud et al., 2003; Madewell et al., 1995). This test shows if the genes are 
present. However, it gives no information as to whether or not the toxins are 
expressed (Båverud et al., 2003). 
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9.2. Clostridium perfringens diarrhoea 
C. perfringens type A has been suggested as a pathogen in diarrhoeic horses 
(Ochoa and Kern, 1980; Wierup, 1977).  
Wierup found that high intestinal counts of C. perfringens were associated 
with diarrhoea in mature horses (Wierup, 1977). Haemorrhagic enterocolitis was 
experimentally induced by enterotoxigenic type A C. perfringens, (Ochoa and Kern, 
1980). Recently, C. perfringens enterotoxin was demonstrated in 16%–19% of faecal 
samples from mature horses with diarrhoea (Donaldson and Palmer, 1999; Weese et 
al., 2001). 
In foals, C. perfringens  type A, B, C and D have been sporadically 
associated with enterocolitis (East et al., 1998; Netherwood et al., 1998; Stubbens, 
1990; Traub-Dargatz and Jones, 1993).  
The gene coding for the new β2 toxin was recently found in some strains of 
C. perfringens. The β2 toxin gene of C. perfringens was found in horses with 
typhlocolitis, whereas β2 toxigenic isolates were not found in control horses (Herholz 
et al., 1999).  
 
9.2.1. Clinical signs  
As C. perfringens may be isolated from healthy mature horses and neonatal 
foals (Tillotson et al., 2002; Traub-Dargatz and Jones, 1993; Wierup, 1977; Wierup 
and DiPietro, 1981), the diagnosis of C. perfringens as a cause of diarrhoea in horses 
is complicated. According to Divers (2002), other causes should be ruled out. Divers 
suggests that, there should be large numbers (>105 colony forming units/ml faeces) of 
C. perfringens and demonstration of enterotoxin and sporulation. The β2 toxin gene 
may be of further interest for study.  
 
9.2.2. Laboratory procedures 
9.2.2.1. Sampling and transport 
For C. perfringens faecal sample (20–30 g) should be directly submitted to 
the laboratory for investigation. If there is a delay in transport and/or in laboratory 
investigation, freezing of samples at −70°C may be an alternative. 
9.2.2.2. Culture and typing 
Culture of C. perfringens is performed on blood agar plates for anaerobic 
culture. For typing (types A–E) of C. perfringens isolates, a multiplex PCR 
demonstrates the genes of the major toxins (Engström et al., 2003).  
9.2.2.3. Detection of toxin 
Enterotoxin may be demonstrated in faecal samples by using enzyme 
immunoassays (Donaldson et al., 1999; Weese et al., 2001).  Presence of the 
enterotoxin gene and the β2 toxin gene may be demonstrated through PCR of C. 
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Clinical condition Clostridial species 
Tyzzer’s disease Clostridium piliforme 
Clostridial enterotoxaemia Clostridium spiroforme 
 
10.1. Introduction 
The aetiological diagnosis of  digestive disorders in rabbits is always very 
exacting to perform. Such diagnosis is illusive without systematic secondary 
parasitical and bacteriological examinations. Basic investigations for Tyzzer's disease 
and C. spiroforme infections should always be included by veterinarians in the 
protocol for diagnosis. 
When these diseases are suspect in rabbits, the best way for owners and 
practitioners to obtain an accurate diagnosis is to send a representative batch of 
animals directly to a specialized laboratory. This batch should include recently 
deceased animals and typically sick, untreated ones, which would be sacrificed for 
complementary examinations. A complete history of death rates and clinical signs 
must be provided.  The  data should include the type and the size (expressed in 
number of does) of specimens from the rabbitry and the feeding, breeding, hygiene 
and management practices of same.   
 
10.2. Clostridium piliforme infections in European rabbits (Tyzzer's 
disease) 
Tyzzer’s disease, while best known in rodents, also occurs in rabbits. It is 
caused by Clostridium piliforme, an intracellular Gram-Negative and filamentous 
Clostridium. 
 
10.2.1. Clinical signs 
On a clinical basis, both acute and chronic forms are described in rabbits 
(Prescot, 1977). In broiler animals, from small as well as from intensive rabbitries, 
acute cases are more frequently observed in young animals around weaning age (5 to 
8–9 weeks old) than those of  breeding age.  
Clinical signs reflect the acute digestive syndrome, which results in 
depression, diarrhoea and high mortality rates (up to 50%). 
Chronic forms are usually seen in the breeding stock (does and bucks). 




10.2.2. Pathological lesions 
At necropsy, gross lesions may be observed on the caecum, liver and 
myocardium. Moderate to extremely severe pseudo-membranous acute typhlitis with 
moderate to severe oedema of the caecal wall is the most frequent finding. Some 
acute ileitis and colitis may also be observed. Unlike in rodents, necrotic foci in the 
liver parenchyma are rarely seen in rabbits which gives rise to diagnosis difficulties 
(Prescot, 1977; Pawaiya et al., 1999). Some necrotic foci and degenerative lesions 
may also be found in the myocardium (Lee et al., 1976; Pawaiya et al., 1999). 




The confirmation of Tyzzer’s disease is always difficult to perform. When 
gross lesions are present, tissues (caecal wall, liver and myocardium) fixed in neutral, 
buffered 10% formalin should be collected at necropsy and submitted to the 
laboratory. C. piliforme may be observed in histopathologic sections after Warthin-
Starry silver-impregnation staining (Okerman, 1994; Pawaiya et al., 1999), though 
results are often disappointing. For a more specific diagnosis, immunofluorescence 
tests such as those conducted for mice (Savage and Lewis, 1972) or rats (Fries and 
Svendsen, 1978) can be adapted to rabbit tissues. 
Serological tests  (indirect immunofluorescence test, ELISA) have been 
described (Fries, 1977a; 1977b; Waggie et al., 1987), but they are seldom used for 
diagnosis, as their results are controversial. 
The isolation and propagation of C. piliforme are both time and labour 
consuming, since C. piliforme does not grow in artificial media. Culturing, in the 
yolk sac of chicken embryonated eggs (Fries, 1977c) and in primary chick embryo 
livers (Waggie et al., 1987), has been described, but the use is limited to research 
methods. 
Theoretically, PCR reactions such as those developed for cattle (Ikegami et 
al., 1999, Furukawa et al., 2002) should work in rabbits.   
 
10.3. Clostridium spiroforme enterotoxaemia 
In rabbits, enterotoxaemia has been identified by Lesbouyries and Berthelon 
since 1936. For a long time, its aetiology was incorrectly attributed to C. perfringens 
type E infection until Carman and Borriello (1982) demonstrated the aetiological role 
of C. spiroforme. This bacteria is an helically coiled Clostridium that produces a 
toxin that can be neutralised by anti-Clostridium perfringens type E sera (Carman 
and Borriello, 1984). This bacteria was reported to be present in 52 % of rabbits with 
digestive disorders and in 83 % of the respective rabbitries (Licois, 1989). 
 
10.3.1. Clinical signs 
The “spontaneous forms” of the disease mostly occur in young broiler 
rabbits (3–4 to 8-9 weeks old), but they may also affect older animals such as does 
 90
about to nest. Usually, there are few typical clinical signs: either the rabbits are in 
poor condition and show watery diarrhoea or are simply found dead. 
“Antibiotics-induced C. spiroforme enterotoxaemia” also occurs. It follows 
the administration of clindamycin, lincomycin (Licois, 1980) or ampicillin (Peeters, 
1989) to rabbits. After the administration of the antibiotics, feed intake quickly 
decreases, and mortality may begin within 2 days after the administration and 
continue until 3 weeks after discontinued use. Total mortality rate may be as high as 
50 %. The same clinical signs, but with lower mortality rate (up to 20%), may also be 
observed after long-term use of other antibiotics such as tetracyclin and neomycin 
(Peeters, 1989). 
 
10.3.2. Pathological lesions 
At necropsy a watery caecal content, usually associated with a severe to 
extremely severe acute haemorrhagic typhlitis, is commonly observed. Lesions 
sometimes are spread out to the distal part of the ileum and proximal part of colon. 
There may also be some mucus in the colon. The bodily condition of the animal 
depends upon the delay between infection and death. 
 
10.3.3. Laboratory 
The final diagnosis is based on the observation of numerous, typically 
curled, U-shaped or spiralled C. spiroforme rods after Gram staining of the caecal 
contents (Borriello et al., 1986). A more sensitive method based on centrifugation of 
caecal content at 20000 g (15 min.; 4°C) and observation of the supernatant-pellet 
interphase after Gram staining has been proposed (Holmes et al., 1988). 
Routinely, isolation of C. spiroforme is rarely performed. If required, it can 
be isolated from caecal content after high-speed centrifugation by the method of 
Holmes et al. (1988). 
The presence of ι-like C. spiroforme toxin in caecal content of affected 
animals may be demonstrated by the method of Carman and Borriello (1983). It is 
almost never done routinely, and the diagnosis is questionable, as 90 % of the strains 
seem toxinogenic (Licois, 1989). As previously mentioned, the easiest way to 
diagnose C. spiroforme enterotoxaemia is to send recently deceased or typically sick 
animals to the lab. Otherwise the use of fresh caecal content is also appropriate 
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11. Enteritis and enterotoxaemia in birds 
 
B. Engström, M. Kaldhusdal and K. Pedersen  
 
Clinical condition Clostridial species Host species 
Necrotic enteritis Clostridium perfringens Chickens, turkey poults, 
domestic ducks, ostrich 
chicks, captive capercaillies 
and wild ducks and geese 
Ulcerative enteritis Clostridium colinum Quail, chickens, turkeys, 
pigeons and game birds, such 
as partridge, pheasants and 
grouse reared in captivity 
 
11.1. Necrotic enteritis 
Necrotic enteritis is caused by Clostridium perfringens, the Clostridium 
species associated with most health problems in poultry today. Clinical necrotic 
enteritis is most often seen in broilers and turkey poults, but may also be seen in 
young broiler breeders and layers kept on litter bedding. C. perfringens may also 
cause subclinical infection in the intestine and liver: subclinical necrotic enteritis and 
C. perfringens–related hepatitis. In young layer chickens (Fossum et al., 1988) a 
disease with gizzard lesions has been reported as a condition related to infection by 
C. perfringens. Similar lesions in the gizzard have been observed in broiler chickens 
and turkey poults, and C. perfringens has also been cultivated from such lesions in 
broilers. 
 
11.1.1. Clinical signs 
Acute outbreaks usually occur in broilers and turkeys of at least 2 weeks of 
age, but are less frequently observed in flocks above 7 weeks old. Mortality is 
variable, but about 1% per day during a week is quite common in a flock. Signs of 
the disease are general depression, anorexia and acute death. Diarrhoea is seldom 
seen in cases of acute outbreaks, but may be found in more protracted cases. Clinical 
signs are variable, and mild necrotic enteritis is probably more common than the 
clinical form of the disease. Although the clinical symptoms of mild and subclinical 
disease are less conspicuous, the effects on production performance may be 
significant.  
Gizzard erosions are observed at roughly the same age as gut lesions in 
clinically healthy broiler chickens.  
 
11.1.2. Pathological lesions 
A typical lesion in acutely diseased chickens appears as severe extensive 
necrosis of the mucosa in the small intestine. Alpha toxin produced by C. perfringens  
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is assumed to cause necrosis of intestinal mucosa, starting at the tips of the villi 
(Long et al., 1974). Necrotic lesions may become widespread, with diphtheritic 
membranes and severe intestinal dysfunction. Alpha toxin may gain access to the 
bloodstream, leading to the development of toxaemia, which, together with intestinal 
lesions, contributes to clinical illness and, in some cases, death (Al-Sheikhly and 
Truscott, 1977; Fukata et al., 1988).  
Subclinical necrotic enteritis (SNE) is characterised by focal ulcers and 
necroses in the  mucosa of the anterior small intestine (Kaldhusdal and Hofshagen, 
1992). SNE has been found in broilers from 1–2 weeks of age up to slaughter. Up to 
80% of examined birds in affected flocks may have typical lesions in the small 
intestine.  
C. perfringens-related hepatitis is characterised by cholangiohepatitis or 
focal necroses in the liver. These lesions are usually found during meat inspection at 
slaughter, but rarely in birds with gut lesions. In most cases, no signs of disease in the 
flock will have been detected during the rearing period. Livers with 
cholangiohepatitis are usually enlarged, firm, pale, and mottled with a lobulated 
pattern (Randall, 1991). The gall bladder wall may be inflamed or necrotic and 
chicken carcasses sometimes show jaundice and/or ascites. Livers with focal 
necroses are characterised by multiple nodules either on the cut surface or protruding 
beneath the liver capsule. The lesions are probably caused by infection with C. 
perfringens in the liver and bile ducts, leading to obstruction of the bile ducts (Sasaki 
et al., 2000). Bacteria may ascend from the duodenum via the bile ducts to the liver 
or come to the liver via vena portae. 
 
11.1.3. Sampling procedure and transport to the laboratory 
Freezing of specimens should be avoided, however, they should be kept and 
transported as cool as possible. Whole birds should be wrapped in fluid-absorbing 
paper and packed in plastic bags to avoid leakage. All sampled material should be 
transported as fast as possible to the laboratory.  
In cases of clinical disease, necropsy of dead birds may be performed in the 
field. Alternatively, or as a supplement, whole birds that have died with the suspected 
disease may be submitted to a laboratory for necropsy and further examination. 
Individuals should be selected that have died as recently as possible, or else 
moribund birds should be euthanised for the purpose. Several birds should preferably 
be submitted, since pathological lesions and bacteriological findings may vary. 
If subclinical disease is suspected, live birds are sampled at random from the 
flock. Again, the birds may be examined in the field and/or submitted (alive) to a 
laboratory for examination. 
Instead of submitting whole birds, organ specimens may be collected and 
submitted. However, due to a high risk of contamination and proliferation of 
contaminant flora, such material is not optimal. For (semiquantitative) bacteriology, 
specimens are collected with cotton-tipped applicators and sent to the laboratory in 
transport tubes containing a suitable medium (e.g. Amies’ medium with charcoal). 
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Specimens may be collected from small intestinal lesions, gall bladders of affected 
livers or gizzard lesions.  
 
11.1.4. Laboratory procedures 
On a routine basis, semiquantitative examination for C. perfringens on 
blood agar plates is adequate support for a presumptive diagnosis based on 
pathology. However, positive identification of C. perfringens requires inoculation on 
differential media (Wages and Opengart 2003). 
 
11.1.4.1. Birds that have died with suspected necrotic enteritis 
Gross necropsy findings of the small intestine are usually diagnostic, but the 
potential role of coccidia should be investigated (intestinal smears and/or histology, 
or oocyst counts). Bacteriology is essential if gut lesions are considered difficult to 
distinguish from those of ulcerative enteritis.  
 
11.1.4.2. Birds sampled alive from a flock with suspected subclinical 
necrotic enteritis 
The birds must be examined immediately after euthanasia, because 
diagnostic gut lesions may disappear rapidly after death. The role of bacteriology is 
the same as described for dead birds. Further, intestinal contents from newly 
euthanised birds can be used for quantitative bacteriology. In broiler chickens, caecal 
or ileal contents of birds with necrotic enteritis usually contain at least 1 million C. 
perfringens/g (median counts often 100 million C. perfringens/g), whereas median 
counts of birds without such lesions have been reported to be 100.000 C. 
perfringens/g (Kaldhusdal and Hofshagen, 1992). There is a large individual 
variation in C. perfringens counts of birds with and without necrotic enteritis, and the 
counts are significantly influenced by the age of the birds.  
 
11.2. Ulcerative enteritis (quail disease) 
Ulcerative enteritis (quail disease), caused by Clostridium colinum occurs in 
many species of birds, including chickens, turkeys, pigeons and game birds, such as 
partridge, pheasants and grouse reared in captivity. Quail is, however, the most 
susceptible species. The disease does not affect waterfowl. In chickens, ulcerative 
enteritis often accompanies or follows coccidiosis, immunosuppressive viral 
infections (e.g. chicken infectious anaemia virus and infectious bursal disease virus), 
or physical stress. Ulcerative enteritis is not a commonly diagnosed disease in 
broilers or turkeys in Europe today. 
 
11.2.1. Clinical signs 
Individual signs vary with the duration of the disease, from acute death to 
watery droppings, listlessness, anorexia and emaciation. Chickens and turkeys 
experience outbreaks in the rearing period of 4–10 weeks and mortality varies from 
2% up to 12%.  
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11.2.2. Pathological lesions 
Lesions include at first, small, round, superficial ulcers with haemorrhagic 
borders, occurring in the mucosa of the small intestine, the caecum and upper large 
intestine. Later the ulcers become deeper and may perforate the intestinal wall, 
causing peritonitis. Liver lesions are variable and involve yellow mottling, large 
irregular yellow areas, and disseminated grey or yellow foci. The spleen may be 
enlarged, congested, and haemorrhagic (Wages, 2003). 
Gross post-mortem lesions (presence of gut, liver and spleen lesions) are 
usually diagnostic. 
 
11.2.3. Sampling procedure and transport to the laboratory 
Sampling and submission procedures are as described for necrotic enteritis 
above. 
 
11.2.4. Laboratory procedures 
The possible significance of coccidia, histomoniasis and C. perfringens 
(necrotic enteritis) must be evaluated.  
Further, necrotic liver tissue may be crushed between two glass slides, fixed 
by heat, and stained using the Gram method. If C. colinum is present, large Gram-
Positive rods containing subterminal spores, and free spores can be seen. A 
fluorescent antibody test has been found to be highly specific for the diagnosis of 
ulcerative enteritis (Berkhoff and Kanitz, 1976).  
C. colinum is strictly anaerobic and needs an enriched medium for growth 
(e.g. tryptose-phosphate agar with 0.2 % glucose, 0.5 % yeast extract adjusted to pH 
7.2, to which 8 % horse plasma is subsequently added). 
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The information given in this chapter refers to packaging and shipping 
regulations for cultures of infectious microorganisms assigned to Risk Group 2 or 3 
(Risk Group 4 includes highly pathogenic viruses only, no bacteria). Among the 
clostridia, there are several pathogens and toxin producers allocated to Risk Group 2 
(WHO, 1993; Europ. Parliament, 2000). Clostridium botulinum, C. perfringens and 
C. tetani are especially noted for their pathogenicity and are considered as a potential 
danger for public health. Regulations are therefore in place governing correct handling 
of such organisms, so permits from Health Authorities are required. Furthermore, the 
Dual-use aspect has to be considered: before shipping an infectious substance, it is 
essential to know the destination of the consignment and to ensure that the receiver is 
authorised to work with the material and has adequate facilities. Supply to private 
persons or unknown institutions is to be avoided. When shipping outside the country, 
the sender must be sure the microorganism does not fall under export restrictions such 
as the Biological and Toxin Weapons Convention (BTWC) or other national 
legislation. In the case of listed “select agents” like C. botulinum and C. perfringens 
export requirements must be adhered to, including possible export permits or end-user 
certificates. If anything is unclear, the national Export Offices, Departments of 
Commerce or Foreign Offices should be consulted (Export Controls-Brief Outlines; 
Smith et al., 1999; Weller et al., 1999; Europ. Parliament, 1994).  
 
Abbreviations used 
 ADR Accord européen relatif au transport international des marchandises 
dangereuses par route 
 DG Dangerous Goods 
 DGR  Dangerous Goods Regulations (IATA) 
 IATA  International Air Transport Association (Montreal, Geneva) 
 ICAO  International Civil Aviation Organization (Montreal) 
 PI  Packing Instruction (IATA) 
 SD  Shipper's Declaration for Dangerous Goods (transport by air) 
 UPU  Universal Postal Union (Berne) 
 UN United Nations (Geneva) 
 WHO  World Health Organization (Geneva) 
 
12.2. The Risk Groups 
The WHO Risk Group definitions offer a unique classification system for 
microorganisms (WHO, 1993) although global harmonisation of their assignments to 
the Risk Groups has not necessarily been achieved, due to different public health care 
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standards in the countries or regions, vaccination and hygiene status of the 
populations, climatic and possibly other considerations. Therefore, slight variations 
in different countries may occur. The Risk Group characterises the pathogenicity of an 
organism, the mode and relative ease of transmission, the degree of risk to both an 
individual and a community, and the reversibility of the disease through the availability 
of known and effective preventive agents and treatment. Risk Group 2 (moderate 
individual risk, limited community risk) includes microorganisms that can cause human 
or animal disease, but are unlikely to spread since there is usually effective prophylaxis 
or treatment available. 
 
12.3. Definitions 
12.3.1. Non-infectious biological substances 
are substances containing viable microorganisms known not causing any 
disease in humans or animals. Organisms assigned to Risk Group 1 may be 
considered as non-infectious. They do not fall under any dangerous goods transport 
regulations. However, other restrictions may apply and certain packaging and 
shipping rules have to be followed. See “International Shipping Regulations” 
(author’s note: plant pathogenic microorganisms do not fall under DG transport 
regulations, but they may of course fall under quarantine or other import restrictions 
(Europ. Parliament Council Directive, 2000). 
 
12.3.2. Dangerous goods 
are substances or articles capable of posing a risk to health, safety, property 
or environment while they are being transported by surface carriers or air (Orange 
book, 2004; IATA DGR, 2005). Dangerous goods (DG) are allocated to one of 9 
classes and to a specific UN number. 
 
12.3.3. Infectious substances 
are substances known to contain, or reasonably expected to contain, 
pathogens. Pathogens are microorganisms  (including bacteria, viruses, rickettsiae, 
parasites, fungi) and other agents such as prions which can cause disease in humans 
or animals (Orange book, 2004; IATA DGR, 2005). Organisms grouped with Risk 
Group 2, 3 or 4 are infectious substances and transport regulations for DG fully 
apply. 
 
12.3.4. Genetically modified microorganisms 
refer to organisms in which the genetic material has been purposely altered 
through genetic engineering in a way that does not occur naturally. For the purpose 
of international transport regulations, such organisms are divided into the following 
categories (Orange book, 2004; IATA DGR, 2005): 
• genetically modified microorganisms meeting the definition of an 
infectious substance must be classified in DG Class 6, Division 6.2 and 
assigned to UN 2814, UN 2900 or UN 3373, as appropriate; this means the 
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fact of being an infectious substance has priority over the fact of being 
genetically modified.  
 
Genetically modified organisms and microorganisms which do not meet the 
definition of infectious substances but which are capable of altering animals, plants 
or microbiological substances in a way which is not normally the result of natural 
reproduction. They must be assigned to UN 3245 (DG class 9). 
 
• animals which contain, or are contaminated with, genetically modified 
microorganisms meeting the definition of an infectious substance must not 
be transported by air unless exempted by the States concerned; 
 
12.4. The philosophy behind shipping rules 
While the availability and world-wide exchange of microbial cultures 
including pathogens is essential for progress in research and application, for 
screening, reference and similar purposes, it is obvious that adequate safeguards have 
to be observed in such a way that biological material presents no hazard to the 
environment or to people who may handle it during transport. There is a need to 
ensure that shipping of possibly hazardous materials is managed with a sound 
knowledge of the relevant regulations. Biological substances are very unlikely to 
cause a problem during transit and can be transported efficiently provided they are 
properly packed, labelled, declared and the quantities per package respect proper 
limits. The universal principle of the triple packaging system (primary receptacle, 
secondary containment and outer packaging) as required by the UN Model 
Regulations (Orange book, 2004) and correct labelling should be strictly followed in 
order to avoid rejected shipments, civil lawsuits and penalties. Therefore, all shippers 
of infectious substances should be thoroughly conversant with the respective 
regulations, which are not just guidelines. It is important to know that these are legal 
requirements and compliance is not optional. When cultures of infectious substances 
are transported, these are classified as DG, Class 6, Division 6.2, assigned to UN 
2814 (affecting humans) or UN 2900 (affecting animals only), but by far most of 
those microorganisms allocated to Risk Group 2 can be sent under the new 
dereglemented shipping requirements as set in force for diagnostic specimens, UN 
3373: the UN Model Regulations, 13th revised edition, have moved away from using 
the Risk Group allocation for packaging and transport regulation. Two new Shipping 
Categories are in place instead:  
Category A: an infectious substance which is transported in a form that, 
when exposure to it occurs, is capable of causing permanent disability, life-
threatening or fatal disease to humans or animals. The UN Model Regulations and 
IATA have published an indicative examples list of organisms of Category A, 
covering many examples of the Risk Groups 3 and 4. 
Category B is defined as follows: An infectious substance which does not 
meet the criteria for inclusion in Category A. Infectious substances in Category B 
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must be assigned to UN 3373. The proper shipping name of UN 3373 is either 
“Diagnostic specimens”, “Clinical specimens” or “Biological substance, Category 
B”.  
 
12.5. International organisations and the plethora of 
implementation rules 
(see “Abbreviations used”) 
In view of the risk that accidents, involving any means of transport and any 
carrier, might lead to the dispersal of dangerous biological material, international 
organisations have arranged for discussions on this subject: 
The UN Committee of Experts on the Transport of Dangerous Goods 
(www.unece.org) regularly updates the Model Regulations, known as the "Orange 
Book", which is the basis for international transportation regulations for DG 
specified items for all carriers (Orange book, 2004). It contains information on safe 
handling, classification and packaging with an up-dated list of all the existing UN 
numbers. The ICAO Council uses these recommendations as the basis for its 
Technical Instructions for the Safe Transport of Dangerous Goods by Air (Council of 
ICAO, 2005-2006). The Dangerous Goods Regulations (DGR) (IATA DGR, 2005) 
are published by IATA and are the legally binding basis for shippers and carriers of 
dangerous goods to be transported by air. However, IATA has additional 
requirements which are necessarily more restrictive than the ICAO Technical 
Instructions on account of several State or operator variations. The Universal Postal 
Union UPU publishes the International Postal Convention (UPU, 1996) and shippers 
should know that there are restrictions in place for sending infectious substances by 
postal mail: many countries prohibit the movement of biological substances and 
especially infectious substances through postal services. The WHO Risk Group 
definition scheme (WHO, 1993) is fundamental for shippers of cultures of infectious 
substances in order to classify their material correctly before offering for transport. 
For DG transport by road in Europe, it is important to be aware of the ADR 
requirements (ECE, 1997). Other modes of transport (rail: RID or maritime 
waterways: IMO) do not play such a predominant role as air and road transport.  
 
12.6. International shipping regulations 
12.6.1. Transport of Biological Materials by Postal Services 
National Post Offices are internationally linked together in the Universal 
Postal Union (UPU, Berne, Switzerland). UPU constantly updates the Letter Post 
Compendium, one of the Universal Postal Convention Acts (UPU, 1996) (last 
revision at Bucharest in 2004). The Convention describes detailed regulations for the 
conditions of acceptance and marking of items containing Perishable Biological 
Substances and Infectious Substances (Articles RE 412 and RE 413, respectively) 
and for special packing requirements (Article RE 207). 
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12.6.1.1. Non-infectious biological substances 
Exchange of perishable biological substances (non-infectious) shall be 
restricted to countries whose postal administrations have declared their willingness to 
admit such items, whether reciprocally or in one direction only. In addition, national 
import or export restrictions as well as quarantine regulations should be taken into 
account. Also, international mail containing biological material is usually subject to 
customs clearance. The green Customs Declaration label for postal mail is required. 
The type and number of materials (e.g. 4 bacterial cultures) and the value should be 
entered on this label. Declare "No commercial value" in case of free exchange 
between laboratories or any other supply free of charge. It is recommended to send 
biological material by First Class, Priority or Express Letter Mail. Please note that no 
biological material is permitted in postal parcels, but in letter mail only. If perishable 
biological substances (non-infectious) are not accepted by postal services, such 
material cannot be sent to or within that country by mail. Shipments have to be made 
by freight using a courier. The courier decides the mode and route of transport. 
 
12.6.1.2. Infectious substances 
Tracking must be possible where infectious substances can be shipped by 
postal mail (registered mail system). Observe all restrictions by UPU, IATA and the 
respective National Postal Authorities. For safety reasons, airlines ask post offices to 
ship infectious substances only if in total conformity with the DGR. Air mail 
containing infectious substances (if permitted!) must therefore be accompanied by a 
Shipper's Declaration for Dangerous Goods (SD) in duplicate, signed by an 
authorised and trained person (see “Shipper’s Responsibilities”) if sent under UN 
2814 or UN 2900. The documents and all additional permits are placed in a plastic 
envelope affixed to the outer shipping container. DG declaration documents are not 
required when infectious substances classified as Category B, UN 3373, are shipped. 
In fact, it is hardly possible to ship infectious substances by international 
postal mail because very few countries permit infectious substances in postal mail. 
The UPU Acts generally forbid DG in the mail and IATA DGR states under chapter 
2.4., “Dangerous Goods in Air Mail: … except as permitted in 2.4.1: The dangerous 
goods listed in this subsection may be accepted in mail for air carriage subject to the 
provisions of the National Postal Authorities concerned (author’s note: these include 
the senders’, consignee’s and all transit countries!) and the parts of these Regulations 
which relate to such materials. (a) Infectious substances, provided a "Shipper's 
Declaration" accompanies the consignment…” (IATA DGR, 2005). 
(Freeze-) dried non-infectious microbial cultures may not be considered to 
be perishable. 
Such cultures may therefore be shipped by mail to any country as far as no 
general import restrictions exist. Infectious, non-perishable cultures, however, should 




12.6.2. Transport of biological materials by freight 
12.6.2.1. Shipper's responsibilities 
Not only trans-border shipping but also transports over long distances within 
countries are often carried out by air. The IATA general philosophy appears very 
reasonable when one considers possible risks during air transport caused by 
fluctuations in air pressure, temperature or vibrations. Air freight is carried out by 
airlines, which are greatly concerned in the transport of dangerous goods, so 
packaging is the most essential component of safe transport. 
The shipper is responsible for correct identification, classification, 
packaging, marking and labelling of all DG (infectious substances) intended for 
transport. In the case of air transport, full compliance with the IATA DGR (IATA 
DGR, 2005) is required. Only the shipper has an exact knowledge of the contents of a 
consignment and carriers must rely on the shipper's ability to properly package 
infectious substances with all the documentation needed. 
If applicable, the Shipper's Declaration for Dangerous Goods (SD) must be 
correctly completed and signed by a trained person:  
Shippers of DG are required to attend one initial then subsequent training 
courses on DG transport: "Training must be provided or verified upon the 
employment of a person in a position involving the transport of dangerous goods by 
air. Recurrent training must take place within 24 months of previous training to 
ensure knowledge is current..." (IATA DGR, 2005).  
This measure is implemented by the National Aviation Authorities, whose 
addresses can be found on the IATA web site (www.iata.org/dangerousgoods). 
Alternatively to the obligatory IATA training course, a shipper may commission an 
authorised agent for packaging and shipping of DG. Any person signing a IATA SD 
form must have the above mentioned training certification. In case of infectious 
substances Category A (UN 2814 or UN 2900) transport, the shipper must have made 
advance arrangements with the consignee. He must have received confirmation that 
the substance may be legally imported without delay in delivery and must also make 
advance arrangements with the operator to ensure expeditious carriage (IATA DGR, 
2005). It is important to know that it is forbidden to carry infectious substances 
including those of UN 3373 or other DG in or as passengers’ checked-in or carry-on 
luggage. Severe penalties are in place.  
 
12.6.2.2. The IATA regulations 
The UN has developed procedures for the safe transport of all dangerous 
goods (Orange book, 2004). ICAO has used these recommendations as the basis for 
developing the regulations for the safe transport of DG by air (biannually updated) 
(Council of ICAO, 2005-2006). The IATA DGR (IATA DGR, 2005) are annually 
updated and published as a book containing all the requirements of the ICAO 
Technical Instructions. By following the IATA DGR, all international laws for 
shipping DG on land and by air are met. The DGR are available in Chinese, English, 
French, German and Spanish language versions and represent a user-friendly manual 
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(it can be purchased from national companies, or as CD-ROM directly from IATA: 
http://www.IATA.org/cargo/dg). 
 
12.6.2.3. Packaging and documentation 
Cultures of infectious substances of Category A (UN 2814 or UN 2900) are 
to be packed according to IATA Packing Instruction PI 602 requiring a UN certified 
combination packaging that is to be used systematically. Any self-made “safe” 
packaging is not permitted. The UN packaging resembles a strong and certified 
(specification marking on packagings) version of the triple packaging containment 
principle for biological substances. There is a growing and cheaper market now for 
such ready-to-use packagings for infectious substances that carry all the necessary 
labels and markings on their outer high quality fibreboard box. The Shipper’s 
Declaration for Dangerous Goods form is the essential document for transport of DG 
including highly pathogenic Category A substances, along with the road transport 
declaration for DG, the transport emergency card and the airway bill. All these 
signed documents are not required for shipment of infectious substances of UN 3373, 
Category B (mostly Risk Group 2 organisms). However, the requirements set by 
Packing Instruction PI 650 apply. 
 
12.6.2.4. Shipment example case: steps in summary  
The organism to be sent is a dangerous infectious substance, affecting 
humans (UN 2814) or animals (UN 2900) classified in Category A ∅ to be shipped 
as a Class 6.2 dangerous goods by freight; national postal mail is rarely permitted, air 
mail is prohibited. Independently of the net weight, the UN Model Regulations apply 
for all modes of transport requiring a UN certified combination packaging system 
(Packing Instruction 602). The shipper is a trained person and is responsible for the 
consignment, including the documents. The IATA DGR have to be followed. Choose 
approved courier service and clarify ALL steps, including possible IATA limitations 
before offering the consignment to the courier (destination manageable? Fast 
delivery? Door-to-door or door-to-airport?). Make advance arrangements with the 
consignee (announce date and kind of shipment) and make clear the 24-h emergency 
contact telephone number. 
 
12.6.3. Transport of diagnostic specimens and of cultures of microorganisms 
meeting the definition of Category B 
The UN Model Regulations have modified the shipping regulations for 
infectious substances and for the first time created a new UN number, UN 3373, that 
is applicable for diagnostic specimens and for such infectious substances sent as 
cultures if the definition of Category B is met (see above). The responsible shipper 
has to properly classify the substance prior to transport: for these considerations, the 
definitions of the Risk Groups and the allocation of microorganism species to them is 
still very helpful. According to the legal requirements and including shipments of 
 105
Category B, it is mandatory that shippers of infectious substances are trained persons 
to ensure knowledge is up-to-date  
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13. Bacteriological identification and antibiotic sensitivity 
testing 
 
J.G. Mainil, M.G. Menozzi, S. Pelkonen, M. Delmée  
 
Clostridia are Gram-Positive rod-shaped spore-forming anaerobic bacteria. 
Their in vitro growth, identification in the routine diagnostic laboratory and antibiotic 
sensitivity testing must therefore follow specific rules and use specific materials. In 
this chapter the general diagnostic methodology, the specific growth requirements, 
the different orientation and identification assays and the antibiotic sensitivity testing 
of clostridia are described. In some of the sections, special emphasis will be placed 
on the growth and identification of Clostridium difficile. 
 
13.1. General methodology 
Probably the most important prerequisite in the laboratory diagnosis of any 
clostridial species is a correct clinical sample sent following the strict requirements 
of anaerobes (Chapter 12). Although the clostridial species differ in their 
requirements for anaerobiosis (Table 13.1), with some being even aero-tolerant, all 
samples should be plated onto appropriate blood agar plates for anaerobic incubation 
and onto classical blood agar plates and selective agar plates for enterobacteria for 
comparative aerobic growth. During the incubation period of up to five days the 
plates should be examined daily for colony growth.  
The whole procedure may sometimes take several days and is often not 
compatible with the field practise, in either human or veterinary medicine. But 
following the whole procedure is absolutely necessary to prevent the diagnostic 
laboratory from using identification and antibiotic sensitivity tests for anaerobes on 
non-strictly anaerobic bacteria. Precise clinical data from the doctor or the 
veterinarian are also of importance in the identification of the major and minor 
pathogen clostridia. 
 
13.2. Specific growth requirements 
Clostridia grow best on enriched media, but apart from being anaerobes, the 
majority of species have no particular growth requirements (with the exception of the 
intracellular C. piliforme, of course!). 
 
13.2.1. Growth media 
Clostridia grow on commercially available 5% sheep blood agar plates for 
anaerobes, such as CDC anaerobe blood agar and Schaedler blood agar. Other 
classical 5% sheep blood agar, such as Columbia, Brucella and Brain-Heart Infusion, 
must be supplemented with yeast extract, vitamin K1 and haemin to favour growth of 
anaerobes (Bisping and Amtsberg, 1988; Quinn et al., 1994; Atlas and Park, 2000). 
Anaerobic storage or pre-incubation of the plates for a few hours in anaerobiosis 
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enhances the chance of isolation of clostridia. Colony swarming can be prevented by 
growing the bacteria on phenylethyl alcohol blood agar (PEA) or on 4% agar media. 
The species of the genus Clostridium can also grow on dozens of selective blood 
agars for use in medical or food microbiology (Bisping and Amtsberg, 1988; Quinn 
et al., 1994; Atlas and Park, 2000; chapter 17), several of which are commercially 
available, with, for instance, aminoglycosides or colistin/nalidixic acid to inhibit 
coliforms and other Gram negative bacteria, or Columbia with cycloserin for 
isolation of C. perfringens (Manteca et al., 2001), or the selective media for C. 
difficile (see section 13.2.4).  
One of the problems is the variation in the colony morphology and in the 
zone(s) of haemolysis when the clostridia grow on different media, leading to 
confusion in the pre-identification criteria. The origin of the blood is also of 
importance. The zone(s) of haemolysis by bovine isolates of C. perfringens toxin 
type A are broader and clearer when grown on ox blood agar than on sheep blood 
agar (Manteca, Mainil and Daube, unpublished data). 
Growth is also possible in liquid media. The broth medium must be 
supplemented with serum and reducing agents, such as thioglycollate or cooked meat 
broths. An alternative is to add liver pieces (from rabbits) to BHI broth. The broth 
with a piece of rabbit liver is most probably the best liquid medium (Kaeckenbeeck 
and Mainil, unpublished), but its preparation is time- and labour-consuming. In most 
liquid media the clostridia grow best in the reduced portion of the medium, i.e. at the 
bottom of the tube, close to the piece of meat or of liver. All liquid media must be 
heated and boiled for 5-10 minutes prior to inoculation, in order to expel the 
absorbed traces of O2, followed by cooling at 37°C (Quinn et al., 1994).  
 
13.2.2. Atmosphere 
Because they are anaerobes, the clostridia were separated early from the 
genus Bacillus (Mainil et al., 2004). In addition, all clostridia prefer to grow in an 
atmosphere with 2 to 10% CO2 (Quinn et al., 1994). Nevertheless, variations exist in 
their anaerobic requirements (Table 13.1). Some species are very strict anaerobes and 
do not grow in presence of even traces of O2. Conversely, other species are 
aerotolerant (C. histolyticum, C. tertium) and can still grow either in a mixture of 5% 
O2, 10% CO2, 85% N2, or even in air, though less extensively than in absence of O2. 
In contrast with Bacillus species, Clostridium species can sporulate only in absence 
of O2 (Peck et al., 2004).  
 
13.2.3. Incubation 
Colony growth normally takes 24h to 48h at a near-neutral pH and 37°C, but 
may be delayed up to 5 days for some species (C. botulinum, C. colinum) or in non-
optimal conditions (Table 13.1). Incubation inside an anaerobic cabinet is the best 
alternative and is very flexible, allowing daily examination of the plates. But this 
equipment is of course very expensive. Incubation in anaerobic jars with envelope 
systems (GasPak≤) generating anaerobiosis (H2 + CO2) is the second best alternative. 
However daily examination becomes costly since new packs must be used each time. 
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Moreover, contact with O2, even shortly, can already reduce the viability of the most 
strictly anaerobic species (Table 13.1). The third alternative is the anaerobic jar with 
replacement of the air by N2 and 5-10% CO2. A catalyst must be present inside the 
jars to remove the remaining O2 traces and to allow the growth of strict anaerobes. 
However, most often this system does not favour the growth of the most strictly 
anaerobic clostridia, while favouring the growth of more aerotolerant species, leading 
to diagnostic confusions and errors. 
Liquid media have the advantage of being aerobically incubated. However, 
one must also be careful, since not all of them support the growth of the most strictly 
anaerobic species. 
Whatever system is used, a strictly aerobic bacterial species, like 
Pseudomonas aeruginosa, and a strictly anaerobic bacterial species should be grown 
in parallel as controls for anaerobiosis. 
 
13.2.4. Clostridium difficile 
Just after the discovery of the pathogenic role of C. difficile, George et al. 
proposed a selective agar plate called CCFA (cycloserine cefoxitin fructose agar) 
(George et al., 1979) for isolation from stool specimens of humans (chapter 8), 
horses (chapter 9) and pet animals (Borrelio and Honour, 1981; Quinn et al., 1994). 
This medium containing yeast extract, haemin, vitamin K, and cysteine is still used in 
most laboratories. The selective agents are cycloserine at the concentration of 500 
mg/L and cefoxitine at 16 mg/L. These concentrations have been reduced to 250 
mg/L and 10 mg/L respectively in some studies (Levett, 1985). Cefotaxime may also 
be used instead of cefoxitine at the concentration of 4 mg/L. The original formulation 
included egg-yolk, which may be replaced by blood. This is commercially available 
from several companies. Stools are directly inoculated and incubated in an anaerobic 
atmosphere for 48h. Anaerobic pre-incubation of the plate may also improve the 
recovery rate (Peterson et al., 1996). The use of an Anoxomat≤ system, which 
enables the obtention of an anaerobic atmosphere in the jar within one minute, allows 
the reading of the plates after only a 24 hour incubation period (Delmée, unpublished 
data). It is worth saying that, in the vast majority of cases, the use of a standard 
CCFA medium with a standard inoculation procedure is quite satisfactory for the 
diagnosis of most cases of C. difficile-associated diarrhoea. Culture is the most 
sensitive method but it is not very specific, due to the possibility of isolating non-
toxigenic isolates. It is a slow method, but one that allows the testing of strains for 
toxigenicity. It is also the only method for epidemiological investigations. 
 
13.3. Identification to the species 
The shapes of the colony and of the haemolysis zone(s) are important 
orientation criteria. Gram and Ziehl-Neelsen (acid-fast) stained smears must be 
performed to study the morphology of the cells and of the spores. Any suspect colony 
must subsequently be subcultured anaerobically, aerobically and microaerobically to 
prove the requirement for anaerobiosis, before applying the identification tests 
(without forgetting that a few minor pathogen species are aerotolerant). Identification 
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is performed by study of the biochemical properties, by gas liquid chromatography 
and by molecular methods, including toxin typing (Bisping and Amtsberg, 1988; 
Alen and Baron, 1991; Barrow and Feltham, 1993; Quinn et al., 1994; Hirsh and 
Biberstein, 2004; Popoff, 2004). 
 
13.3.1. Colony morphology and haemolysis zone(s) 
In strict anaerobic conditions, colonies appear within 24 to 48 hours. Some 
species are, however, fastidious growers and require longer incubation (Table 13.1). 
The three criteria to examine carefully are the colony morphology (surface, form), 
the presence/absence of colony swarming and the haemolysis pattern (number and 
width of haemolysis zones). 
 
13.3.2. Orientation tests 
The orientation tests are generally similar to those for non anaerobes : Gram 
and Ziehl-Neelsen stained smears, catalase, cytochrome peroxidase and motility 
tests. Production of lecithinase and lipase are also considered useful pre-
identification tests.  
Though clostridia are Gram-Positive bacteria, Gram stained smears display 
a mixture of Gram-Positive and Gram-Negative bacterial cells after in vitro growth. 
In Gram stained smears, most clostridia appear as straight or curved rods, but the 
shape of a few species can also vary from coccoid rods to long filamentous forms. 
The ends of the rods are rounded, tapped or blunt. The cells of many species occur 
singly or in pairs and several can also form chains of varying lengths and numbers of 
cells. In chains, the individual cells are of similar length (C. chauvoei) or can be of 
greatly different lengths (C. septicum). The chains formed by a few species can form 
tight coils or spiral-shaped (C. spiroforme) configurations. Specific arrangements are, 
however, more frequent and typical in smears from the lesions than in smears from 
the colonies. The shape and arrangements of the major pathogen clostridia in Gram 
stained smears from colonies (Table 13.1) are of course very important for pre-
identification, but other minor or non pathogen clostridial species can resemble one 
or other of the major pathogen species.  
In modified Ziehl-Neelsen (acid-fast) stained smears, spores are ovoid or 
spherical, centrally, subterminally or terminally localized, and cell-distending. Some 
species sporulate very easily and quickly, while others only rarely.  
Clostridia give negative results at the catalase (in contrast with Bacillus 
species) and cytochrome peroxidase tests. Some species can, however, give a weakly 
positive result at the catalase test. On the other hand, most species are motile, but 
quickly loose their motility in the presence of O2. 
 
13.3.3. Identification tests 
Most clostridia are saccharolytic or proteolytic, or both, but a few species 
are neither. The biochemical-based minisystems [e.g. API20A® (Analytab Products, 
Plainview, NY)] are best suited for identification of saccharolytic, fast growing 
clostridia. With these systems the identification can be obtained after 24 to 48hrs of 
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anaerobic incubation by reading the colour reactions manually. A code number is 
generated and interpreted from the code book or computerized database provided by 
the manufacturer [e.g. ATB Expression® (bioMérieux, Marcy l’Etoile, France)]. The 
rapid pre-existing enzyme-based minisystems (e.g. RapID ANA II® [Innovative 
Diagnostic Systems, Atlanta, GA], AN-Ident and API-ZYM [Analytab Products, 
Plainview, NY], ANI card® [Vitek systems, Hazelwood, MO], ATB 32A® 
[bioMérieux, France], Rapid Anaerobe Identification panel® [Baxter Healthcare 
Corp., MicroScan Division, West Sacramento, CA], BBL CrystalTM ANR ID System 
[Becton Dickinson Microbiology Systems, Cockeysville, MD]), utilise chromogenic 
or fluorogenic/chromogenic substrates for detection of bacterial glycosidases, 
aminopetidases and some other enzymes. They are best suited for rapid identification 
of slow growing clostridia. The inoculation of a heavy bacterial suspension, equal to 
McFarland standard n° 3 to 5, allows the reading of the results of the reactions after 4 
hours of aerobic incubation. The identification can be reached either manually by 
using a code book or by a computer-assisted automated reader, such as ATB 
Expression® (bioMérieux, Marcy l’Etoile, France) and MicroScan (AutoScan-4) 
(Engelkirk et al., 1992; Summanen et al., 1993). 
Nevertheless, none of the identification kits is 100% reliable, even for the 
identification of the major and minor pathogenic species (60-80%). So, final 
identification is completed by anti-whole cell antibody immunofluorescent assays (C. 
chauvoei, C. septicum, C. sordellii, C. novyi, C. haemolyticum; chapter 3), genetic 
tests (chapter 14), gas liquid chromatography (chapter 15) and/or toxin typing assays 
(chapter 16), if necessary (Allen and Baron, 1991; Quinn et al., 1994). 
 
13.3.4. Clostridium difficile 
Colonies of C. difficile are easily recognised on culture plates, due to their 
typical ground glass appearance when observed under a magnifying glass (Table 
13.1). A yellow-green or chartreuse fluorescence under ultraviolet illumination is 
another characteristic of the colonies, but this may vary with the medium used. The 
typical odour (horse manure) is also an aid to identification. Gas liquid 
chromatography (GLC) of an agar plot around a suspected colony is the best and 
easiest method for definite identification. C. difficile displays a typical GLC profile, 
with large amounts of butyric and iso-caproic acids (chapter 15). Such a device, 
however, is not available in many laboratories. Individual biochemical tests or 
anaerobic panels may also be used (rapid pre-existing enzyme-based minisystems are 
strongly recommended), as well as a somatic antigen latex kit. Cross-reactions, 
however, have been documented with this latter reagent. 
Production of proline-aminopeptidase by a disc test has been recently 
proposed as a means of rapid identification of C. difficile, when used in conjunction 
with the typical morphology of the colonies (Delmée, 2001, 2004). A direct enzyme 
immunoassay (EIA) for toxin A (chapter 16) may also be used but then, of course, it 
will only recognise toxigenic isolates. Enzyme immuno-assays detecting glutamate-
dehydrogenase (GDH) , an enzyme specific to C. difficile, can also help to identify 
this species, in faeces and after in vitro growth (Snell, 2004 ; Delmée, unpublished 
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data). In combination, these two EIAs for toxin A and for GDH can identify and 
differentiate non-toxigenic and toxigenic isolates of C. difficile, either after in vitro 
growth or directly in faeces (TRIAGE C. difficile [Biosite, San Diego, CA]). 
 
13.4. Antibiotic sensitivity and resistance 
 
13.4.1. Intrinsic and acquired resistance 
All or most clostridia species are intrinsically resistant to aminoglycosides 
(like all anaerobes), sulfonamides (C. perfringens is one exception) and 
diaminopyrimidines. Acquired resistance to members of other families of antibiotics, 
especially to the macrolides, lincosamides, tetracyclines and phenicols, has 
progressively developed at different frequency rates in clostridia species of clinical 
importance. Several clostridia species can indeed harbour antibiotic resistance 
genetic determinants on transferable molecules (plasmids, transposons, conjugative 
transposons) and may serve as reservoir of antibiotic resistance genes for other 
clostridial species and even genders (Cato et al., 1986; Dubreuil, 2004; Mainil et al., 
2004). 
For instance, resistance of human isolates of C. difficile and of human and 
ruminant isolates of C. perfringens to macrolides and lincosamides is mediated by 
different erm (Erythromycin Resistance Methylase) genes, possibly originating from 
Enterococcus or Streptococcus, some of which are located on a conjugative 
transposon or on a plasmid. Similarly, resistance to tetracyclines is most frequently 
mediated by the tetA gene amongst human, ruminant and poultry C. perfringens 
isolates, that can be located on a conjugative plasmid, and by the tetM gene amongst 
human C. difficile isolates, that can be located on a conjugative transposon which is 
similar to a conjugative transposon of Enterococcus faecalis. A third example is the 
resistance of C. perfringens and C. difficile to chloramphenicol, which is mediated by 
two different CAT (Chloramphenicol Acetyl Transferase) enzymes in C. perfringens, 
one of which is synthesised by transposon located genes (catP) and is closely related 
to the catD genes of C. difficile, located on a similar transposon. Different 
percentages of isolates of other species are also resistant to these three families of 
antibiotics, but the mechanisms for this are mostly unknown (Cato et al., 1986; 
Dubreuil, 2004; Mainil et al., 2004; Mastrantonio and Spigaglia, 2004)  
Acquired resistance to other antibiotics, like β lactams (mainly penicillins, 
more rarely cephalosporins), glycopeptides, fluoroquinolones and metronidazole 
have also been described. In most species the percentage of resistant isolates remain 
low. Nevertheless, a high percentage of resistant isolates is found in some minor and 
major pathogen clostridia. These resistances develop as a consequence of mutations 
in chromosomal genes or after acquisition of new genes (such as those coding for the 
production of β lactamase active on penicillins in C. butyricum, C. clostridioforme,  
C. innocuum and C. ramosum) or are mediated by still unidentified mechanisms 
(Cato et al., 1986; Dubreuil, 2004; Mainil et al., 2004). 
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13.4.2. Antibiotic sensitivity testing 
The determination of the sensitivity/resistance patterns of a clostridial 
isolate may be important clinically in human medicine, but much less in veterinary 
medicine. In human hospital medicine, clostridia are tested for antibiotic sensitivity 
in particular cases, such as the occurrence of several cases of infection or the 
persistence of an infection in a patient despite instauration of treatment(s) based on 
the intrinsic sensitivity of the species isolated. Another exception, in veterinary 
medicine, is probably C. difficile-associated diarrhoea in horses (chapter 9) and pet 
animals. The main problem is the availability of the results only after 3 to 5 days, so 
that a treatment must be empirically initiated by the clinician. Testing the antibiotic 
sensitivity patterns of clostridia is therefore important mainly for epidemiological 
purposes in both human and veterinary medicines, not only for local hospitals, but 
also because these patterns can vary according to geography following the 
epidemiology of the specific resistance genetic determinants.  
The antibiotics to test are narrow and/or broad spectrum β lactams 
(penicillins, cephalosporins and carbapenems, with β lactamase inhibitors), 
glycopeptides (vancomycin, teicoplanin), macrolides (erythromycin), lincosamides 
(clindamycin), phenicols (chloramphenicol, florfenicol), tetracyclines, recent 
fluoroquinolones, and/or metronidazole (Prescott et al., 2000). Macrolides can not be 
tested in anaerobic conditions with CO2 concentrations between 5 and 10%. It must 
also be remembered that chloramphenicol (but not florfenicol) was banned years ago 
for use in farm animals, and that metronidazole has been banned more recently in the 
European Union. Bacitracin has been used for years in poultry to prevent 
enterotoxaemia caused by C. perfringens, but is today also banned in the European 
Union. Nitrofuranes are recommended against C. colinum infections in birds 
(Prescott et al., 2000; chapter 11), but are also not allowed in farm animals in the 
European Union.  
A variety of methods is available for susceptibility testing of anaerobic 
isolates, although problems are encountered with all of them. Agar plate methods 
include agar dilution, Wadsworth modified agar dilution, spiral gradient endpoint 
(SGE [Spiral System Instruments, Bethesda, MD]), PDM Epsilometer (E- test [AB 
Biodisk, Solna, Sweden]) and disk diffusion. Broth methods include broth dilution, 
broth micro-dilution and broth disk-elution. Not all of these procedures are currently 
endorsed (e.g. disk diffusion and broth disk-elution) by the NCCLS (National 
Committee for Clinical Laboratory Standard, 2004) whose guidelines are followed by 
the majority of the commercially available systems (Engelkirk et al., 1992 ; 
Summanen et al., 1993). 
Agar dilution, broth macro- and micro-dilution are the techniques suggested 
to be used in research studies to determine the minimal inhibitory concentrations 
(MIC) of different antibiotics against a clostridial isolate in anaerobic conditions. The 
systems used in routine diagnostic laboratories are generally based on broth micro-
dilution methods. There are commercial sources for frozen trays (MSI/Micro-Media 
System [Cleveland, OH], MicroTech Medical System [Aurora, CO] and Innovative 
Diagnostic Systems [Atlanta, GA]) or lyophilized trays [Radiometer 
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America/Sensititre, Westlake, OH]). The limited number of appropriate anti-
anaerobic drugs in some of these trays is a disadvantage, but the laboratories can be 
supplied with custom-poured MIC panels by MicroTech Medical System and by 
Sensititre (Engelkirk et al., 1992 ; Summanen et al., 1993). 
E-test is another agar-diffusion method used successfully for anaerobes. It is 
quite easy to perform and to read; it shows a high categorical agreement with the agar 
dilution reference method in research studies but it is costly. Therefore this method is 
particularly suited for studying individual isolates against few selected agents 
(Engelkirk et al., 1992 ; Summanen et al., 1993). 
In human anaerobic bacteriology the MIC values are interpreted and the 
tested strains categorized (Susceptible, Intermediate, Resistant) according to the 
breakpoint concentrations recommended either by NCCLS (National Committee for 
Clinical Laboratory Standard, 2004), or by the EUCAST (European Committee on 
Antimicrobials Susceptibility Testing, 2003), or by national committee guidelines 
(e.g. Comité de l’ Antibiogramme de la Société française de Microbiologie [2005], 
Deutsches Institute für Normung [2004]) in an attempt to achieve a good predictive 
value on the basis of in vivo correlations (Kahlmmeter et al., 2003). 
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Table 13.1: General morphological and cultural criteria of major pathogenic clostridia (Carter, 1986; Bisping and Amtsberg, 
1988; Biberstein and Zee, 1990; Allen and Baron, 1991; Quinn et al., 1994; Hirsh and Biberstein, 2004). 
 
Clostridium Morphology Spores Culture features Colonies/Haemolysis 
argentinense 1.5 to 2.0 x 1.5 to 10.0 µm Oval, subterminal, Very strict anaerobe Circular to irregular, 
Toxintype G  Motile 




Up to five days 
 
raised, transluscent, smooth, shiny 
Haemolysis zone 




Singly or in pairs 
Straigth to slighly curved rods 
bulging Up to five days flat to raised, transluscent to semi-opaque, gray 
Haemolysis zone 




Singly or in pairs 
Straight rods 
bulging (usually)  Up to five days to opaque, gray-white 
Haemolysis zone 
botulinum Groupe III 0.5 to 2.5 x 3.0 to 22.0 µm Oval, subterminal, Very strict anaerobe Circular to slightly  
Toxintypes C/D Motile 
Singly or in pairs 
Straight rods 
bulging Up to five days irregular, flat to raised, transluscent, gray-white 
Haemolysis zone 
chauvoei 0.6 to 1.5 x 3.0 to 8.0 µm  Oval, subterminal, Very strict anaerobe Compact, spherical, 
 Pleimorphic, motile bulging Needs blood, cysteine smooth, greyish 
 Singly or in short chains  Slow growth Slight haemolytic 
 Straight sides, rounded ends    
colinum 1.0 x 3.0 to 4.0 µm Oval, subterminal,  Very fastidious,   Growth on blood agar 
  bulging, rare primary growth in broth only after several passages 
difficile 0.5 to 2.0 x 3.0 to 17.0 µm Oval, subterminal, Fastidious, Rhizoid (grounded glass), 
 Motile 
Singly or in short chains 
Slender rods 
slightly bulging Special blood agar flat or low convex, opaque, gray-white 
haemolyticum 0.5 to 1.5 x 3.0 to 6.0 µm Oval, subterminal, Very strict anaerobe Lenticular, then woolly 
 Motile, mainly singly bulging, abundant Slow growth Haemolysis zone 






Table 13.1 (continued). General morphological and cultural criteria of major pathogenic clostridia (Carter, 1986; Bisping and 
Amtsberg, 1988; Biberstein and Zee, 1990; Allen and Baron, 1991; Quinn et al., 1994; Hirsh and Biberstein, 2004). 
 
Clostridium Morphology Spores Culture features Colonies/Haemolysis 
histolyticum 0.5 to 1.0 x 1.5 to 9.0 µm Oval, subterminal, Can grow aerobically Circular to irregular, flat to low convex, 
 Singly or in short chains 
Straight rods 
slightly bulging No spore formation during 
aerobic growth 
translucent to semi-opaque, gray-white 
Haemolysis zone 
novyi 0.5 to 1.5 x 3.0 to 10.0 µm Oval, subterminal, Very strict anaerobe Haemolysis zone 
 Motile, mainly singly bulging, abundant Slow growth gray-white 
 Straight sides, rounded ends   Haemolysis zone 
perfringens 1.0 to 1.5 x 4.0 to 8.0 µm Oval, subterminal, Aero-tolerant Round, smooth, opaque 
 Singly or in pairs, encapsulated bulging, rare  glistening, ochre 
Haemolysis zone(s) 
 Thick, straight sides   
 
piliforme 0.5 x 8.0 to 10.0 µm ? Only on cell- Not relevant 
 Motile, intracellular  containing media  
septicum 0.6 to 1.0 x 3.0 to 8.0 µm Oval, subterminal, Strict anaerobe Swarming, cottony 
 Motile, long chains including filamentous 
forms (10-30 µm) 
bulging Rapid growth (veil-like or lawn-like) 
 Straight or slightly curved   Haemolysis zone 
sordellii 0.5 to 1.5 x 1.5 to 10.0 µm Oval, central or Strict anaerobe Round to irregular,  
 Motile, singly or in pairs subterminal, not  translucent to greyish 
 Straight or weakly bulging   
spiroforme 0.3 to 0.5 x 2.0 to 10.0 µm Round, terminal  Strict anaerobe Circular, convex, shiny, 
 Non motile 
Coiling, long chains 
(subterminal), slightly 
bulging 
 Semi-opaque to opaque, gray-white to 
gray-brown 
tetani 0.5 to 1.0 x 2.0 to 18.0 µm Round, terminal, Strict anaerobe Circular or rhizoid, flat,  
 Motile, mainly singly 
Straight, slender 
bulging Slow growth translucent, gray (swarming) 









The main aim of this chapter is to discuss the molecular characterisation of 
clostridia. However, some preliminary remarks on molecular identification in general 
are necessary to provide a background.  
 
14.1.1. Classification, characterisation and identification of micro-organisms 
in general 
Classification is the theory and process of ordering organisms into 
recognisable groups. Different classification schemes may exist in parallel. However, 
today the initial step of classification is mainly based upon characterisation of gene 
coding sequences for RNA of the small subunit of ribosomes (named 16S rRNA gene 
in the following pages), the sequences being the basis for unravelling evolutionary 
lines of descent.  
In the pre-molecular era, classification systems were based, for example, on 
selected cellular and metabolic properties (such as presence or absence of spores and 
of photosynthetic apparatus) or the relationship to oxygen. Moreover, at the dawn of 
bacterial systematics, classification was even based on shape, colour or motility. It is 
obvious that characterisation and classification are inter-dependent, as the type of 
classification defines the range of properties to be determined.  
Present day classification, following the polyphasic approach, is much more 
demanding than any other previous classification strategy. This is because a broad 
spectrum of properties needs to be determined at the genetic level (information 
carried directly on the genes, including non-coding regions) and at the epigenetic 
level (information carried on the products of the genes).  
Bacterial systematics consists of a series of sequential steps. The first step is 
characterisation, i.e. obtaining data on the properties of an organism. These 
properties are then compared to those of described species, usually following a 
dichotomic key or focusing on salient characteristics. Results will show whether the 
isolate can be identified, i.e., affiliated to a described taxon. If identification is not 
possible, the isolate is likely to represent a novel taxon which may be described 
following more extensive characterisation. The extent to which characterisation 
needs to be performed depends upon the range of properties assigned to phylogenetic 
neighbouring taxa, to which the new taxon belongs. If sufficient properties have been 
determined allowing the organisms to be classified (i.e. placed into a systematic 
framework), a name is given to the appropriate rank of the classified organism. It is 
named as a new species either of an established genus or of a novel genus. It may be 
concluded that the purpose and efficiency of a taxonomy is tested by its use in 
identifying organisms (Stackebrandt et al., 1998).  
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A chapter on molecular identification methods should not give the 
impression that non-molecular approaches have lost their significance (even though 
the molecular approach may one day replace these more traditional methods). In fact, 
molecular identification constitutes only one, albeit large, segment of a broader 
spectrum of methods required unambiguously to affiliate isolates to taxa today. 
Nucleic acid based identification approaches also have obvious advantages over 
more traditional methods. These are: cost, time, reproducibility, reliable 
authentification, existence of cumulative databases and their universal application. 
Nucleic acid based identification approaches are especially advantageous when large 
strain numbers from the clinical environment need to be identified rapidly, some 
expressing the most potent toxins known.  
   
14.1.2. Prerequisites for a suitable identification marker 
Nucleic acid stretches suitable for the identification of members of a given 
phylogenetic level are molecules showing some of the same characteristics also 
demanded of suitable phylogenetic markers. The stretches should be present among 
all representatives of a given group of phylogenetically related organisms in order to 
enable their study. Since every individual sequence position can only carry 
information on a rather narrow range of evolutionary time, an increasing number of 
independently evolving positions or regions raises the number of phylogenetic levels 
that can be detected.  
Depending on the method applied, a nucleic acid stretch should contain at 
least one region of conserved structure to allow one PCR primer. The conserved 
region would also have a second primer targeting a taxon-specific variable stretch, to 
amplify a specific DNA fragment of a wide range of taxa. Between these conserved 
regions, the nucleotide composition should contain one or more regions of high 
sequence divergence (e.g., for sequence analyses of intergenic space [ITS] regions 
and intrageneric stretches). In addition, the rrn operons (coding for rRNA) should 
contain sequence idiosyncrasies (to allow fluorescent in situ hybridisation [FISH]), 
together with discriminative sequence analyses and/or electrophoretic separation of 
DNA fragment of different lengths. 
The sequence should contain one, preferably more, restriction sites to allow 
generation of DNA patterns by Amplified rRNA Digest Restriction Analyses 
(ARDRA), a 16S rRNA gene-based RFLP method.  
The availability of the rapidly increasing database of sequenced genes and 
of completely sequenced genomes will facilitate the comparative search for nucleic 
acids suitable for identification. Likewise, the following will facilitate the 
development of identification protocols: the curated database of certain housekeeping 
genes (MLST, Multi-Locus Sequence Typing), search programs for tandem repeats 
(MLVA, Multi-Locus Variable-number tandem repeat Analysis) and probe design 
(ARB software). 
Table 14.1 lists some of the genes presently being investigated in detail in 
order to unravel the phylogenetic structure of prokaryotes. Table 14.2 compares the 
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suitability of the gene coding for 16S rRNA and gene coding for proteins to serve as 
phylogenetic markers.  
 
Table 14.1: Examples of genes used for phylogenetic studies 
Widely used conservative and 
ubiquitous gene coding for 
Genes of restricted use and not 
ubiquitous gene coding for 
16S rRNA, 23S rRNA, alanyl-tRNA Pyrophosphatase 
Ribosomal proteins Ferredoxin oxidoreductase 
DNA gyrase B, DNA synthase, recA Chitinase, serine proteinase, biotin 
synthase 
HSP70 (DNAK), HSP60 (chaperonin) Acetyl-CoA acytransferase,  
melonavate pathway 
 
Table 14.2: Major differences between gene coding for 16S rRNA and proteins, as 
judged from the viewpoint of phylogenetic significance 
Property 16S rRNA gene Protein-coding genes 
Intracellular amplification mainly multiple gene copies single copy 
Universally distributed + some, mostly not 
Availability of conservative  
PCR primers 
+ Rarely 
Evolution orthologous orthologous, but 
often paralogous 
Degeneration of the code -, not coding for proteins + 
Database large (<50.000 sequences) rare (few substantial) 
 
14.2. Molecular characterisation of clostridia 
14.2.1. The 16S rRNA genes 
Determination of the 16S rRNA gene sequence is among the first steps 
applied in the identification process. Either purified nucleic acid preparations or 
crude extracts of bacterial cells can be used for in vitro amplification of rrn genes (= 
rDNA). In principle, a few bacterial cells are sufficient to perform the analysis. The 
worldwide application of rDNA gene sequencing makes description of a detailed 
protocol unnecessary. The reader is referred to the publication by Rainey and 
Stackebrandt (1992); PCR primer sequences have been indicated by Lane (1991) and 
updates are regularly included in recent publications on the phylogeny and 
systematics of prokaryotes. The almost complete gene is amplified using two primers 
located at the 5’ terminus (position 27 forward) and the 3’ terminus (position 1525 
reverse). A series of internally binding primers (usually 14–20 bases in length) 
(Lane, 1991) allows rapid sequencing by means of the primer-directed chain 
termination method.  
More than 98% of the Clostridium species type strains have been sequenced 
(Stackebrandt and Hippe, 2001), including pathogenic species (Stackebrandt et al., 
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1999), the remaining species being unavailable from public collections. Major 
findings of phylogenetic studies have demonstrated that the genus Clostridium 
constitutes a broad assembly of distantly related major branches within the 
Firmicutes (Collins et al., 1994). Studies have also shown that the species C. 
botulinum, phenotypically circumscribed by the presence of neurotoxins, embraces at 
least five moderately related strain clusters, each being defined by the presence of a 
unique neurotoxin. Nearly full length 16S rRNA gene sequences have been subjected 
to RFLP analysis, digesting the amplificate with restriction enzymes (e.g. TaqI, 
RsaI), resulting in the discrimination of C. perfringens from other species (Cordoba 
et al., 2001) and in the classification of pathogenic strains (Gürtler et al., 1991).  
 
14.2.1.1. Variable 16S rRNA gene regions  
As the position of variable regions is known where the majority of species-
specific nucleotide differences occur, only parts of the complete gene need to be 
sequenced. Within the 16S rRNA gene, variable regions are located between the 
following positions: (I) 60 and 106, (II) 146 and 219, (III) 440 and 494, (IV) 588 and 
651, (V) 821 and 879, (VI) 997 and 1044, (VII) 1117 and 1154, (VIII) 1240 and 
1296, as well as (IX) 1435 and 1466 (E. coli numbering). The degree of variation 
differs between members of the main lines of descent (phyla and orders). 
Amplification of rDNA stretches by polymerase chain reaction (PCR), flanking the 
variable regions, provides easy access to sequenceable material. The sequences of the 
members of Clostridium differ mainly in the variable regions located in region I. 
Long insertions with moderate sequence similarities have been detected in variable 
region I in Clostridium paradoxum (Rainey et al., 1996) and in members of the genus 
Desulfotomaculum (Stackebrandt et al., 1997), a neighbouring taxon of Clostridium. 
The multiple rrn operons may show strong micro-heterogeneity, requiring a cloning 
step for unambiguous sequence determination.  
Regions displaying length heterogeneity are ideal candidates for 
identification protocols based on electrophoretic analysis of PCR products, especially 
when species-specific PCR primers are used (Van Dyke and McCarthy, 2002). 
Application of two species-specific PCR primers, followed by restriction analysis of 
one of the resulting fragments, has led to the discrimination of C. estertheticum from 
other organisms detected in vacuum-packed meat (Helps et al., 1999). Sensitivity can 
be increased by application of nested PCR, where amplification is achieved by 
applying two sets of PCR primers, the second one amplifying a subset of the 
fragments generated by the first set of primers (Klijn et al., 1995) 
 
14.2.1.2. Oligonucleotide probes targeting rrn genes 
The identification of highly variable regions with the gene coding for 16S 
rRNA has  led to the development of oligonucleotide probes directed against these 
mainly species-specific regions. The phylogenetically broader the taxonomic group, 
the more difficult it is to design a single probe capable of detecting all taxon 
members. This is especially true for members of the genus Clostridium, which is 
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phylogenetically heterogeneous. A broad group would also detect members of other 
genera that cluster with certain Clostridium species (e.g. Ruminococcus, 
Eubacterium, Sarcina), while a species-cluster-specific probe would exclude 
detection of a major part of the Clostridium species.  
Originally, radioactively and digoxigenine labelled probes (Rainey and 
Stackebrandt, 1992) were designed that hybridised with one of the following: 
membrane-bound rRNA, isolated DNA or DNA released from lysed filter-fixed 
colonies. Examples were C. perfringens-specific probes (Rönner et al., 1994a) and 
probes directed against C. botulinum (Rönner and Stackebrandt, 1994b). Later, 
fluorescently labelled probes were developed that were able to target RNA directly 
within the cells. Application of multiple probes carrying different fluorescent labels 
to the same 16S rRNA, increased sensitivity and allowed detection of non-cultured 
cells directly within the environment (Amann et al., 1995).  
Little data is available for clostridial species, as detection of these organisms 
in environmental samples has not yet been of high research priority. Examples 
include the use of fluorescence in situ hybridisation (FISH) probes in the 
enumeration of human colon bacteria (Harmsen et al., 2000a) and intestinal flora in 
breast-fed and formula-fed newborn infants (Harmsen et al., 2000b). A combination 
of a method of PCR amplification of a 16S rRNA gene region, followed by probe 
hybridisation, increases the sensitivity of detection of Clostridium tyrobutyricum, a 
bacterium involved in the late blowing of certain cheeses (Klijn et al., 1995). 
 
14.2.1.3. 23S rRNA genes and intercistronic spacer regions 
Some data is available for the 23S rRNA gene, though this molecule is 
mainly used for phylogenetic studies. Partial 23S rRNA gene sequences have been 
used to detect C. chauvoei in clinical materials (Sasaki et al., 2000). Using primers 
directed against the 3' terminus of 16S rDNA and the 5' terminus of 23S rDNA, the 
intergenic spacer region is accessible for amplification followed by electrophoretic 
separation of the resulting fragments. One example is the molecular differentiation of 
some clostridia associated with “blown pack” spoilage (Broda et al., 2003), a species 
causing the clinical diagnosis in cows of blackleg or malignant oedema (Sasaki et al., 
2001). A further example is the identification of intestinal clostridia, including 
several species pathogenic to humans and animals (Song et al., 2002).   
 
14.2.2. Multi-Locus Sequence Typing (MLST) 
This method has been introduced to base population genetics and 
epidemiology on a molecular level. Stretches of about 400–500 nucleotides of seven 
genes, coding for housekeeping proteins, are carefully analysed and differences in 
alleles recorded. Examples of genes used in MLST are DMSO reductase, 
aspartokinase glutamin synthase, thymidilate kinase, phosophomannomutase and 
anthranilate synthase. The selection of genes needs to be evaluated for each new 
taxon undergoing investigation, as genes common to a particular set of organisms 
may not be universally distributed. Prominent examples are strain-rich species such 
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as Neisseria gonorrhoea and N. meningitidis, Yersinia pestis and Y. 
pseudotuberculosis, as well as Bacillus anthracis and B. cereus. The evolutionary 
distance between strains is quantified in MLST as the number of differing loci. All 
strains identical to a particular strain at 5 or more loci are considered members of a 
clonal complex, or “ecotype”. Each species consists of several ecotypes, which 
should be considered the starting point for independent evolution from within a 
species as defined today.    
The topology of trees of housekeeping genes not involved in recombination 
is similar to that of trees representing the core of the genome, i.e. genes coding for 
rRNA. These organisms are considered clonal organisms. In cases where the 
topologies of these two sets of genes differ, recombination has occurred and these 
organisms are considered panmictic. Epidemic populations are panmictic, but contain 
islands of clonal structure, i.e., the population structure is not coherent. 
No MLST data is as yet available for clostridia, but will very likely be 
generated because of the availability of strain-rich species with significant 
pathogenic potential.  
 
14.2.3. Analysis of genomic DNA 
The analyses of DNA patterns comprise a broad range of different 
techniques involving electrophoreses, including restriction fragment analyses and the 
specific and non-specific generation of PCR-mediated amplification products.  
 
14.2.3.1. Restriction Fragment Length Polymorphism (RFLP)  
This method should be considered a traditional approach. Originally it was 
used in two-dimensional physical mapping by separation of macro-restriction 
fragments using pulsed field gel electrophoresis (PFGE). This included a wide 
spectrum of different variations, for example: CHEF (Contour-clamped 
homogeneous electric field), FIGE (Field inversion gel electrophoresis), TAFE 
(Transverse alternating field electrophoresis) and PHOGE (Pulsed homogeneous 
orthogonal field gel electrophoresis). The advantage of high one-dimensional 
electrophoretic RFLP resolution was soon evaluated for taxonomic purposes and is 
used today for the discrimination of highly related strains. The quality of results 
depends on the generation of high molecular DNA and reproducible separation 
techniques, as well as on sophisticated software programs to recognise small 
differences in migration behaviour of fragments. Only a small amount of data is 
available for members of Clostridium, such as in the study by Cordoba et al. (2001). 
This study differentiated C. perfringens from other strains of other Clostridium 
species. 
 
14.2.3.2. Amplified Fragment Length Polymorphism (AFLP)  
AFLP is the method indexing variations in the whole genome, depending on 
the presence of restriction sites, and is one which is highly reproducible. The method 
consists of three steps. Firstly, total DNA is digested using 2 restriction enzymes and 
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the resulting restriction fragments subsequently ligated to halfsite-specific adaptors. 
Secondly, a subset of the fragments is selectively amplified, using 2 restriction-
site/adaptor-specific primers. Use of fluorescently labelled primers (FAFLP), will 
refine this method. Thirdly, the PCR products (30–50 fragments of size 80–550 bp) 
are electrophoretically separated on polyacrylamide gels and fragments numerically 
evaluated by computer assistant analysis (Vos et al., 1995; Janssen et al., 1996). The 
AFLP method has been used to detect C. novyi and C. perfringens in drug users 
(McLauchlin et al., 2002) and to investigate C. perfringens food poisoning in seven 
outbreaks in the UK. A comparison of PFGE and AFLP has been published by Autio 
et al. (2003) concerning persistent and sporadic Listeria monocytogenes strains, 
distant relatives of Clostridium genus members.  
 
14.2.3.3. Multi-Locus Variable-number tandem repeat Analysis 
(MLVA) 
The most recent development using DNA patterns for characterisation, 
identification and epidemiology uses the polymorphism of tandem repeats (TR) as 
informative markers. Although this technique has not yet been used for 
differentiation of clostridial strains, it should be briefly mentioned here, as its 
application to clostridia can be anticipated. Originally found in mammalian cells, TR 
reminiscent of mini- and micro-satellites have also been found in pathogenic 
prokaryotes (van Belkum et al., 1997). This is despite the fact that these species 
constitute genetically very homogeneous entities. The role of TR in the regulation 
and translation of genes has been discussed by Le Flche et al. (2001), and the 
position of TRs has been elucidated by analysis of fully sequenced genomes. The 
data of these authors indicate firstly, that the density of TR array length (< 100 bp) 
varies widely in prokaryotic genomes (excess of repeats in Buchnera sp., 
Ureaplasma urealyticum). Secondly, it indicates that some species have a very strong 
excess of TR, with repeat unit lengths comprising a multiple of three (e.g. 
Mesorhizobium loti, Mycoplasma tuberculosis and Pseudomonas aeruginosa). A TR 
database is available at (http://minisatellites.u-psud.fr). This locates tandem repeats 
according to a number of criteria, among others, array length (length of gene 
fragment enclosed), repeat unit length and number of repeats.  
A number of epidemiological molecular subtyping analysis studies have 
been published, with probably the most well known involving Bacillus anthracis 
(Keim et al., 2000). Here, two different methods were used to enable typing of 
strains of B. anthracis, including those involved in bioterrorism. The methods were 
firstly, sequencing of the protective antigen gene on plasmid pXO1MLVApagA and 
secondly, Multi-Locus Variable-number tandem repeat Analysis (MLVA). For 
MLVA analyses, 8 variable number TR markers (6 chromosomal markers and 2 
plasmid markers), were combined in 4 multiplex PCR reactions. The PCR products 
were labelled with fluorescent primers using different coloured dyes, and the 
amplificates pooled for visualisation on an ABI Genescan. Thus, the location and 
length of amplificates were easy to detect and to evaluate by applying numerical 
analyses. The advantage of this system lies in the use of defined DNA regions across 
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the entire genome. The creation of a cumulative database has enabled the use of 
standardised amplification and separation methods. The disadvantage of this system 
lies in the need to have sequence information (preferably of more than a single strain 
of a species) available prior to the design of PCR primers.  
 
14.2.4. Identification of as yet uncultured clostridia 
With the combination of methods covering the isolation of DNA from any 
environmental sample (PCR amplification of 16S rRNA genes, cloning and sequence 
analysis), even as yet uncultured bacteria and microbial communities from natural 
samples have become accessible for identification and phylogenetic analysis. The 
presence of cells directly in the environment can be detected by in situ hybridisation 
techniques (FISH). These studies have demonstrated the enormous taxonomic, hence 
biotechnological, potential of hitherto unrecognised clostridia in nature. Some 
examples of the presence of hitherto uncultured clostridial cells in the environment 
are listed in Table 14.3.  
  
Table 14.3: Examples of evidence of as yet uncultured clostridial species in 
environmental samples, as determined by sequence analysis of cloned 16S rRNA 
genes 
Habitat Representative  
16S rRNA gene  
accession 
number 




Rice straw in anoxic 
paddy soil, Italy 
AJ289217 I, II, IV, XIVa Weber et al., 2001 
Coral surfaces, Curaçao AF441866 III, XII, XIVa Frias-Lopez et al., 
2002 
Lake Fryxell mat, 
Antarctica  
AJ287732 I, II, III, IV, 
IVb,  
Brambilla et al., 
2001 
Bulk soil anoxic rice 
paddy, Italy 
AJ229234  IX, XIVa Chin et al. 1999 
Intestine termite 
Reticulitermes peratus 




Municipal landfill sites, 
UK 




Saale river sediment; 
Germany 
AJ009473 I Von 
Wintzingerode et 
al., 1999 
Oil field, Canada U46505 XVIII Voordouw et al., 
1996 
Marine sediment, Puget 
Sound, Wash. USA 
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15. Gas chromatography of metabolic end products and 




Conventional methods of identifying anaerobic bacteria are based on 
morphology observation, culture and classical biochemical tests. In contrast to 
aerobes, these techniques are often insufficient to permit definitive identification, and 
additional investigations are required to complete the diagnosis. One of the most 
established methods consists of the detection and determination of organic 
compounds. 
Two main groups of compounds may serve as support in the identification 
of anaerobes: 
• Metabolites, produced by bacteria as a result of carbohydrate 
fermentation and/or breakdown of amino acids.  
• Long-chain fatty acids, which are the major constituents of lipids (cell 
membranes), lipopolysaccharides (Gram-Negative bacteria) and lipoteichoic 
acid (Gram-Positive bacteria).  
Gas chromatography (GC) is a well known technique allowing analysis of 
these metabolic or structural substances. Thus, GC offers 2 possibilities of additional 
means for the identification of anaerobes. In this chapter we examine the procedures 
and potential of each one of these approaches in anaerobic bacteriology. 
 
15.1. Metabolic end products 
Anaerobic bacteria produce numerous metabolites, which mainly result from 
sugar fermentation and/or from the breakdown of amino acids by deamination, 
decarboxylation or Stickland reaction. These metabolites accumulate in the growth 
medium and are characteristic of bacterial genera and of some species. Most of them 
have been described in the last 2 decades and consist of 2-oxo-acids (Tsuchiya et al., 
1990), 2-hydroxy-acids (Carlier and Sellier, 1987), (methylthio)-acids (Carlier, 1992; 
Moss and Nunez-Montiel, 1982), aromatic acids (Moss et al., 1970; Van Assche, 
1978) and phenolic compounds (Elsden and Hilton, 1976). A list of these molecules 
is presented in Table 15.1. Their detection by GC is the most common and most 
documented technique with regard to the identification of anaerobic bacteria. 
Nevertheless, some other analytical procedures including HPLC (High-Performance 
Liquid Chromatography) (Guerrant et al., 1982; Paavilainen and Korpela, 1993; 
Stein et al., 1992), capillary electrophoresis and indirect UV detection (Arellano et 






Table 15.1: Microbial metabolites that can be detected by GC from culture media  
Compounds Usual names 





















Non-volatile fatty acids and phenolic compounds 





























Aromatic acids and phenolic compounds  
2-phenylacetic  
3-phenylpropanoic Hydrocinnamic 
Phenol   
4-methylphenol p-cresol 
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15.1.1. GC procedures 
From an analytical point of view, microbial metabolites are classified as 
volatile fatty acids (VFAs), also called short-chain fatty acids (SCFAs), and as non-
volatile fatty acids (NVFAs). In general, VFAs (acetic to heptanoic), which are the 
main metabolic products of interest in taxonomy, are directly analysed as free acids 
after extraction from the growth medium using either diethyl ether (Carlier, 1985; 
Holdeman et al., 1977; Jousimies-Somer et al., 2002) or methyl tert-butyl ether. The 
latter is a safer solvent, since it is considered less flammable (Thomann and Hill, 
1986). 
Other methods have been developed, such as headspace chromatography, a 
complicated technique used for alcohols (C1–C4) and VFA analysis (Seifert et al., 
1990). Because peak areas are very dependent on analytical conditions (syringe and 
sample temperature), quantitative analysis is only possible with an automated GC 
system.  
Direct analysis of the supernatants of acidified spent media, faecal or 
purulent material has also been proposed (Rogosa and Love, 1968; Reed and 
Sanderson, 1979; Tangerman and Nagengast, 1996). A major drawback of this 
method is that non-volatile compounds tend to decompose in the injector and 
column. This problem can be solved by pre-treatment procedures or by use of a glass 
liner in the injector port. This liner is stopped with glass wool plugs and acts as a pre-
column (Tangerman and Nagengast, 1996).  
In the last few years, an original extraction technique has been developed, 
which may be applied to the identification of anaerobic bacteria. Solid-phase micro-
extraction (SPME) is a new solvent-free sample preparation technique, which is 
inexpensive and time efficient (Lord and Pawliszyn, 2000). It utilises a small, fused-
silica fibre coated with a thin layer of polymer to extract analytes from the sample 
matrix. Then the fibre is introduced into the gas chromatograph and the analytes are 
thermally desorbed into the injector and subsequently chromatographed. The analysis 
of fatty acids (C2–C10) with SPME can be carried out directly from liquid (broth 
culture) or from the headspace above the sample (Abalos et al., 2000; Mills and 
Walker, 2000). Although this technique has not yet been applied to bacterial cultures, 
SPME seems to be a promising method for analysis of VFAs produced by anaerobes. 
Since this method allows for the making of derivatives (Pan and Pawliszyn, 1997), it 
is certainly also applicable to NVFA analysis. In conclusion, the use of SPME 
deserves to be developed in anaerobic microbiology. 
NVFAs, such as oxo-acids, hydroxylated acids, dicarboxylic acids etc., have 
a high boiling point, and therefore cannot be directly detected by GC. They must 
undergo a derivatisation procedure prior to chromatographic analysis. The most 
commonly used method consists of esterification of analytes by direct incubation of 
media with methanol-hydrochloric or methanol-sulphuric acid followed by solvent 
extraction (Carlier, 1985; Holdeman et al., 1977; Jousimies-Somer et al., 2002). 
However, the methylation reaction is incomplete and the recovery rate of methyl 
esters varies according to the acid. In addition, 2-oxo acids yield at least 2 products 
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(Carlier and Sellier, 1989). A typical example is the methylation of pyruvic acid 
which produces methylpyruvate as expected, and a second component, identified as 
methyl-2,2-dimethoxypropanoate (Carlier and Sellier, 1989; Hautala and Weaver, 
1969). In order to overcome these problems and to obtain reproducible accurate 
quantitative results, the method has been standardised and a known amount of 
internal standard (2-methylbenzoic acid) is added in advance to start the methylation 
reaction (Carlier, 1985). 
 
15.1.2. Other procedures 
Esterification of fatty acids can be carried out using different alcohols such 
as n-butanol, 2-butanol, propanol and methanol. A previous method consisted of 
converting VFAs and NVFAs to butyl esters with 14 % w/v boron trifluoride – 
butanol reagent (Lambert and Moss, 1972). This method permitted separation of fatty 
acids (formic acid to heptanoic acid), lactic and succinic acids. Although this 
technique is no longer used in microbiology, it is always employed for the analysis of 
fatty acids in dairy products and can be very useful in accurate analysis of VFAs. 
Indeed, substituting the methyl group with a butyl group improves the flame-
ionisation efficiency of fatty acid esters. Moreover, VFA butyl esters have a uniform 
flame-ionisation detection (FID) response, irrespective of the number of carbon 
atoms contained in the molecule (Ulberth et al., 1999). Many other derivatisation 
procedures can be employed, but their description is beyond the scope of this chapter. 
(Review: Taguchi, 1990). 
 
15.1.3. Application to Clostridium genus 
The analysis of metabolic end products can be utilised in 2 different ways: 
firstly, for a rapid presumptive diagnosis of anaerobic infection in the patient, or 
sometimes for identification by chemical marker of a particular species; secondly, as 
a tool in the identification of bacteria isolated from a clinical specimen. 
 
15.1.3.1. Rapid presumptive diagnosis 
Proteolytic Clostridium species degrade amino acids (such as valine, 
leucine, isoleucine, phenylalanine, tyrosine and tryptophan), to iso acids and phenolic 
compounds. These latter compounds can be considered as microbial markers. 
Therefore, their detection by headspace analysis or direct injection of body fluids, 
acidified liquid or solid culture medium (Pankuch and Appelbaum, 1986; Wiggins et 
al., 1985), indicates the presence of these proteolytic species in the sample. However, 
a microscopic examination of the sample is needed, since branched chain acids are 
also produced by Peptostreptococcus anaerobius and some Gram-Negative bacilli 
(Porphyromonas, Tissierella). In the same way, a presumptive identification of 
species can be encouraged by the detection of a specific compound after growth on 
supplemented broth culture. For example, C. difficile produces p-cresol on 
cycloserine-cefoxitin-fructose-egg yolk agar (CCFA) or pre-reduced anaerobically 
sterilised (PRAS) peptone yeast broth supplemented with tyrosine or p-
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hydroxyphenylacetic acid (Sivsammye and Sims, 1990). C. malenominatum, C. 
tetani, C. tetanomorphum, C. cochlearium and C. limosum produce phenol from 
tyrosine (Elsden and Hilton, 1976).  
 
15.1.3.2. Bacterial identification 
Quantitative analysis of metabolic end products in conjunction with some 
simple tests such as gas, indole or catalase production, allows rapid identification of 
many common anaerobes. However, care must be taken to obtain reproducible 
results. Inoculum size, culture medium and time and condition of incubation must be 
standardised (Carlier, 1985). The more commonly isolated Clostridium may be 
subdivided into 2 chromatographic groups. The first is composed of species 
producing one or several straight chain volatile fatty acids, i.e. acetic, or acetic, 
propionic and butyric acids, whereas the second includes species generating both 
straight and branched-chain fatty acids. 
 
15.1.3.2.1. Group 1 
 
Table 15.2: Chromatographic profiles of main Clostridium producing butyric acid 
SPECIES A* P B C L H-B H-V Phenol 
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   * Mean values expressed in mmol/l; ± standard deviation in parentheses 
   Abbreviations: A: acetic acid; P: propionic acid; B: butyric acid; C: 
caproic acid; L: lactic acid;  H-B: 2-hydroxybutanoic acid; H-V: 2-hydroxyvaleric 
acid; tr: trace amount < 0.1 mmol/l.  
 
If acetic acid is the only volatile acid produced, bacteria cannot be 
identified, since this chromatographic profile is common to many species. 
Consequently, biochemical tests are required for speciation except for C. 
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clostridioforme, which often stains Gram-Negative and forms characteristic 
elongated cells. Among the species yielding butyric acid, C. perfringens produces 
propionic and 2-hydroxybutyric acids.  
Non-proteolytic C. botulinum produces a similar pattern to that shown in 
Table 15.2 (Lund and Peck, 2000). 
It is easy to recognise by its morphology and the presence of a double zone 
of haemolysis on a sheep-blood agar plate. Other species belonging to group 1 may 
be tentatively differentiated by some chromatographic characteristics (Table 15.2). C. 
beijerinckii, unlike C. butyricum, does not produce acetic acid and only synthesises 
small amounts of lactic acid. C. innocuum exhibits a very specific profile, making its 
identification very easy without any other test. Two small peaks of acetate and 
caproate are always detected in addition to prominent peaks of butyric and lactic 
acids (Carlier, 2003). C. paraputrificum and C. tertium are very similar and must be 
identified on the basis of biochemical tests. C. tertium is nitrate-positive, whereas C. 
paraputrificum is not. C. symbiosum, a species morphologically similar to C. 
clostridioforme, is characterised by the production of butyric acid. Another related 
species, C. sphenoides, does not produce butyrate, but is indole positive (Holdeman 
et al., 1977). As seen above, 5 species possess chromatographic profiles similar to 
that of C. perfringens in their production of propionic and 2-hydroxybutyric acids. 
However, they differ in terms of phenol production. Moreover, their cellular 
morphology is very different. In particular, these bacteria display terminal spores.  
 
15.1.3.2.2. Group 2 
Distinctively, on the basis of aromatic and branched-chain acid production, 
the bacteria belonging to this group form 3 major subgroups (Table 15.3). 
The first subgroup includes species producing isocaproate and one aromatic 
acid, namely 3-phenylpropionate, as differential metabolites. Note the higher 
production of 3-phenylpropionic acid associated with both C. sporogenes and 
proteolytic C. botulinum species. These species are phenotypically similar. In 
particular, they are lipase positive and proteolytic (milk- digested). Therefore, precise 
identification must be performed by a toxicity test. Neither related species, C. 
bifermentans nor C. sordellii, produces butyric acid, but they are both lecithinase 
positive and proteolytic. Interspecies differentiation can be carried out using the 
urease test, which is positive for C. sordellii. However, some urease negative strains 
have been described (Nakamura et al., 1976), and thus, these particular strains cannot 
be identified by GC pattern alone. 
The second subgroup is formed by species producing mainly isocaproic acid 
and both aromatic acids, i.e. 2-phenylacetic and 3-phenylpropionic acids. C. 
mangenoti, is phenotypically very similar to the C. sporogenes/proteolytic C. 
botulinum group and also yields high levels of 3-phenylpropionic acid. However, it is 
lipase negative and non-toxigenic. This species is rarely present in clinical 
specimens. C. difficile is easily identifiable by its characteristic metabolic end 
products. Indeed, almost all organic acids usually encountered in anaerobes are 
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produced by this organism. The particular horse-stable odour, together with non-
proteolytic activity complete identification. 
The third subgroup comprises only 3 species: C. hastiforme, C. argentinense 
(formerly C. botulinum type G) and its non-toxigenic counterpart, C. subterminale. It 
is defined by the presence of isovaleric acid and the absence of 3-phenylpropionic 
acid. Also, much more importantly, production of 2-phenylacetic distinguishes this 
subgroup from the others. Production of propionic acid differentiates C. hastiforme 
from C. argentinense/C. subterminale. 
  
Table 15.3: Chromatographic profiles of main Clostridium producing branched-
chain fatty acids 



















































































































0 0 0 0 4.1 
(2.3) 
0 










0 0 0 0 2.5 
(1.2) 
0 
* Mean values expressed in mmol/l; ± standard deviation in parentheses 
Abbreviations: A: acetic acid; P: propionic acid; iB: isobutyric acid; B: butyric acid; 
iV: isovaleric acid; V: valeric acid; iC: isocaproic acid; iH: isoheptanoic acid; 4-MeS 
C4: 4-(methylthio)-butyric acid; PhA: 2-phenylacetic acid; PhP: 3-phenylpropionic 
acid; tr: trace amount > 0.1 mmol/l. 
 
15.2. Long-chain fatty acids 
Cellular fatty acid (CFA) composition of micro-organisms has been used 
extensively for bacterial identification and taxonomic purposes. Variability in 
number of carbon atoms, number and position of double-bonds, cis or trans isomers 
and substitution groups are stable parameters, provided that highly standardised 
analysis and culture conditions are observed. (Review on technology and 
applicability of CFA analysis: Welch, 1991). The usual method consists of lysing 
bacterial cells by suspension in a saponification mixture, causing the release of their 
fatty acids, which are converted to methyl ester derivatives (FAME), and then 
analysed by gas chromatography. Esterification of fatty acids can be carried out by 
many other procedures involving acid or base-catalysed transesterification (Review: 
Eder, 1995). In general, CFA analysis includes saturated, unsaturated, hydroxylated, 
straight and branched molecules with 9 to 20 carbon atoms. Identification is 
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performed by comparison of sample retention times with those of commercially 
prepared FAME standard mixes. Tentative identification of unknown acids is 
achieved by measuring their equivalent chain length (ECL)2 against a homolog of the 
saturated straight-chain monocarboxylic acids.  
The amount of each acid is determined via peak areas as a percentage of the 
total FAME peak areas. However, this technique is not practical for non-specialised 
laboratories. A major drawback involves the problem of reproducibility and of 
comparison of multivariate recordings. Besides, many other compounds other than 
FAMEs may be detected, making the chromatograms difficult to interpret. For 
example, many anaerobes contain plasmalogens, which are particular phospholipids 
possessing a vinyl ether bond at the sn-1 position, instead of the usual ester bond 
found in fatty acids. In this case, the methylation procedure leads to the formation of 
aldehydes, which are converted into dimethylacetals (DMAs). These derivatives are 
practically impossible to separate from most FAMEs. As a consequence, in addition 
to the need for a highly standardised procedure, the use of an automated apparatus 
coupled with a database is strongly recommended for effective interpretation of 
chromatograms and the accurate identification of micro-organisms.  
Today, the only commercially available system for this purpose is the 
Sherlock® Microbial Identification System (MIS) produced by Microbial ID (MIDI, 
Newark, DE, USA. http://www.midi-inc.com) and distributed by Agilent 
Technologies http://www.agilent.com. The MIS requires bacteria to be streaked on 
agar plates and incubated for 24 h before the derivatisation procedure and gas 
chromatography. The software takes into account both the presence or absence of 
FAMEs and DMAs and the ratio of the acids in the sample. The chromatographic 
profiles are compared with those contained in identification libraries by using a 
similarity index based upon calculation of the distance between the profile of the 
unknown strain and the mean profile of the closest library entry. A similarity value of 
0.5 or greater is considered an acceptable identification, and a value below 0.5 is 
taken as an uncertain identification. However, the MIS is not very sensitive and 30–
40 mg of cells (wet weight) must be used in the analysis. This is a major drawback 
for fastidious or slow-growing organisms, requiring a long incubation period. 
Moreover, because CFA composition of bacteria varies with growth media and 
culture conditions, strict adherence to the analytical protocol recommended by the 
manufacturer must be followed to avoid misidentification (Ghanem et al., 1991). 
 
                                                 
2
 Definition of ECL is as follows: For a specified column and carrier gas, in 
the range where there is a linear relationship between the molecular weight of the 
reference saturated straight-chain monocarboxylic methyl esters and logarithm of 
their retention times, interpolation between the retention times of the reference esters 
allows determination of an ECL for each compound. This value is independent of 
experimental conditions (Miwa et al., 1960). 
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15.2.1. Application to Clostridium genus 
In general, studies demonstrating the utility of CFA analysis by MIS for 
identification of Clostridium species are lacking. According to Allen et al. (1995), 
among 216 strains representing 18 species, MIS identified 86% of the strains 
correctly to species level without supplemental tests (C. perfringens, C. difficile, C. 
butyricum, C. sporogenes, C. septicum, C. glycolicum and C. symbiosum) and 6% of 
the strains were identified to species level with the aid of some complementary tests. 
3% of the strains, including C. ramosum and C. clostridioforme species, were 
misidentified to genus level. Another study showed that 100% of C. difficile strains 
(n=62) were correctly identified by the system, while misidentification was obtained 
for one strain of C. butyricum, one strain of C. sordellii and one strain of C. septicum 
(Anderson et al., 1995). From 686 analyses of 285 C. botulinum strains and related 
organisms, Ghanem et al. (1991) found 14 CFA groups for toxigenic strains and 6 
other CFA groups for non-toxigenic strains. Depending on the toxin type or CFA 
group, the MIS system permitted a correct identification for 74 to 100% of the 
analyses, 89 to 100% for the toxigenic strains, and 60 to 100% for the non-toxigenic 
strains tested. The authors concluded that CFA analysis offers a reasonable 




Demonstration of the presence of metabolites in spent media or headspace 
and analysis of CFA are 2 effective applications of GC for identification of bacteria. 
Detection of metabolic end products is the most used, simplest and least expensive 
method. Interpretation of chromatograms can be facilitated by comparison with data 
contained in numerous publications (Carlier and Sellier, 1989; Carlier, 2003; 
Holdeman et al., 1977; Jousimies-Somer et al., 2002) or by chromatography of 
reference strains. CFA analysis is an application requiring a highly standardised 
procedure. Furthermore, it is strongly dependent on the apparatus and software 
provided by the manufacturer. However, this technique allows the differentiation of 
more than 140 bacterial compounds (Ghanem et al., 1991), and is considered as an 
important feature in polyphasic taxonomy (Vandamme et al., 1996). 
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16. Toxintyping by phenotypic and genetic assays 
 
M. Popoff and R.W. Titball 
 
16.1. Glucosyltransferases 
Glucosylating toxins are also referred to as large clostridial toxins (Table 
16.1) and are single chain proteins ranging in size from 250 to 300 kDa. The large 
clostridial toxin family encompasses Clostridium difficile toxins A and B (ToxA and 
ToxB), Clostridium sordellii lethal toxin (LT), and haemorrhagic toxin (HT) and 
Clostridium novyi  toxin.  
ToxB and LT are highly related (76% amino acid sequence identity) and are 
more distantly related to ToxA and  toxin of C. novyi (48-60% identity) (Richard et 
al., 1999). 
 
Table 16.1: Enzymatic activity and substrates of the large clostridial toxins 
Clostridium 
species 
Toxins Enzymatic reaction Substrates 
 




C. novyi  
 





















Rho, Rac, Cdc42 
Rho, Rac, Cdc42 
Rac, Rap, Ral 
 
Rho, Rac, Cdc42 
 
Rac, Ras, Rap, 
Ral 
Rac, Cdc42, Ras, 
Rap 
Rho, Rac, Cdc42 
C. difficile is the aetiological agent of pseudomembranous colitis and is 
responsible for about 30% of cases of post-antibiotic diarrhoea. ToxA, which 
experimentally induces necrotic and haemorrhagic intestinal lesions, seems to be the 
main virulence factor in naturally-occurring disease. In addition, ToxB and ToxA 
appear to participate in the recruitment of inflammatory cells, which are abundant in 
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lesions. C. sordellii and C. novyi are also the aetiological agents of gangrene, and C. 
sordellii is also an agent of haemorrhagic enteritis and enterotoxaemia in cattle. 
The large clostridial toxins catalyse the glucosylation of 21 kDa G-proteins 
from UDP-glucose, except for C. novyi, which uses UDP-N-acetylglucosamine as co-
substrate. ToxA and ToxB glucosylate Rho, Rac and Cdc42 at Thr-37, whereas LT 
glucosylates Ras at Thr-35, Rap, Ral and Rac. The large clostridial toxins cleave the 
co-substrate and transfer the glucose moiety to the acceptor amino acid of the Rho 
proteins (Just et al., 1995a, 1995b; Popoff et al., 1996). The conserved Thr, which is 
glucosylated, is located in switch I. Thr37/35 is involved in the coordination of Mg++ 
and subsequently in the binding of the  and  phosphates of GTP. The hydroxyl 
group of Thr37/35 is exposed on the surface of the molecule in its GDP-bound form, 
which is the only accessible substrate of glucosylating toxins. The nucleotide binding 
of glucosylated Ras by LT is not grossly altered, but the GEF activation of GDP 
forms is decreased (Hermann et al., 1998). Glucosylation of Thr35 completely 
prevents the recognition of the downstream effector, blocking the G-protein in the 
inactive form (Hermann et al., 1998). 
The large clostridial toxins, by modifying Rho proteins, induce cell 
rounding with loss of actin stress fibres, reorganisation of the cortical actin and 
disruption of the intercellular junctions. ToxA and ToxB disrupt apical and basal 
actin filaments and subsequently disorganise the ultrastructure and component 
distribution (ZO-1, ZO-2, occludin, claudin) of tight junctions, whereas E-cadherin 
junctions show little alteration (Chen et al., 2002; Nusrat et al., 2001). In contrast, 
LT which modifies only Rac among the Rho proteins, alters the permeability of 
intestinal cell monolayers, causing a redistribution of E-cadherin, while ZO-1 
labelling is not significantly affected (Richard et al., 1999). 
The toxins are produced in the late exponential growth phase and early 
stationary phase of growth. Glucose and other rapidly metabolisable sugars are 
inhibitors of ToxA and ToxB synthesis in C. difficile (Dupuy and Sonenshein, 1998; 
Mani and Dupuy, 2001). When grown in liquid medium containing peptones and 
yeast extract, the toxins are produced in 2 to 4 days. 
 
16.1.1. Biological methods for large clostridial toxin detection 
16.1.1.1. Mouse lethality test 
The toxins are lethal to mice upon intraperitoneal injection, but the toxicity 
varies for each toxin. The lethal dose in mice (LD50) is estimated to be 10-26 ng for 
ToxA and 1.5-4.4 g for ToxB and LT (Lyerly et al., 1988). Specific neutralising 
antibodies are required for the identification of the toxins with the mouse lethality 
test, but such sera are not commercially available. 
 
16.1.1.2. Cytotoxicity 
By modifying Rho proteins, the large clostridial toxins induce cell rounding, 
with loss of actin stress fibres, reorganisation of the cortical actin, and disruption of 
the intercellular junctions. ToxB induces loss of actin stress fibres and reorganisation 
of focal adhesions accompanied by cytoplasmic retraction and cell rounding, whereas 
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long protrusions radiating around the cell give a particular morphology (Ottlinger and 
Lin, 1988), which is called actinomorphic or arborising (Fig. 16.1) 
 
Figure 16.1: Cytopathic effects induced by toxins modifying the actin cytoskeleton. 
MRC5 fibroblasts or Hela cells have been treated with C. perfringens E iota toxin, C. 
botulinum C3 enzyme, C. difficile Toxin B or C. sordellii lethal toxin from IP82 
(LT82). Control cells and cells treated with toxins have been observed by phase 




ToxA and C. novyi  toxin cause similar cell alterations, but LT produces 
cell rounding without arborisation. ToxB is a very potent cytotoxin (the minimal 
cytotoxic dose is about 0.2-1 pg), whereas ToxA is less active (minimal cytotoxic 
dose 10-40 ng) (Lyerly et al., 1998). Many cell lines are sensitive to large clostridial 
toxins; Vero cells and fibroblasts such as MRC5 are among the most used for the 
detection of C. difficile toxins. In C. difficile-dependent colitis, toxins are present in 
patients’ stool specimens. Most of the toxigenic C. difficile strains produce both 
ToxA and ToxB. Since ToxB is extremely cytotoxic, tissue culture assay is highly 
sensitive and is considered as the reference test to detect C. difficile toxins in stool 
samples and in bacteria cultured in vitro. Faecal specimens or culture supernatants 
are diluted in Hanks solution or PBS and filtered. A 100 l portion and serial 2-fold 
dilutions are added to confluent cell monolayers in 96-well microtitre plates. Plates 
are incubated at 37 °C in 5% CO2, and then examined over 48 h for cytopathic effects 
characteristic of C. difficile toxins. The ability of antisera to bind the toxin in order to 
neutralise the cytotoxic effects can provide an identification of the toxin. However, 
ToxB and LT show immunological cross-reactivity, and antiserum against LT is able 
to neutralise the cytopathic effects induced by ToxB. 
 
16.1.2. Immunological methods, ELISA 
Numerous immunoassays have been developed for the rapid detection of 
ToxA and ToxB in clinical samples, and many of them are commercially available 
(Table 16.2).  
These assays use polyclonal or monoclonal antibodies against ToxA or 
ToxB. The advantage of immunoassays is their rapidity, about 90 min versus 18-24 h 
for the cytotoxicity test. In addition, immunoassays do not require equipment, such as 
cell culture facilities, and certain manipulations can be automated. Immunoassays are 
less sensitive than the cytotoxicity test, but most of the tests range between 85 and 
95% for sensitivity (Table 16.2). The best diagnostic strategy is to detect the toxin in 
faecal samples by immunoassay for a rapid presumptive diagnosis and then to 
confirm this result using tissue culture assay. Most of the C. difficile strains involved 
in colitis produce both ToxA and ToxB, but approximately 5% of toxigenic strains 
are A-B+ and were shown to occur in about 25% of hospitals surveyed by Wilkins 
and Lyerly (2003). For these reasons, immunoassays directed against ToxA and 
ToxB are preferred to those only detecting ToxA. 
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Table 16.2: Performance of immunoassays compared with tissue culture assay for 
the detection of C. difficile toxins in faeces specimens. PPV, positive predictive 
value; NPV, negative predictive value 
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Alfa et al., 2002 
 
 




16.1.3. Biochemical methods: glucosylation 
The large clostridial toxins are glucosyltransferases, the substrates of which 
are indicated in Table 16.1. The activity of these toxins can be evidenced using a 
glucosylation assay. Toxin preparation is incubated with the recombinant appropriate 
substrates, UDP-[14C]glucose, in HEPES buffer 20 mM, (pH 7.4), containing 2 mM 
MgCl2, 100 mM KCl, 0.1 mM GDP and protease inhibitors. After incubation (30 
min, 37 °C), the proteins are separated by SDS-gel electrophoresis (PAGE). Gels are 
then stained, dried and autoradiographed. Glucosylation activity can be detected 
using cell lysate instead of the recombinant substrates, but this method does not 
permit identification of each substrate. For α-novyi toxin, UDP-[14C]-N-
acetylglucosamine is used instead of UDP-[14C]glucose (Just et al., 1997). 
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16.1.4. Detection of toxin encoding genes 
The C. difficile toxA and toxB genes have been characterised and PCR-based 
methods have been developed for the toxinotyping of C. difficile isolates and 
detecting this bacteria directly in stool samples (Alonso et al., 1999; Arzese et al., 
1995; Boondekhun et al., 1993; Kato et al., 1993; Wolfhagen et al., 1994; Wren et 
al., 1993). The PCR-based methods are more rapid than the standard cultures in 
anaerobic conditions and in the characterising of isolates from stool. Commercial 
extraction kits, such as the QIAmp DNA Stool kit, enable easy purification of DNA 
from stool samples. 
An evaluation of a PCR method for the detection of the toxB gene has 
shown that of 118 stool samples, all the specimens negative in the tissue culture 
assay were also shown to be negative by the PCR method (specificity of 100%). 
Moreover, of the 59 cytotoxin-positive samples, 54 were PCR positive (91.5% 
sensitivity). The detection limit obtained by PCR was estimated at 106 C. difficile 
cells/g of stool (Guilbault et al., 2002). A rapid method by real time PCR directed 
against toxA and toxB genes was able to give the results in about 20 min with a limit 
level of detection of C. difficile in stool samples of 5 x 104 bacteria/g. The specificity 
of this method was 100% and the sensitivity 97% in the case of 59 faecal specimens 
from hospitalised patients (Bélanger et al., 2003). 
Epidemiological studies have shown that C. difficile strains are highly 
polymorphic. Several methods have been developed to differentiate the C. difficile 
strains from different outbreaks and to trace strains which could be more virulent. 
For example the following have been used in C. difficile typing: pulsed-field gel 
electrophoresis of total DNA, restriction with enzymes having infrequent DNA 
recognition sites and ribotyping (Clabots et al., 1993; Gürtler, 1993; Kato et al., 
1994; Kristjansson et al., 1994; Stubbs et al., 1999). Amplified fragment length 
polymorphism technique showed equivalent results with pulsed-field gel 
electrophoresis. Moreover, this technique is easier to perform even in the presence of 
partial DNA degradation, which has the effect of impairing pulsed-field gel 
electrophoresis, leading to inconclusive results with that method (Klaassen et al., 
2002). Interestingly, a new method of PCR (based on the amplification of repetitive 
non-coding sequences through the genome [rep-PCR]) gave comparable results for 
differentiating C. difficile isolates to those obtained with pulsed-field gel 
electrophoresis and was more discriminatory than PCR ribotyping (Spigaglia and 
Mastrantonio, 2003). 
A pioneering method of C. difficile typing was based on serogrouping by 
slide agglutination with rabbit antisera, together with the protein profiles obtained by 
polyacrylamide gel electrophoresis. In this way, 20 groups and subgroups were 
differentiated corresponding to somatic antigens and common flagellar antigen 
(Delmée et al., 1986; Toma et al., 1998). A novel toxinotyping scheme was 
developed involving PCR amplification of toxA and toxB genes in 3 fragments for 
each gene, and 4 other fragments (1 intergenic, 2 upstream of toxB gene, and 1 
downstream of toxA gene), thus covering the entire pathogenicity locus (PaLoc). 
Analysis of the PCR products by restriction enzymes (PCR-RFLP, restriction 
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fragment length polymorphism) individualises at least 20 toxinotypes (noted I to XX) 
(Table 16.3). This toxinotyping correlates with ribotyping and slide agglutination 
typing (Rupnik et al., 1998, 1997, 2001, 2003). Most toxigenic C. difficile strains 
contain both toxA and toxB genes. However, variations occur in the toxA and toxB 
genes that can be detected by restriction profiles of PCR fragments. Some strains 
(mainly from serogroup F) contain a toxB gene, which is a hybrid between typical C. 
difficile toxB and C. sordellii LT genes. The resultant ToxB variant glucosylates a 
RhoGTPase set intermediate between the 2 classical toxins (Chaves-Olarte et al., 
1999; Depitre et al., 1993). A proportion of C. difficile strains (0.2 to 12% according 
to various investigations) isolated from patients with pseudomembranous colitis or 
antibiotic-associated diarrhoea only produce ToxB (Alfa et al., 2000; Barbut et al., 
2002; Brazier et al., 1999; Johnson et al., 2003; Kato et al., 1999, 1998; Limaye et 
al., 2000; Lyerly et al., 1988; Moncrief et al., 2000; Rupnik et al., 2003; Sambol et 
al., 2000). These A-/B+ strains contain variable deletions in ToxA gene or nonsense 
mutations leading to the lack of detection of the toxin (Barbut et al., 2002; Rupnik et 
al., 2003; von Eichel-Streiber et al., 1999). In addition, some C. difficile strains (6-
8%) contain a binary toxin called CDT (see below), the pathogenic significance of 
which is still poorly understood (Perelle et al., 1997; Rupnik et al., 2003; Stubbs et 
al., 2000). A PCR strategy is also used to routinely identify the presence of the genes 
encoding both CDT components. Most of the strains that harbour CDT genes also 
produce ToxA and ToxB. However, a low percentage of strains (2%) only produce 
CDT and are ToxA- and ToxB-negative (Geric et al., 2003; Stubbs et al., 2000). 
 
Table 16.3: Main toxinotypes of C. difficile based on toxA, toxB and cdt gene 
detection and restriction fragment length polymorphism (RFLP) of toxA and toxB 
genes 
 
cdt gene detection toxA and toxB gene 
detection 






A+  B+ 
A+  B+ 
A-  B+ 
A-  B+ 
 
toxinotypes I to XX 
CDT+ 
CDT- 
A-  B- 
A-  B- 
 
 
16.2. Actin-ADP ribosyltransferases 
The clostridial actin-ADP ribosyltransferases have a common structure 
consisting of 2 independent protein components linked by a covalent or a disulfide 
bridge, one being the binding component (~100 kDa), and the other the enzymatic 
component (~ 45 kDa). Both components are required for biological activity. Two 
families can be distinguished: firstly, the Iota family, which encompasses ι toxin 
produced by C. perfringens type E, C. spiroforme toxin and C. difficile ADP-
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ribosyltransferase (CDT) synthesised by some strains of C. difficile and secondly, the 
C2 family, which corresponds to the C2 toxins from C. botulinum C and D. At the 
amino acid sequence level, the components of the Iota family are highly related (80-
85% identity), whereas C2 toxin shows 31-40% identity with the Iota family 
proteins. Components from Iota and C2 families show no immunological cross-
reaction and no functional cross-complementation (review: Popoff, 2000). These 
toxins are also related to the vegetative insecticidal proteins (VIP) produced by 
Bacillus cereus and Bacillus thuringiensis (Warren et al., 1996). 
The toxin components are encoded by two genes, which are closely located 
and are organised into operon. The Iota family components are synthesised during 
the exponential growth phase and are secreted as inactive proteins by means of a 
signal peptide. They are proteolytically activated by removal of a 20 kDa N-terminal 
peptide from the binding component (80 kDa for the active form) and 9 to 11 N-
terminal residues from the enzymatic component (Gibert et al., 2000). In contrast, C2 
toxin components are produced during the sporulation phase and are released during  
bacterial lysis. Signal peptides are absent from the C2 toxin proteins. The C2 toxin 
binding component also requires proteolytic processing resulting in the removal of a 
20 kDa N-terminal peptide (Ohishi, 2000). 
16.2.1. Biological methods 
Actin ADP-ribosyltransferases are lethal for mice. Classically, a mouse 
lethality test has been used to identify these toxins. Note that, in order to be active, 
C2 toxin from C. botulinum requires trypsinisation prior to injection into the mouse. 
Polyclonal antibodies against crude supernatant of C. perfringens type E have been 
prepared for the toxinotyping of C. perfringens. Anti-ι toxin antibodies cross-react 
with C. spiroforme toxin (Stiles and Wilkins, 1986). Iota toxin induces a circular 
white necrosis upon intradermal injection in guinea pigs, which is neutralised by 
incubating the toxin with serum against C. perfringens type E. In the past, this 
method has been used for C. perfringens toxinotyping (Sterne and Batty, 1975). 
Actin ADP-ribosyltransferases are cytotoxic, causing cell rounding and 
complete disorganisation of the actin cytoskeleton. Confluent cells, such as 3T3, 
Vero and MRC5 are incubated with preparations containing binary toxins. 
Observation under phase contrast microscopy reveals the rounding up of cells. 
Fixation and staining of the cells with fluorescent phalloidin, which specifically 
labels actin filaments, is used to reveal the actin-dependent actin depolymerisation 
(Fig. 16.1) (Aktories et al., 1997). Effects on the cell can be neutralised with the 
corresponding antibody. A quantitative assay of actin filament depolymerization is 
based on fixation of control and toxin-treated cells, staining with rhodamine-
phalloidin and analysis with spectrofluorimetry. 
 
16.2.2. Immunological methods 
Antibodies against each component of the binary toxins have been prepared, 
but are not commercially available. Cross-reactions occur between the enzymatic and 
binding components of iota, C. spiroforme toxin and CDT, whereas anti-C2-I and 
anti-C2-II only recognise homologous antigens. Western blotting of crude 
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Clostridium culture supernatant has been used to identify the toxin components. 
ELISA tests have not been developed for diagnostic purposes. 
 
16.2.3. Biochemical methods 
Actin ADP-ribosylation assay consists of incubating the toxin preparation 
with globular actin or crude cell lysate and [32P]-NAD in 50 mM triethanolamine 
buffer (pH 7.5) containing 1 mM MgCl2, 1 mM dithiotreitol, 10 mM thymidine and 
protease inhibitors. After 30 min incubation at 37 °C, the proteins are separated by 
SDS-PAGE, and the gel is dried and analysed by autoradiography. The actin band 
becomes labelled by the incorporation of [32P]-ADP ribose in the presence of the 
clostridial binary toxin. Iota toxin, C. spiroforme toxin and CDT recognise both 
muscular and non-muscular actin, whereas C2 toxin is reactive only with non-
muscular actin. A quantitative assay is based on actin ADP-ribosylation with serial 
dilutions of toxin preparation. Alternatively, ADP-ribosylation reactions are 
precipitated with trichloracetic acid, filtered on cellulose filters, washed and counted 
for radioactivity (Aktories et al., 1997). 
 
16.2.4. Detection of toxin encoding genes 
Genes encoding the clostridial actin ADP-ribosylating toxins have all been 
cloned and sequenced. PCR-based methods have been developed for the detection of 
these genes in clostridia. In particular, this method is used for C. perfringens typing 
and for the detection of the CDT gene in C. difficile.    
 
16.3. Rho-ADP ribosyltransferases 
In addition to C2 toxin, C. botulinum C and D produce another ADP-
ribosyltransferase, which is termed C3 enzyme. C3 related enzymes are also 
produced by Clostridium limosum, Bacillus cereus, Bacillus thuringiensis and 
Staphylococcus aureus (epidermal cell differentiation inhibitor, EDIN), and are 
specific to Rho proteins. 
C3 enzyme (28 kDa) possesses only a catalytic domain and lacks the 
binding and translocation domains permitting the entry of toxins into cells. Thus, C3 
enzyme is not cytotoxic. The crystal structure shows that C3 consists of a core 
structure of 5 antiparallel -strands packed against a three-stranded antiparallel -
sheet flanked by four consecutive -helices (Han et al., 2001). Interestingly, the C3 
structure is similar to that of the catalytic domain of the enzymatic components VIP2 
and Ia (Han et al., 1999; Tsuge et al., 2003).  C3 enzyme ADP ribosylates Rho 
protein at Asn-41. ADP-ribosylation of Rho-Asn41 by C3 does not impair the 
exchange of GDP with GTP, the intrinsic and GAP-stimulated GTPase activity, or 
the interaction with its effectors (Ren et al., 1996; Sehr et al., 1998) It does, however, 
prevent Rho translocation to the membrane, where it is required for activation and 
interaction with its effectors (Fujihara et al., 1997). This results in disorganisation of 
actin filaments and cell rounding. C3 recognises RhoA, B and C, whereas EDIN also 
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modifies RhoE. The C3 gene is located on phage DNA in C. botulinum C and D, 
which also harbour the neurotoxin genes C1 and D, respectively. C3 enzyme is 
produced during the exponential growth phase and is secreted in the culture 
supernatant by means of a signal peptide. 
 
16.3.1. Biological methods 
Since C3 enzyme lacks a binding and translocation domain, it cannot enter 
cells efficiently and is not biologically active. C3 enzyme, even at high 
concentration, is not lethal for mice. To evidence the cytotoxic effects of C3, 
confluent cells, such as 3T3 or Vero cells are incubated with high concentrations of 
enzyme (50 to 100 g/ml) for 24-48 h at 37 °C. The cells are then fixed and the actin 
filaments stained with fluorescent phalloidin. ADP-ribosylation of Rho by C3 
induces rounding of the cells and disappearance of actin stress fibres (Fig. 16.1). An 
alternative method uses C3 microinjected into cells (Nobes and Hall, 1997). 
 
16.3.2. Immunological methods  
Specific antibodies have been raised against C3 enzyme, and Western 
blotting with crude Clostridium culture supernatant has been used to evidence this 
protein. No ELISA test has been developed for the identification of C3 and related 
enzymes. 
 
16.3.3. Biochemical methods 
C3 enzymatic reaction is performed by incubating C3 preparation with [32P]-
NAD and recombinant Rho protein or crude cell homogenate in a 50 mM 
Triethanolamine (pH 7.5) buffer containing 1 mM dithiotreitol, 5 mM MgCl2 and 10 
mM thymidine. After 1 h incubation, the mixture is loaded on an SDS-PAGE. The 
gel is then dried and autoradiographed (Saito and Narumiya, 1997). 
 
16.3.4. Detection of toxin encoding genes 
The C3 gene has been characterised in C. botulinum C and D, C. limosum, 
Staphylococcus aureus (EDIN) and Bacillus cereus, and can be detected by PCR. 
 
16.4. Metalloproteases 
Clostridial neurotoxins, botulinum neurotoxins (BoNTs) (responsible for 
flaccid paralysis called botulism) and tetanus toxin (TeTx), (by contrast producing a 
spastic paralysis, tetanus) are all zinc-dependent proteases. 
C. tetani forms a homogeneous bacterial species, which produces only one 
type of TeTx, whereas botulinum neurotoxin (BoNT)-producing strains are 
heterogeneous. C. botulinum is divided into 4 groups, which, on the basis of 
phenotypic and genotypic parameters, correspond to different species (Stackebrandt, 
2002). In addition, some strains of other species, such as C. butyricum and C. baratii, 
can produce a related BoNT type E and F respectively. Seven toxinotypes of BoNT 
(A, B, C1, D, E, F and G) are individualised according to their antigenic properties. 
 152
BoNTs and TeTx share a common structure. They are synthesised as a 
precursor protein (about 150 kDa), which is inactive or weakly active. The precursor, 
which does not contain signal peptide, is released from the bacteria possibly by a 
cell-wall exfoliation mechanism (Call et al., 1995). The precursor is proteolytically 
activated in the extra-bacterial medium either by Clostridium proteases or by 
exogenous proteases, such as digestive proteases in the intestinal content. The active 
neurotoxin consists of a light chain (L, about 50 kDa) and a heavy chain (H, about 
100 kDa), which remain linked by a disulfide bridge. The structure of BoNT shows 
three distinct domains: the L-chain containing -helices and -strands and including 
the catalytic zinc binding motif, the N-terminal part of the H-chain forming two 
unusually long and twisted -helices and the C-terminal part of H-chain consisting of 
two distinct subdomains involved in the recognition of the receptor (Emsley et al., 
2000; Lacy and Stevens, 1999; Lacy et al., 1998; Umland et al., 1997). 
Although BoNTs and TeTx are toxic by different routes, they display a 
similar intracellular mechanism of action. BoNTs enter the host by the oral route 
with transcytosis across the digestive mucosa (Maksymowych et al., 1999). After 
diffusion in extracellular fluid and circulation in the bloodstream, BoNTs target 
motoneuron endings. In contrast, TeTx is formed in wounds colonised by C. tetani. 
TeTx diffuses in the extracellular fluid and can be internalised in all types of nervous 
endings (sensory, adrenergic and motor neurons).  
Molecular genetic studies revealed that clostridial neurotoxins contain a 
conserved zinc- dependent proteolytic site (His-Glu-x-x-His) in the middle of the L 
chain (Niemann, 1991; Popoff and Marvaud, 1999). A variety of studies have 
demonstrated that the clostridial neurotoxins are zinc endopeptidases; the toxins are 
inhibited by metalloprotease-specific inhibitors and specific antibodies to the zinc-
binding motif. In addition, zinc ions are found in the neurotoxins and mutation of the 
zinc-binding motif abolishes activity. These toxins cleave previously identified 
synaptic proteins. TeTx, BoNT/B, D, F and G cleave VAMP/synaptobrevin, a 
membrane protein from synaptic vesicles. BoNT/A and E cleave SNAP25, a 
presynaptic membrane protein and BoNT/C1 cleaves both SNAP25 and syntaxin, 
which is also a presynaptic membrane protein. VAMP, SNAP25 and syntaxin are 
called SNARE proteins for SNAP receptors. They form a large protein family, since 
many isoforms have been identified in almost all the cells. Each clostridial 
neurotoxin recognises its substrate at a specific binding site (SNARE motifs, 2 in 
VAMP and syntaxin, and 4 in SNAP25), and cut at a specific cleavage site. When an 
individual SNARE protein is cleaved by a clostridial neurotoxin, the SNARE 
complex formation is not inhibited, but its stability is reduced and the release of 
neurotransmitter is blocked. Even the physiological properties induced by the 
cleavage of either VAMP, SNAP25 or syntaxin are not equivalent at the 
neuromuscular junctions. All the clostridial neurotoxins cause a blocking of the 
regulated neurotransmission, which varies in intensity and duration according to each 




In humans or animals suspected of suffering from botulism, BoNTs can be 
found in serum samples, in faeces, in intestinal content or sometimes in samples of 
organs, such as the liver. In cases of botulism consequent to infection, such as infant 
botulism, BoNT is recovered from faeces or from serum. In adult humans and birds 
suffering from botulism, BoNT is commonly detected in serum. Cattle occasionally 
show the presence of BoNT in blood circulation (25-30% of the cases) (Popoff, 
1989). BoNT has also to be investigated in suspected food to determine the source of 
the contamination. 
BoNTs and TeTx are synthesised during the late growth phase and early 
stationary phase of culture. They are exported in the external medium by an unknown 
mechanism. Classically, clostridial neurotoxins are identified in supernatant of 1 to 4-
day cultures. 
 
16.4.2. Biological methods 
16.4.2.1. Mouse test  
The mouse test consists of the intraperitoneal injection of toxin-containing 
samples into mice: (18-22 g) culture supernatant or filtrates from clinical or 
environmental samples (Schantz and Kautter, 1978). A volume of up to 1 ml may be 
inoculated. Culture supernatants from non-proteolytic (Group II) C. botulinum E and 
B must first be treated with trypsin (200 g/ml for 20 min at room temperature) to 
activate the neurotoxin. The mice are observed for the appearance of characteristic 
symptoms of flaccid paralysis (difficulty of mobility, severe generalised weakness, 
contraction of the abdomen or wasp-shaped abdomen, respiratory distress) and for 
death up to 4 days post-injection. The confirmation of the presence of BoNT and its 
typing is achieved by incubating the samples with specific neutralising antibodies 
against each BoNT type before injection into mice. The neutralising antisera against 
each type of BoNT are specific. Partial cross-neutralisation is, however, observed 
between types C and D and between types E and F. Until recently, the mouse 
lethality test has been the most sensitive diagnostic test for BoNTs. The BoNT/A 
lethal dose for mice after intraperitoneal injection is estimated to be 2-4 pg.  
The quantitative determination of the toxin is usually performed by the 
intraperitoneal injection of 4 mice with 0.5 ml of 10-fold or 2-fold serial dilutions in 
gelatine-phosphate buffer. After four days, the LD50 is determined, often by the 
Reed and Münch method. Toxin can also be given by the intravenous route. Mice 
injected intravenously die within some minutes according to a definite and 
reproducible dose-survival time relationship (Boroff and Fleck, 1966). Standard 
curves have been prepared for different types of toxins (Sakaguchi et al., 1968). 
 
16.4.2.2. Effects on isolated organs 
An isolated hemidiaphragm from a rat, guinea pig or mouse can be used to 
measure the flaccid paralytic effects of BoNT. Muscle contraction is monitored in 
response to electrical stimulation of the phrenic nerve. BoNT inhibits muscular 
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contraction. This model is less sensitive than the mouse test and cannot be used 
routinely in the laboratory. 
 
16.4.2.3. Cell test  
Neuroblastoma cells and adrenal medullary cells, such as the PC12 line, 
have been used with BoNT. These cells secrete catecholamines and/or acetylcholine 
upon stimulation, for example, by high K+ concentrations. The cells are loaded with 
radioactive neurotransmitters and the blocking of their release by BoNT measured 
(Habermann, 1989). The primary nerve cell or chromaffin cell cultures are the most 
sensitive, but the cell models are less sensitive than the animal tests and are not 
appropriate for routine identification of BoNTs. 
 
16.4.3. Immunological methods 
The development of immunoassays for the detection of BoNTs was 
pioneered by Notermans. Polyclonal and monoclonal antibodies have been developed 
against the various purified BoNTs and have been tested in immunoassays (Kozaki et 
al., 1989; Notermans and Nagel, 1989). Using culture supernatants from various 
proteolytic C. botulinum B strains and standard sandwich ELISA, polyclonal 
antibodies detect about 8 to 90 mouse ip LD50/ml and monoclonal antibody between 
600 and 700 mouse ip LD50/ml. Polyclonal antibodies were less effective with non-
proteolytic C. botulinum strains (limit detection of 700-800 mouse ip LD50/ml), 
reflecting differences in the antigenicity of BoNT/B from proteolytic and non-
proteolytic strains (Notermans and Nagel, 1989). 
In order to improve the sensitivity of ELISA tests, amplifying techniques 
have been developed. A system proposed by Shone et al. is based on enzymatic 
transformation of NADP+ to NAD+ by alkaline phosphatase that is coupled to the 
IgG anti-BoNT. The NAD+
 
molecules produced are used in another enzymatic 
reaction, leading to the formation of several hundred coloured formazan molecules. 
This system increases the sensitivity of the immunoassay by about 50 to 100 times 
(Shone et al., 1986). 
A modified ELISA, derived from the coagulation assay is called an enzyme-
linked-coagulation assay (ELCA). A coagulation activating enzyme (RVV-XA) 
isolated from the venom of Russel's viper is combined with affinity-purified horse 
antibodies specific for BoNT/A, BoNT/B or BoNT/E. Plates are coated with affinity-
purified antibodies and incubated with the toxin samples. Detection is achieved with 
anti-toxin antibodies labelled with RVV-XA, with washing and with the addition of a 
modified plasma substrate, which contains all the coagulation factors mixed with 
alkaline phosphatase-fibrinogen and solid phase fibrinogen coated on silicone rubber 
nubs. In a second phase, the nubs are removed from the plate, washed three times 
with saline in beakers, and placed on a second plate containing an alkaline phosphate 
substrate and incubated for 30 min. The coloured reaction is then measured with a 
plate reader. ELISA-ELCA allows detection of about 0.1 pg/ml of BoNT using 
culture filtrates (Doellgast et al., 1994, 1993). This method has been used to detect 
BoNT/E production in fish inoculated with C. botulinum E (Roman et al., 1994). 
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A sensitive ELISA has been proposed for the titration of BoNT/A in 
therapeutic preparations. Toxin-specific antibodies coated on plate are used to 
capture BoNT/A, and the detection is achieved with affinity-purified antitoxin and 
species-specific immunoglobulins labelled with horseradish peroxidase. Ekong et al. 
(1994) found the limit of detection to be 4-8 pg of purified toxin/ml, equivalent to 1-
2 mouse bioassay units/ml. Using affinity-purified horse polyclonal antibodies 
directed against the C fragment (Fc) of the heavy chain of BoNT/A or BoNT/B, the 
sensitivity of the detection was 20 pg per well (200 pg/ml). Szilagyi et al. (2000) 
used the purified antibodies as capture, and the same antibodies labelled with biotin 
enabled the detection of the toxin in association with neutravidin-linked alkaline 
phosphatase. 
The sensitivity of an ELISA directed against BoNT/C1 and BoNT/D is 
typically 70% and the specificity 96% on samples from animals with botulism, 
compared to the mouse bioassay (Thomas, 1991). 
 
16.4.4. Biochemical methods. 
A biochemical test has been proposed for the detection of the BoNTs. 
BoNTs are proteases, which specifically cleave an intracellular target in the neuronal 
cells. BoNT/B, C, D, F and G cleave synaptobrevin, BoNT/A and E cleave SNAP25 
and BoNT/C1 cleave both syntaxin and SNAP25. These substrates are called 
SNARE proteins and have an essential role in neuroexocytosis. They can be obtained 
as recombinant proteins and used for in vitro reaction with BoNTs. The test 
developed for the detection of BoNT/A consists of the coating of SNAP25 in wells of 
plastic plate, incubation with samples containing the neurotoxin and washing. 
BoNT/A releases a small C-terminal fragment of SNAP25 and the cleaved form, 
which remains attached to the bottom of the well, is detected with a specific antibody 
recognising only the proteolysed SNAP25 and not the intact molecule. The assay is 
developed with a conjugate linked to peroxidase or alkaline phosphatase and directed 
against the first antibody. Concentration of the toxin with an immunoaffinity column 
increases the sensitivity of the method. This assay allows detection of type B toxin at 
a concentration of 5 pg/ml (0.5 mouse 50% lethal dose per ml) (Wictome et al., 
1999a, 1999b). A variant method uses synthetic cleavable oligopeptide labelled with 
fluorescein and covalently attached to multiwell plates. Solubilised products after 
incubation with botulinum neurotoxin are measured with a spectrofluorometer. The 
sensitivity of this method ranges from 10 to 100 ng/ml (Schmidt et al., 2001). A 
similar fluorescence-based assay has been proposed for the determination of tetanus 
toxin and BoNT/B protease activity (Anne et al., 2001; Soleilhac et al., 1996). 
 
16.4.5. Detection of toxin encoding genes 
The routine identification of neurotoxin-producing Clostridium is hampered 
by the need for anaerobic conditions for growth and the variable bacteriological 
characteristics of the different groups. The molecular characterisation of bont genes 
offers the possibility of using genetic methods, such as polymerase chain reaction 
(PCR) and DNA-DNA hybridisation. 
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The sequences of the different BoNT types are distinct. The overall 
similarity between the available neurotoxin sequences ranges from 34 to 97% 
identity at the amino acid level. The neurotoxin sequences from the same toxinotype 
and from the same physiological groups are almost identical, except for BoNT/A1 
and BoNT/A2, which are highly related (90% identity) but differ in 129 residues 
(Binz et al., 1990; Thompson et al., 1990; Titball, 1993). The strains isolated from 
infant botulism in Japan fall into the A2 group, the strains from foodborne and infant 
botulism from the USA and the UK fall into the A1 and A2 groups  (Cordoba et al., 
1995). BoNTs of the same toxinotype, but produced by strains from different C. 
botulinum groups or Clostridium species, show a high level of identity (70 to 97%). 
BoNT sequences from C. botulinum E and C. butyricum have 97% identity (Fujii et 
al., 1993; Poulet et al., 1992). BoNT/B sequences from proteolytic and non-
proteolytic C. botulinum B share 93% identity (Hutson et al., 1994; Whelan et al., 
1992), but BoNT/F from C. botulinum F and C. baratii have only 70% identity (East 
et al., 1992; Thompson et al., 1993). 
C. botulinum A, B, E, F and G identification using specific primers from 
each toxin gene has been described by several authors (Ferreira et al., 1993; 1994; 
Franciosa et al., 1994; Hielm et al., 1996; Kakinuma et al., 1997; Szabo et al., 1992; 
1993; 1994; Takeshi et al., 1996). 
In order to minimise the number of PCR reactions, a multiplex PCR 
consisting of a mix of primers specific to the neurotoxin types (A, B, E, and F) 
involved in human botulism has been designed (Henderson et al., 1997). We have 
developed a primer pair, partially degenerated on their 3' end, able to amplify a 
conserved region of bont genes from type A, B, E, F and G. Internal probes specific 
to each type, allow typing by hybridisation. Where this method was used in 
contaminated food samples, it showed a 95.6% correlation with the standard method 
(Fach et al., 1995). A similar strategy was used by other authors (Aranda et al., 1997; 
Campbell et al., 1993). A single internal probe was designed to recognise the 
amplification products, without distinction of type, in the work of Aranda et al. 
(1997). A double PCR procedure has also been proposed for identification of C. 
botulinum C and D (Fach et al., 1996). 
Quantification of toxigenic Clostridium is required for certain biological or 
food samples. For example, monitoring levels of C. perfringens is important in the 
food industry, since certain levels (50-200 per gram) of these bacteria are tolerated in 
some food products. The standard detection by PCR, as described above, is not 
quantitative. A quantitative technique based on the most probable number method, 
consisting of inoculating serial dilutions of food samples into an enrichment medium 
and performing PCR with each dilution culture, has been proposed for enumeration 
of C. botulinum (Hielm et al., 1996), and could be used for other toxigenic clostridia. 
A new technology of quantitative PCR based on detection by fluorescent probe has 
been introduced (TaqMan assay). This method has been developed for quantitative 
detection of C. botulinum E (Kimura et al., 2001). It allows the enumeration of C. 
botulinum in the 102 to 108 CFU/g range within 1 or 2 h. 
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Evidence of a toxin gene does not mean that the toxin is actually produced. 
A toxin gene can be silent. This is the case for botulinum neurotoxin B gene in some 
C. botulinum type A strains (Hutson et al., 1996). A possible means of detecting 
toxin genes, which are effectively expressed, consists of the PCR method from 
mRNA. A reverse transcription-PCR has been described to monitor botulinum 
neurotoxin E production (McGrath et al., 2000).  
 
16.5. Clostridial collagenases 
C. histolyticum is responsible for dramatic myonecrosis and gangrene. The 
main secreted toxins are collagenases (also called -clostripain), which exist in at 
least 6 different forms with molecular masses ranging from 68 to 125 kDa. They are 
divided into 2 classes, ColG and ColH, based on amino acid sequence similarities 
and specificities toward peptide substrates. The  collagenases are encoded by 2 
genes, colG and colH. Both genes, which probably derive from duplication of an 
ancestral gene, encode for a 116 kDa precursor, which is processed in the C-terminal 
part to yield the multiple forms (Matsushita et al., 1999). ColH consists of 4 
segments, S1, S2a, S2b, and S3, while S2a and S2b are homologous; ColG also 
possesses 4 segments, S1, S2, S3a and S3b. All collagenase forms contain in the N-
terminal part (segment 1) the consensus active site HExxH of zinc metalloprotease 
(Jung et al., 1993). The other segments are involved in substrate recognition and 
binding. Thus, S3 is required for binding to collagen (Matsushita et al., 1998; 
Matsuchita and Okabe, 2001). 
C. histolyticum collagenases are specific to collagen and gelatine. They 
cleave peptide bonds on the amino side of the glycine residue in the PXGP sequence, 
and they degrade their substrates in small dialysable peptides. Collagenases play an 
important role in the degradation of the connective tissue. 
C. perfringens produces a collagenase, ColA, which is related to ColG from 
C. histolyticum and contains the characteristic motif, HExxH (Matsushita et al., 
1999; 1994). ColA has an additional effect to the phospholipase α toxin in the 
destruction of tissues. 
A gene encoding a collagenase (Col-T) related to C. histolyticum 
collagenases has been identified on the same plasmid, which contains the tetanus 
toxin (TeTx) gene. ColT could be involved in the destruction of tissue, permitting 
invasion by C. tetani (Brüggemann et al., 2003).  
 
16.5.1. Biological methods 
C. histolyticum collagenases are lethal to mice upon intraperitoneal 
injection, and a neutralisation test in mice is used to identify C. histolyticum. An 
antiserum against crude supernatant of this bacterium is commercially available. 
Production of myonecrotic lesions upon intramuscular injections to guinea pigs has 
also been also used to characterise the toxigenic C. histolyticum strains. 
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16.5.2. Biochemical methods 
A collagenase assay is based on the digestion of collagen from bovine 
Achilles' tendon. Collagen (5 mg/ml) is swollen in Tris-HCl (pH 7.5) containing 0.36 
mM CaCl2. One unit of enzyme activity equals 1 mol of L-leucine equivalents 
liberated from collagen during 5 h at 37 °C (Jung et al., 1999). Another collagenase 
assay consists of using the Pz peptide (Sigma) (4-phenylazobenzyloxycarbonyl-Pro-
Leu-Gly-Pro-D-Arg). One unit of enzyme activity is defined as the amount of 
enzyme causing an increase of 0.1 A320 unit per min. (Jung et al., 1999). A qualitative 
test uses photographic film in culture medium. The presence of gelatinase induces a 
deposition of silver nitrate particles in the bottom of the culture tube. 
 
16.6. Clostridial phospholipases  
Two types of phospholipase C are produced by the clostridia. A 
phosphatidylinositol hydrolysing enzyme is produced by Clostridium novyi (β toxin) 
(Taguchi and Ikezawa, 1978), but enzymes with similar substrate specificity 
produced by other clostridia have not been reported. The C. novyi β toxin is 
relatively poorly characterised and is not discussed further in this section. In contrast, 
a wide range of clostridia produce zincmetallophospholipases C that are exported 
from the bacterial cell into the culture medium (Titball, 1993) (Table 16.4).   
 
The best characterised of these phospholipases C is the C. perfringens -
toxin, and much of the information on assay systems has arisen from work with this 
protein over the past 50 years. All  the clostridial enzymes contain zinc ions in the 
active site cleft. These ions not only play a role in catalytic activity, but also stabilise 
the tertiary structure of the protein (Naylor et al., 1998; Titball, 1993). The enzymes 
are produced maximally during the late logarithmic phase of growth, and early 
stationary phase cultures are usually used for the isolation of the proteins from 
culture medium (Jolivet-Reynaud et al., 1988; Krug and Kent, 1984; Mollby, 1978). 
Providing the growth medium contains zinc ions these enzymes are all relatively 
stable in culture fluid (Sato et al., 1978). However, although the zinc-
metallophospholipases C can be isolated and purified from culture medium, they are 
not the only exported proteins. This has always presented the potential problem of 
co-purification of additional proteins, since some of these are also toxins. Therefore, 
more recently, recombinant forms of the zinc-metallophospholipases C, produced in 
Escherichia coli, have been used for many experimental studies (Clark et al., 2003; 
Titball et al., 1989; Tso and Siebel, 1989).  
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Table 16.4: Characterised phosphatidylcholine hydrolysing Phospholipases C 
produced by clostridia 
Enzyme Substrate specificity Properties Reference 
C. perfringens  toxin PC, SM and PS  toxic, haemolytic Krug and Kent, 1984 
Clostridium absonum PLC PC, SM  toxic, haemolytic  Clark et al., 2003 
Clostridium baratii PLC NR NR  
Clostridium bifermentans PLC PC, SM  weakly toxic,  
weakly haemolytic  
Jepson et al., 1999 
Tso and Siebel, 1989 
Clostridium novyi  toxin PC, SM, PE,  
PS, PG  




PC, SM toxic, haemolytic  
Clostridium sordellii PLC PC  non-toxic, weakly 
haemolytic  
Karasawa et al., 2003 
PC: phosphatidylcholine, SM: sphingomyelin, PS: phosphatidylserine,  
PE: phosphatidylethanolamine, PG: phosphatidylglycerol, NR: not reported  
 
16.6.1. Detection of phospholipase C activity on solid media 
Because the clostridial phospholipases C are enzymes, detection of their 
activity on solid media is relatively straightforward. The most common assay 
involves the growth of bacteria on medium (such as Brain-Heart Infusion agar), 
which contains, typically, 10% (v/v) egg yolk emulsion (Gubash, 1991; MacFarlane 
and Knight, 1941). The egg yolk emulsion is added to molten media, which has been 
cooled to approximately 50 oC, before pouring. Suitable egg yolk emulsion for use in 
such plates is available from Oxoid Ltd (Basingstoke, UK), but must be centrifuged 
before use (for example, at 10,000 x g for 20 minutes) to remove particulate matter. 
After growth of the bacteria at 37 oC on egg-yolk agar, typically for 18 h, 
phospholipase C activity is evidenced as a zone of turbidity around bacterial colonies 
(Fig 16.2) (MacFarlane and Knight, 1941; Titball et al., 1989). In the case of C. 
perfringens, a refinement of this test involves the addition of antiserum to part of the 
agar plate (for example, by swabbing antiserum across part of the plate before 
inoculation). The resultant absence of a zone of turbidity in the area swabbed with 
antitoxin (the so-called Nagler reaction) is considered to be diagnostic for the 
bacterium (MacFarlane and Knight, 1941; Willis and Gowland, 1962). However, it is 
known that many other clostridial phospholipases are also partially or fully 
neutralised by antitoxin to C. perfringens  toxin. Therefore, more accurately, this 
test may indicate the presence of a clostridial species rather than C. perfringens. 
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Figure 16.2: C. perfringens growing on agar containing egg yolk. The diagonal line 















Because some clostridial phospholipases are also haemolytic, it is also 
possible to detect their activities on blood-agar plates (Gubash, 1980). In order to 
produce such plates, either sheep or mouse erythrocytes are added to molten agar at 
50 oC before pouring. The zones of haemolysis caused by clostridial phospholipases 
are typically less clear than the zones caused by other haemolytic toxins produced by 
these bacteria. For this reason, the unequivocal identification of phospholipase C 
activity on the basis of zones of haemolysis around bacterial colonies is difficult. 
 
16.6.2. Detection of biologically active phospholipase C activity in culture 
medium 
A wide range of assays have been described to measure phospholipase C 
activity in culture supernatant fluid. These different assays have advantages and 
disadvantages which reflect the relative importance of the head group and carbonyl 
group for substrate recognition. Fatty acyl chain lengths of between C6 and C14 are 
necessary for efficient phospholipid hydrolysis (El-Sayed et al., 1985; Nagahama et 
al., 1996). Phospholipase C activity also appears to be dependent on calcium ions for 
substrate binding (but apparently not for hydrolysis per se), and this has been 
elegantly demonstrated using  toxin and phospholipid monolayers (Moreau et al., 
1988). In some of the older literature it has been suggested that these calcium ions 
balance the charge on phospholipid head groups, but it is now known that calcium 
ions play a more direct role in substrate binding (Naylor et al., 1999). Therefore, all 
assays which involve phospholipids require the addition of calcium ions (typically at 
5mM final concentration). It is also desirable to have excess zinc ions (typically at 
2mM final concentration) in the reaction buffer; one of the zinc ions in the active site 
cleft is relatively loosely bound and the enzymes show a low level of activity in the 
absence of this ion.  
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16.6.2.1. Simple phospholipid-hydrolysis assays 
One of the simplest assays for clostridial phospholipases involves incubating 
a suspension of egg yolk emulsion (which is rich in phosphatidylcholine linked to 
protein) with either culture supernatant or purified enzyme at 37 oC. The resultant 
increase in turbidity of the mixture can be monitored spectrophometrically at, for 
example, 540nm (Takahashi et al., 1981). Kinetic studies are possible using this 
assay system, but most researchers use a simple 50% end-point assay, when the 
turbidity of the suspension is measured after incubation with dilutions of the enzyme 
(Jepson et al., 1999; Titball et al., 1989). Microtitre-tray based assays have proved to 
be simple and robust for carrying out such end-point assays (Titball et al., 1989). 
Using such assays, it is possible to detect as little as 15g of  toxin and 25g of the 
C. bifermentans phospholipase C (Jepson et al., 1999). 
The use of “pure“ phospholipids in assays can provide an indication of 
substrate specificity. However, for solution-based assays the phospholipid must be 
below the critical micellar concentration, or alternatively used at higher 
concentrations in the presence of detergents. Hydrolysis can be visualised after 
separation of the reaction products by thin layer chromatography (Taguchi and 
Ikezawa, 1975; Titball et al., 1991), but the precise quantification of hydrolysis often 
requires the use of radiolabelled substrates or the measurement of released 
phosphate. In an attempt to resolve the problems of solubilising phospholipids for use 
in these assays, various researchers have proposed the use of synthetic derivatives 
which lack the hydrophobic tail groups. Water-soluble phospholipid analogues, such 
as in -nitrophenolphosphorylcholine (NPPC) have the phospholipid tail groups 
replaced with the chromophore -nitrophenol (Kurioka and Matsuda, 1976). Assays 
utilising NPPC are relatively simple to perform, involving the spectrophotometric 
monitoring of the release of the chromophore (Kurioka and Matsuda, 1976). 
Although, the Km value for NPPC is high, reflecting the importance of the fatty acyl 
chains for substrate recognition, a microtitre tray assay using NPPC is reportedly 
able to detect as little as 4 g of C. perfringens  toxin (Jepson et al., 1999). Other 
researchers have devised water-soluble substrates, such as 
dioctanoylthiophosphatidylcholine, where the head group is modified and short fatty 
acyl chains are present (Synder, 1987). This compound may be more similar to the 
natural substrate, but it is unlikely that these substrates fully reflect the interaction of 
the enzyme with membrane phospholipids. Despite these concerns, phospholipid 
derivatives, such as NPPC and dioctanoylthiophosphatidylcholine do have a place 
in some studies, especially when the interaction of the active site with substrate is 
being probed.  
 
16.6.2.2. Activity towards artificial and natural membranes 
Some clostridial phospholipases are active towards membrane-packed 
phospholipids, whether in natural or artificial membranes. The use of liposomes 
composed of a single phospholipid type, and containing an entrapped dye, such as 
carboxyfluorescein or calcein, allows phospholipids to be presented in a form similar 
to that found in cell membranes (Jepson et al., 1999; Lim et al., 1997). Within the 
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liposome, the natural fluorescence of these dyes is quenched. The incubation of these 
liposomes with clostridial phospholipases results in the release of the entrapped dye, 
which then fluoresces and can be measured using a fluorimeter (Lim et al.,1997). 
The activity of clostridial phospholipases towards natural membranes is 
often measured as cytolytic or cytotoxicity activity (Taguchi and Ikezawa, 1976). 
One of the simplest assays involves the use of erythrocytes in suspension (typically at 
5% v/v) and the measurement of lysis as a decrease in turbidity of the cell suspension 
at 540nm. Simple 50% end-point assays, where dilutions of the enzyme mixed with 
erythrocytes in microtitre trays are often used (Titball et al., 1989). Erythrocytes 
from different species differ widely in their susceptibility to lysis. Many researchers 
use sheep erythrocytes, in which case complete lysis is seen only when the mixture is 
first incubated at 37 oC and then cooled to 4 oC (Taguchi and Ikezawa, 1976). The 
authors have found mouse erythrocytes to be highly susceptible to lysis without the 
requirement for the additional cooling step after incubation with phospholipase at 37 
oC (Titball et al., 1989). Using a microtitre tray assay with mouse erythrocytes it is 
possible to detect as little as 4g of C. perfringens  toxin (Jepson et al., 1999). 
A range of cell types is susceptible to the cytotoxic effects of clostridial 
phospholipases, such as the C. perfringens  toxin, including lymphocytes (Titball et 
al., 1993) and Chinese hamster cells (Flores-Diaz et al., 1998). As an alternative to 
measuring cell death, some researchers have measured the release of cell metabolites 
as evidence of membrane damage (Bryant et al., 2003; Bunting et al., 1997; 
Gustafson and Tagesson, 1990). These types of assay are complex, and their use is 
not warranted for routine purposes.  
 
16.6.2.3. In vivo toxicity studies  
The level of toxicity of different clostridial phospholipases in animals is not 
similar. The most potent, such as C. perfringens  toxin, have LD50 doses in the 
range of 0.1-1.0 g after  intraperitoneal (i.p.) inoculation into mice (Titball, 1999; 
Titball et al., 1989). Others, such as the C. bifermentans enzyme, are relatively non-
toxic, with LD50 doses of greater than 10 g (Jepson et al., 1999; Titball and Rood, 
2000; Tso and Siebel, 1989). For toxic enzymes, death usually occurs within 24 
hours of challenge (Schoepe et al., 1997; Titball et al., 1989). The ability of toxin-
specific antiserum (or monoclonal antibodies) to neutralise toxicity in mice has, in 
the past, been used as one of the tests for typing strains of C. perfringens. However, 
the use of such assays is not encouraged nowadays, and there are now immunological 
or genetic tests able to detect the production of toxin or the presence of toxin-
encoding genes. Moreover, the LD50 appears broadly to correlate with the haemolytic 
or cytotoxic activities of the enzymes. For some purposes, therefore, these assays 
provide alternatives to toxicity studies involving animals. 
 
16.6.3. Immunological detection and identification of clostridial 
phospholipases C 
A number of researchers have reported the development of enzyme-linked 
immunosorbent assay (ELISA) tests that are able to detect C. perfringens  toxin 
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(Aschfalk and Muller, 2001; Hale and Stiles, 1999; Hauer and Clough, 1999; 
Holdsworth and Parratt, 1994; Naylor et al., 1997). The full protocols for these 
assays are detailed in these reports. These assays use either polyclonal or monoclonal 
antibodies developed against the toxin. It is not clear whether these tests also react 
with other clostridial phospholipases. However, since there is a degree of 
immunological cross-reactivity between these proteins (Nakamura et al., 1973; 
Willis, 1977), it is possible that tests using polyclonal antibody would react with all 
clostridial phospholipases. These tests often form one element of a panel of ELISA 
assays, which are used to detect the production of the major toxins produced by C. 
perfringens and, therefore, to type strains. 
 
16.6.4. Detection of toxin encoding genes  
One of the major applications of tests to detect the presence of toxin genes is 
in the typing of strains. For example, C. perfringens can be typed into one of 4 
biotypes, depending on the differential production of 4 major toxins (Table 16.5). 
The phospholipase C is produced by all biotypes of C. perfringens, and a range of 
PCR tests to detect the presence of the  toxin-encoding gene have been reported 
(Aschfalk and Muller, 2002; 2001; Garmory et al., 2000; Gkiourtzidis et al., 2001; 
Miserez et al., 1998; Waters et al., 2003).  
 
Table 16.5: Typing of C. perfringens strains based on toxin production or toxin gene 
presence 
C. perfringens type α toxin β toxin ε toxin ι toxin Disease association 
A + - - - 
gas gangrene of humans and animals, 
fowl and porcine necrotic enteritis, 
bovine and ovine enterotoxaemia, food 
poisoning in humans, colitis in horses, 
canine haemorrhagic gastroenteritis 
B + + + - lamb dysentery, enterotoxaemia of foals, sheep and goats 
C + + - - 
pig-bel (necrotic enteritis) in humans, 
enterotoxaemia of sheep (struck), 
calves, lambs and piglets  
D + - + - enteroxaemia of lambs and sheep (pulpy kidney), goats and cattle 
E + - - + rabbit enteritis, enterotoxaemia of 
calves and lambs 
 
The full methodologies for carrying out such PCR tests are described in 
these reports. In some cases, multiplex PCR tests have been devised allowing the 
simultaneous identification of all 4 major toxin genes, although PCR-based tests are 
now considered to be the simplest and most reliable for the typing of C. perfringens 
(Meer and Songer, 1997; Petit et al., 1999). However, it is important to note that 
these tests do not necessarily indicate that the gene is functional (Petit et al., 1999). It 
may therefore be valuable to carry out, in parallel, immunological typing tests. 
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The genes encoding clostridial phospholipases are generally sufficiently 
dissimilar for PCR tests, devised to detect the phospholipase C gene in one species, 
not to amplify gene fragments from other species. However, in the case of C. 
perfringens, there is also increasing evidence of significant differences in the 
sequence of the  toxin gene from atypical strains (Justin et al., 2002). Therefore, 
although a positive PCR test for the phospholipase C from C. perfringens might be 
interpreted as diagnostic for the species, care should be taken when interpreting 
negative results.   
 
16.7. Cholesterol-dependent cytolysin toxins 
A wide range of clostridia produce cholesterol-dependent cytolysins (Table 
16.6; also previously known as thiol-activated or oxygen labile cytolysins) but only 
3, perfringolysin (Hauschild et al., 1973; Smyth, 1975; Yamakawa et al., 1977), 
tetanolysin (Alving et al., 1979; Mitsui et al., 1980) and  botulinolysin (Haque et al., 
1992) have been purified and characterised. The cholesterol-dependent cytolysins are 
synthesised with signal peptides and are exported from the bacteria as soluble 
extracellular proteins Tweten, 1988). The proteins are relatively easy to isolate from 
culture supernatant, but many researchers now use purified recombinant protein 
produced in E. coli for experimental studies (Shepard et al., 1998).  
 
Table 16.6: Known cholesterol-dependent cytolysins produced by the clostridia 
cholesterol dependent cytolysin Origin 
Bifermentolysin C. bifermentans 
Botulinolysin C. botulinum 
Chauveolysin C. chauvoei 
Histolyticolysin C. histolyticum 
Novyilysin C. novyi 
Perfringolysin ( toxin) C. perfringens 
Septicolysin C. septicum 
Sordellilysin C. sordellii 
Tetanolysin C. tetani 
 
The most striking feature of the cholesterol-dependent cytolysins is the 
apparent requirement for reduction for full biological activity (Alouf, 1999). Initially, 
it was believed that this reflected the critical role of the single cysteine residue. 
However, it is now known that this residue does not play a major role in the cytolytic 
or cytotoxic activity of theses toxins (Alouf, 1999). Rather, it is now thought that this 
residue is close to a functionally critical region of the molecule, and that other 
cysteine-containing molecules, which become complexed with toxin, markedly 
reduce the activity of the toxin. Irrespective of the function of the single cysteine 
residue, there has always been a need to reduce samples containing toxin before 
measuring their activity. Usually this involves the addition of a reducing agent, such 




16.7.1. Detection of cholesterol-dependent cytolysins on solid media 
The cholesterol-dependent cytolysins form large pores (250-300 Å) in host 
cell membranes that allow the passage of most proteins (Alouf, 2000). The cytolytic 
activity is most easily demonstrated towards erythrocytes, and these toxins are 
usually responsible for the clear zone or β-haemolysis that surrounds colonies of 
bacteria on blood agar plates (Alouf, 2000). The toxins are active towards a wide 
range of erythrocyte types (Table 16.7), and human, rabbit, horse or sheep 
erythrocytes are often used to detect cytolytic activity.   
 
Table 16.7: Susceptibility (relative to rabbit) of erythrocytes from various species, to 
lysis by C. perfringens θ toxin (Smyth and Duncan, 1978)   
 












sheep  100 
 
16.7.2. Detection of cholesterol-dependent cytolysins in culture medium 
The presence of cholesterol-dependent cytolysins in culture supernates can 
be determined using haemolysis assays with the erythrocytes identified above. Prior 
reduction of the sample is necessary before testing. Care needs to be taken when 
testing crude culture supernates because many other exoproducts of the clostridia are 
also able to cause haemolysis. This problem can be overcome to some extent by 
selecting erythrocytes and testing conditions that provide maximum sensitivity to 
cholesterol-dependent cytolysins. For example, horse erythrocytes are relatively 
insensitive to C. perfringens  toxin, but highly sensitive to C. perfringens  toxin. 
Also, the finding that haemolytic activity increases on reduction of the sample, 
provides a good indication of the presence of a cholesterol-dependent cytolysin.  
 
16.7.3. In vivo toxicity  
Only some of the clostridial cholesterol-dependent cytolysins have been 
tested for toxicity in mice. However, in general the cholesterol-dependent cytolysins 
have LD50 doses of approximately 1g/mouse (Smyth and Duncan, 1978). 
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16.7.4. Immunological detection and identification of cholesterol-dependent 
cytolysins 
Immunoassays for the detection and/or identification of clostridial 
cholesterol-dependent cytolysins have not been reported. 
 
16.7.5. Detection of toxin-encoding genes  
There is one report that a PCR test has been used to screen isolates of C. 
perfringens from foals for the  toxin-encoding gene in addition to the genes 
encoding the 4 other major toxins (Netherwood et al., 1998). However, PCR tests for 
the clostridial cholesterol-dependent cytolysins are generally not widely used.   
 
16.8. Aerolysin-like pore-forming toxins 
Both the C. septicum  toxin and the C. perfringens  toxin are believed to 
form pores in host cell membranes and may be related to the pore-forming toxin, 
aerolysin. Both toxins are produced as relatively non-toxic prototoxins, which are 
exported from the bacterial cell and accumulate in culture medium. The toxins can be 
purified from culture medium, and the yield can differ markedly from strain to strain. 
(Ballard et al., 1992; Cortinas et al., 1997; Hunter et al., 1992; Parreiras et al., 2002). 
The genes encoding these prototoxins have been expressed in E. coli (Goswami et 
al., 1996; Hunter et al., 1992; Imagawa et al., 1994) and recombinant proteins are 
now used for many studies (Diep et al., 1999; Oyston et al., 1998). 
Both prototoxins are activated on exposure to proteases. In the case of C. 
septicum  toxin, trypsin or furin treatment removes a carboxy-terminal peptide 
(Ballard et al., 1995; Gordon et al., 1997). Treatment of C. perfringens  toxin with 
proteases, such as trypsin, chymotrypsin or C. perfringens 	-protease removes both 
amino- and carboxy-terminal peptides (Minami et al., 1997). However, it is the 
removal of the carboxy-terminal peptide that is believed to be responsible for toxin 
activation (Minami et al., 1997). Depending on the time of harvesting and the level 
of co-produced protease, the proteins isolated from culture filtrates may be 
prototoxin, toxin or, more likely, a mixture of both. Whilst this may not be important 
when immunological identification tests are used, full biological activity is dependent 
on exposure to an appropriate protease. For some assays, activation can result from 
exposure to cell surface proteases. 
 
16.8.1. Detection of toxins on solid media 
There are no simple methods for the detection of production of C. 
perfringens  toxin on solid media. However, C. septicum  toxin is haemolytic 
(Ballard et al., 1992; Imagawa et al., 1994) and can therefore be detected as a zone of 
-haemolysis surrounding colonies of bacteria on agar containing rat or human 
erythrocytes. It is important to use unwashed cells for this assay, since washing can 
remove cell surface proteases, which are required to fully activate the toxin. 
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16.8.2. Detection of biologically active toxins in culture medium 
The haemolytic activity of C. septicum  toxin can be measured relatively 
easily using a 0.5- 1% (v/v) suspension of rat (Diep et al., 1999; Gordon et al., 1997) 
or human erythrocytes (Ballard et al., 1992; 1993; Diep et al., 1999) in phosphate- or 
Tris-buffered saline. Toxin and erythrocytes are typically incubated together for 
anywhere between 1 and 18 h. The activity towards human erythrocytes is reported 
to lie in the range 1.5x106 to 2x107 haemolytic units (HU)/mg protein (Ballard et al., 
1992; 1993). Rat erythrocytes appear to be less susceptible to lysis (Diep et al., 
1999). Microtitre tray assays, which are simple and easy to use, have been described, 
but some researchers use more complex assays (Ballard et al., 1992). For example, 
released haemoglobin can be separated from cell debris by centrifuging, and the 
concentration of released haemoglobin estimated from the OD540nm of the 
supernatant fluid (Gordon et al., 1997).  
Both toxins are active towards cultured cells, but in the case of  toxin only 
a limited range of cell types are susceptible to the toxin. Of these, only Madin Darby 
Canine Kidney cells (MDCK) are considered to be susceptible enough to form the 
basis of a cytotoxicity assay (Payne et al., 1994; Shortt et al., 2000). The C. septicum 
 toxin shows cytotoxic activity towards a much wider range of cell types, including 
CHO cells (Gordon et al., 1997), FD11 cells (Gordon et al., 1997) 13 ng/ml and EL4 
T-cells (Diep et al., 1999).  
 
16.8.3. In vivo toxicity  
The toxicity of C. septicum  toxin can be measured after the i.p. injection 
of toxin into mice with monitoring for 48 h (Ballard et al., 1992). Typically, the LD50 
dose of the toxin is 10g/kg (Ballard et al., 1992). In comparison, the C. perfringens 
 toxin is highly potent after intravenous administration into mice, with an LD50 dose 
in the 16-50 ng/kg range (Habeeb, 1969; Miyata et al., 2001)  
 
16.8.4. Immunological detection and identification of toxins 
Tests for C. perfringens  toxin are not only important for the typing of 
isolates of the bacterium, but also form an important part of the test for the potency 
of clostridial vaccines, as outlined in monograph 363 of the European Pharmacopoeia 
(Eur. Ph.). In the current potency test, neutralising antibodies against C. perfringens 
 toxin are determined in a mouse neutralisation test (MNT). The lack of reliable and 
simple assays for the measurement of C. perfringens  toxin may be one of the main 
drivers for the development of immunoassays to detect this toxin. These assays may 
use either monoclonal  or polyclonal antibodies and are frequently configured as 
simple ELISA tests (Aschfalk and Muller, 2002; 2001; Hauer, 1993). Some 
derivatives of these immunoassays are used to determine the antibody responses to 
toxoid vaccines, and these assays are valuable replacements for the MNT (Ebert et 
al., 1999; 1998). Immunoassays for the detection or identification of C. septicum 
 toxin have not been reported. 
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16.8.5. Detection of toxin-encoding genes  
There are no reports of the wide-scale use of PCR tests for the C. septicum 
 toxin gene, but PCR based tests for the C. perfringens  toxin gene have been 
reported by a number of researchers (Ashfalk and Muller, 2002; 2001; Garmory et 
al., 2000; Gkiourtzidis et al., 2001; Goswami et al., 1996; Meer and Songer, 1997; 
Miserez et al., 1998; Netherwood et al., 1998). These tests are now widely used for 
the typing of strains of C. perfringens. Although the  toxin is produced by 2 
biotypes of C. perfringens (types B and D), the sequences of the encoding genes 
appear to be very similar (Havard et al., 1992).  
 
16.9. Hla-like pore-forming toxins 
The only known Hla-like toxin produced by the clostridia is the  toxin of C. 
perfringens. The  toxin is one of the 4 major toxins that may be produced by the 
bacterium (Table 16.5), and the detection of this toxin, or the toxin-encoding gene, 
forms one of the important tests for the typing of strains of C. perfringens (Petit et 
al., 1999). The toxin is synthesised with an N-terminal signal sequence, and is 
exported across the bacterial cell wall (Hauer, 1993; Hunter et al., 1993). However, 
the detection of the toxin in culture supernatant is not easy because the toxin is 
extremely labile (Lawrence et al., 1979; Pal et al., 1990; Sakurai and Duncan, 1977; 
Worthington and Mulders, 1975). It may, therefore, be necessary to test culture fluid 
taken at various points in the late logarithmic or early stationary phase of growth for 
the presence of toxin. Like tests for C. perfringens  toxin, tests for  toxin are 
important for the typing of isolates and form an important part of the European 
Pharmacopoeia (Eur. Ph.) test for efficacy of clostridial vaccines. In the currently 
used potency test, neutralising antibodies against C. perfringens  toxin are 
determined using an MNT. 
 
16.9.1. Detection of  toxin on solid media 
There are no simple methods for the detection of  toxin on solid media. 
 
16.9.2. Detection of biologically active  toxin in culture medium 
There are no simple tests for detecting biologically active  toxin in culture 
medium. However, there are some reports that the toxin is active towards certain cell 
types, such as Chinese hamster ovary cells (Jolivet-Reynaud et al., 1986) and guinea 
pig monocytes (Allan, 1963). Assays that exploit these observations have not yet 
been devised.   
 
16.9.3. In vivo toxicity studies  
Until relatively recently, the measurement of toxicity in the mice that could 
be neutralised by antiserum or antibody has been the most frequently used test for the 
presence of β toxin. The 50% lethal dose of the toxin in mice by the i.p. route is 
reported to be in the 0.68-1.87 g range (Sakurai and Fujii, 1987; Worthington and 
Mulders, 1975). The toxicity of  toxin for mice has been exploited in tests for the 
potency of antisera raised against toxoids that are to be used in veterinary vaccines. 
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However, the use of this type of test for the presence of  toxin (or antibody to 
 toxin) is no longer encouraged, and immunological or genetic tests provide 
excellent alternatives (see below). 
 
16.9.4. Immunological detection and identification of  toxin 
Because of the difficulties associated with the detection of  toxin in culture 
filtrates, and because of the need to replace the MNT with tests that do not use 
animals, a number of researchers have reported the development of immunological 
tests for the detection and identification of  toxin. The simplest of these involve the 
use of an ELISA, with either monoclonal or polyclonal antibodies (Aschfalk and 
Muller, 2002; 2001; Hauer and Clough, 1999). Variations of this assay, which are 
configured to allow the capture and quantification of antibodies to  toxin, have also 
been reported (Ebert et al., 1998). These assays are of particular value for the 
assessment of the potency of veterinary vaccine, which contains  toxoid (Ebert et 
al., 1999, 1998). A more elegant immunoassay involves the use of surface plasmon 
resonance (SPR), where the SPR chip is coated with monoclonal antibody and the 
sample (which can be fermenter broth) is passed over the chip, with the subsequent 
capture of  toxin (Hsieh et al., 1998). This assay can reportedly detect toxin within 
20 minutes. 
 
16.9.5. Detection of toxin-encoding genes  
PCR tests are now the method of choice for typing strains of C. perfringens 
and are often used in conjunction with other tests for the detection of the other major 
toxins (Garmory et al., 2000; Gkiourtzidis et al., 2001; Meer and Songer, 1997; 
Miserez et al., 1998; Walters et al., 2003). These tests have been widely used to 
genotype C. perfringens isolates from diseased animals, though currently it is not 
possible to carry out these tests without first isolating and culturing the bacterium. 
Details of the PCR primers and amplification conditions are detailed in the relevant 
publications, and many researchers have used the protocol originally reported by 
Meer and Songer (1997).  
 
16.10. Enterotoxin 
The clostridial enterotoxin of major significance is produced by C. 
perfringens. Methods for the isolation of this toxin and for the identification using 
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17. Methods for use with foodpoisoning clostridia 
 
P.E. Granum, M.W. Peck 
 
17.1. Introduction 
17.1.1. Clostridia of importance in relation to foodborne illness 
The two clostridia of most significance with respect to foodborne illness are 
Clostridium botulinum and C. perfringens. These organisms are responsible for two 
very different diseases. Foodborne botulism is an intoxication due to consumption of 
preformed neurotoxins in foods. Although relatively rare, foodborne botulism is a 
serious disease that is often fatal, and treatment usually involves long-term 
hospitalisation. Infant botulism is an infection of the gut of infants less than 12 
months of age, and can be associated with consumption of honey. This disease is also 
severe, but rare. On the other hand, C. perfringens type A is the cause of one of the 
most common foodborne diseases (infections) in the Western world, but is mostly 
self-limited diarrhoea and normally lasts for less than 24 hours (Peck et al., 2004). 
Except for occasional dehydration in the infirm and elderly, treatment is not 
necessary. C. perfringens type C food poisoning (infection) is rare in the 
industrialised world today and has not been recorded in Europe during the last 
decade. Symptoms start with an acute sudden onset of severe abdominal pain and 
diarrhoea (often bloody), sometimes with vomiting, followed by necrotic 
inflammation of the small intestine. Untreated, the disease is often fatal and has a 
mortality rate of 15-25%, even with treatment. Further information on these diseases 
is given in our scientific booklet (Peck et al., 2004).  
 
17.1.2. Outbreaks of foodborne illness associated with clostridia 
Outbreaks of clostridial foodborne diseases are almost always through 
contamination of spores in the foods. Since the bacteria are anaerobic only spores 
will survive in food production environments. The final product must allow the 
spores to germinate and outgrow, and anaerobic conditions are created after cooking. 
When such products are cooled to below the maximum growth temperature, 
germination followed by growth will start. With the short generation time of C. 
perfringens (8 min) multiplication of the bacterium is fast (Brynestad and Granum, 
2002). This is also reflected by the types of products that are usually involved in food 
poisoning incidents (Labbe, 2000). Outbreaks of foodborne botulism are only rarely 
associated with commercial foods, although when this does happen the consequences 
can be serious. More commonly outbreaks of foodborne botulism involve home-
prepared foods when known control measures have failed to be implemented. 
Examples include, the home-canning of vegetables, the home-preparation of meats, 
and the home-preparation of fish (Lund and Peck, 2000; Peck et al., 2004).  
In order to ensure the safety of foods with respect to C. botulinum and C. 
perfringens, various recommendations and guidelines have been drawn up. For C. 
perfringens, products of concern include meats mishandled during catering 
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operations or in the home, with slow cooling, holding at room temperature or for 
extended periods prior to serving. Control of cooling rates has therefore been the 
major target for reduction of C. perfringens risks, and there are various regulations 
and recommended cooling criteria in different countries. These often aim to restrict 
the possibility of growth (e.g. less than a 1 log increase in the finished product 
(USDA, 1999)). To achieve this, chilling from 54.4ºC to 26.6ºC should be achieved 
in less than 90 min, and from 26.6°C to 4.4°C in less than 5 hours (USDA, 1999). 
Alternatively predictive models may be used for guidance (e.g. Perfringens Predictor 
(www.ifr.ac.uk/Safety/GrowthPredictor/default.html), Pathogen Modeling Program 
(www.arserrc.gov/mfs/PMP6_Start.htm). Methods of controlling C. botulinum in 
foods have been reviewed (Hauschild, 1989; Lund and Peck, 2000). One example is 
the Fo3 process (121°C/3min) that is given to low acid canned foods to reduce by a 
factor of 1012 the number of viable spores of proteolytic C. botulinum. Procedures to 
ensure the safety of chilled foods with respect to non-proteolytic C. botulinum have 
also been reviewed elsewhere (Lund and Peck, 2000; Martens, 1997; Peck and 
Stringer, 2005). A committee of the European Food Safety Authority (EFSA) has 
recently considered the risk presented by foodborne clostridia (EFSA, 2004). 
 
17.1.3. Incidence of C. botulinum and C. perfringens in the environment 
C. perfringens is a spore-forming bacterium and a natural inhabitant of soil 
and the intestinal tract of many warm-blooded animals and humans. The ubiquitous 
nature of this bacterium and its spores makes it a frequent problem for the food 
industry and establishments where large amounts of foods are prepared (Andersson et 
al., 1995). Spores of C. botulinum are also ubiquitous in the environment, albeit 
generally in low numbers (Lund and Peck, 2000). 
 
17.1.4. Working with C. botulinum and C. perfringens 
Since clostridia are anaerobic microorganisms, skills in anaerobic 
techniques are necessary to work with these organisms. Both C. botulinum and C. 
perfringens can be handled in laboratories without anaerobic chambers, although 
difficulties may be encountered (e.g. achieving sporulation for some strains of C. 
perfringens). 
 
17.2. Methods for use with Clostridium botulinum 
In view of the danger presented by C. botulinum and its potent neurotoxins, 
work on this pathogen is restricted to containment laboratories offering the 
appropriate degree of protection. It should be ensured, before work is started, that all 
appropriate safety guidelines are followed. In most countries, work with C. 
botulinum is restricted to a small number of highly specialised laboratories. 
 
17.2.1. Detection, isolation and quantification of C. botulinum 
Six different clostridia are capable of producing a botulinum neurotoxin. 
Two of these organisms, proteolytic C. botulinum and non-proteolytic C. botulinum 
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are responsible for most cases of foodborne botulism. Since, these two clostridia 
differ physiologically, a single method cannot be relied on for both organisms. 
Conditions that are optimum for enrichment and isolation of proteolytic C. botulinum 
are often not the best for non-proteolytic C. botulinum, and vice-versa. For example, 
heating samples at 80°C for 10 min to inactivate competing, vegetative bacteria is 
valuable for isolation from spores of proteolytic C. botulinum, but would probably 
inactivate spores of non-proteolytic C. botulinum. Culture at 35°C is suitable for 
isolation of proteolytic C. botulinum, while a lower temperature of 26°C is 
recommended for isolation of non-proteolytic C. botulinum (Solomon et al., 1995). 
In attempts to detect and isolate C. botulinum from the environment or foods 
it is important to assess the adequacy of the method or methods used, by 
demonstrating that strains of all relevant groups of C. botulinum can be isolated 
following addition of low numbers to test samples (Sugiyama et al., 1970; Del Torre 
et al., 2004). The failure to include such controls may be a limitation of some 
previous studies. 
Isolation may be required for studies of the incidence of C. botulinum in the 
environment or in foods, for detection of the organisms in foods suspected of being 
implicated in outbreaks of botulism or from clinical samples from patients and for 
investigation of the properties of isolates. The various types of sample present 
different problems of isolation. Heat treatment of samples is often used to eliminate 
competing vegetative bacteria. Heating at 75°-80°C for 10-15 min is useful in 
culturing from spores of proteolytic C. botulinum, while 60°C is more appropriate for 
use during isolation of non-proteolytic C. botulinum and the addition of lysozyme to 
the enrichment medium can increase recovery of the heated spores (Peck et al., 1993; 
Sebald and Petit, 1994). There may also be merit in tested unheated samples in order 
to isolate vegetative bacteria or spores that are not fully heat-resistant. Treatment 
with ethanol may be an alternative to heat treatment for isolation of spores of non-
proteolytic C. botulinum (Smith and Sugiyama, 1988; Solomon et al., 1995). Media 
for enrichment must be fully anaerobic (Hatheway, 1988; Kautter et al., 1992; Sebald 
and Petit, 1994; Solomon et al., 1995), and the redox dye resazurin can be a useful 
indicator (Lund and Wyatt, 1984). To enrich for proteolytic C. botulinum, samples 
should be inoculated into cooked meat medium (CMM) and incubated at 35°C, while 
for non-proteolytic C. botulinum CMM glucose medium, chopped meat glucose 
starch medium (Hauschild, 1989) or trypticase-peptone-glucose-yeast extract broth 
containing trypsin (TPGYT) can be used with incubation at 26°C (Solomon et al., 
1995). Filter sterilised trypsin is included to inactivate bacteriocins (boticins) that 
may be produced by closely related clostridia. In a previous study, it was found that 
sediment samples from the Fox river in the USA were highly inhibitory to non-
proteolytic C. botulinum type E and it was necessary to add 106 spores of this 
bacterium to one gram of sediment before type E toxin could be detected in culture 
(Kautter et al., 1966; Sugiyama et al, 1970). Cultures should be incubated for seven 
days, or longer if necessary, to allow growth, sporulation and toxin formation. After 
enrichment a portion of the culture can be used to test for botulinum neurotoxin and a 
further portion plated onto a suitable solid medium. Before plating, the sample of 
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enrichment culture may be treated by heating or treatment with ethanol in order to 
eliminate competing vegetative bacteria (Solomon et al., 1995). A suitable non-
selective solid medium is egg-yolk agar on which colonies of proteolytic C. 
botulinum and non-proteolytic C. botulinum have a typical appearance associated 
with their lipase activity. Several selective plating media have been used including 
Botulinum Selective Medium (BSM) (Mills et al., 1985) and C. botulinum Isolation 
(CBI) agar (Dezfulian et al, 1981). However, the trimethoprin in these media may 
inhibit non-proteolytic C. botulinum (Hatheway, 1988). Colonies suspected to be C. 
botulinum are characterized by toxin formation and physiological characteristics 
(Hatheway, 1988; Smith and Sugiyama, 1988). 
 
17.2.2. Detection and quantification of C. botulinum neurotoxins and their 
genes 
17.2.2.1. Detection and assay of neurotoxins by injection into mice 
Intraperitoneal injection into mice has been the standard method for 
detection and identification of botulinum neurotoxin (Hatheway, 1988). The 
procedure, controls necessary and the interpretation have been described (Solomon et 
al., 1995). In order to detect toxin formed by non-proteolytic C. botulinum treatment 
of samples with trypsin is necessary to convert the single chain toxin to the more 
toxic dichain form. A collaborative study showed that this method was repeatable 
and reproducible for the detection of toxin produced by proteolytic C. botulinum and 
non-proteolytic C. botulinum in foods (Kautter and Solomon, 1977). The specificity 
of the test is achieved by the use of specific antisera and by observations of typical 
symptoms of botulism in the mice prior to death. Assays for quantitative 
determination of toxin have been developed and a stable reference standard 
preparation of type A toxin was prepared, enabling the response of laboratory mice 
under a given set of conditions to be assessed and the toxin content of an unknown 
sample to be expressed in terms of the equivalent of weight of type A toxin per gram 
or ml (Schantz and Kautter, 1978). Intraperitoneal injection will detect as little as 5-
10 pg of type A toxin and provides a measure of the biological activity of the toxin 
(Hatheway, 1988). Alternative methods involving a range of animals have been 
described (Pearce et al., 1997), these include subcutaneous injection into mice 
resulting in flaccid paralysis of muscles rather than death, which is as sensitive as 
intraperitoneal injection but may be less convenient. Further details of methods for 
the detection and assay of neurotoxins by injection into mice are given in section 
16.4. Advantages of these biological tests are their extreme sensitivity and their 
ability to detect previously undescribed toxins, atypical toxins and antigenic variants. 
Disadvantages are the undesirability of using animals and the need to wait several 
days before a sample can be judged negative.  
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17.2.2.2. Detection and assay of neurotoxins by ELISA and other 
immunological techniques 
Immunological methods for the detection of botulinum neurotoxins include 
enzyme-linked immunosorbent assays (ELISAs) and other tests (Pearce et al., 1997). 
Some of the ELISAs have the same sensitivity and specificity as the mouse test and 
are cheap and easy to use. The ELISA tests have the following limitations: (i) some 
may react with biologically inactive toxin; (ii) some may react differently with toxins 
of a specific type produced by different strains, since these toxins may differ in 
antigenicity (Doellgast et al., 1993; Ekong et al., 1995; Gibson et al., 1987; Gibson 
et al., 1988; Huhtanen et al., 1992) (iii) some of the tests use antibodies that were 
raised to preparations containing a mixture of antigens, so that the tests are not 
specific for neurotoxins (Huhtanen et al., 1992; Potter et al., 1993; Sakaguchi, 1979); 
(iv) many ELISAs need a complex and expensive amplification system to achieve the 
sensitivity of the mouse test (e.g. Doellgast et al., 1993; Flemmig and Stojanowic, 
1980; Modi et al., 1986; Shone et al., 1985). Despite these limitations, ELISAs have 
been widely used, some of which are described in Table 17.1. An ELISA developed 
by Ferreira and colleagues (Ferreira and Crawford, 1998; Ferreira , 2001; Ferreira et 
al., 2001; Ferreira et al., 2004) offers independent detection of types A, B, E and F 
toxins. This assay has been used to detect toxin in food associated with botulism 
outbreaks (Ferreira et al., 2001; 2004). The sensitivity is about ten-time less than the 
mouse bioassay. A similar ELISA and standards are commercially available from 
Metabiologics (www.metabiologics.com/default.htm). Immunological techniques for 
detection and assay of neurotoxins are also discussed in section 16.4.  
Immunological techniques have also been used to identify colonies of 
proteolytic C. botulinum types A and B (Goodnough et al., 1993) and non-proteolytic 
C. botulinum type E (Goodnough et al., 1993; Dezfulian, 1993).  
Recently, highly specific in vitro assay for botulinum neurotoxins have been 
developed that are based on a combination of their endopeptidase activities and an 
immunological reaction. The advantages of these methods over ELISA procedures 
include (i) the tests measure the biological activity of the light chain of the toxin (but 
not of the heavy chain); (ii) variations in antigenicity of toxins of a specific type do 
not influence the response; (iii) the problem resulting from antibodies having been 
raised to a mixture of antigens is eliminated. In these tests, a fragment of the target 
protein (SNAP-25 for type A toxin, VAMP for type B toxin) is attached to a 
microtitre plate, and serves as the substrate. The sample containing neurotoxin is then 
added and, after a period of incubation, specific antibodies are added that bind to the 
cleaved target protein, followed by secondary antibodies and detection system.  
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Table 17.1:  Examples of some of the more sensitive ELISAs developed for 









A (5-10) Failed to detect toxin produced by one type A strain. No cross 
reaction with, other clostridia, denatured toxin, or other toxin 
types. Complex amplification system. Used with foods. 
(Shone et al., 1985; 
Gibson et al., 1987) 
B (20) Failed to detect toxin produced by one type B strain. No cross 
reaction with other clostridia or other toxin. Used with foods. 
Complex amplification system. 
(Modi et al., 1986; 
Gibson et al., 1988) 
F (10) No cross reaction with other clostridia or type A, B or C toxin, 
slight cross reaction with type D and E toxin. Tested with 
foods. 
(Ferreira et al., 1990) 
A (1-32), B 
(<1-16) 
ELISA may respond to antigens with no neurotoxicity. 
Correlation between the response from ELISA and mouse 
bioassay not always consistent. Used with foods. 
(Huhtanen et al., 
1992) 
A (9), B (<1), 
E (<1) 
Cross reaction with other clostridia. Used extensively to 
measure formation of type A, B, and E toxin in meat and in 
vegetable preparations. Also reacted with type F toxin. 
(Potter et al., 1993; 
Carlin and Peck, 
1995; Fernandez and 
Peck, 1999; Stringer 
et al., 1999) 
A (1), B (1), 
E (1) 
Weak reaction with toxin from some strains, suggesting the 
presence of biologically inactive, but immunochemically 
reactive neurotoxin. Used to measure toxin production by 
non-proteolytic C. botulinum in fish fillets. Complex 
amplification system used. 
(Doellgast et al., 
1993; Doellgast et al., 
1994; Roman et al., 
1994) 
A (1-20) Developed for therapeutic preparations. (Ekong et al., 1995) 
E (1-10) No cross reaction with other toxins or other clostridia. Used 
with foods. 
(Wong, 1996) 
A, B, E, F  
(10 for each) 
Tested in a ring trial. Used to quantify toxin present in food 
samples associated with botulism outbreaks  
(Ferreira and 
Crawford, 1998; 
Ferreira , 2001; 
Ferreira et al., 2001; 
Ferreira et al., 2004) 
 
Endopeptidase assays have been developed for type A toxin and type B 
toxin that were specific, and did not cross react with other neurotoxins (Hallis et al., 
1996), the mean detection limits were 260 MLD50/ml for type A toxin and 380 
MLD50/ml for type B toxin. Sensitivity was increased approximately ten-fold by an 
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amplification system. An endopeptidase assay developed for therapeutic preparations 
of type A toxin correlated well with the mouse assay and was more sensitive, with a 
detection limit of 0.2-1.0 MLD50/ml (Ekong et al., 1997). A combination of 
endopeptidase and ELISA has many advantages but possible problems include: (i) 
interference by other proteases; (ii) positive reaction with toxin that is inactive in 
vivo, this is because the endopeptidase assays relate to the biological activity of the 
light chain and would not be affected by inactivation of the biological activity of the 
heavy chain. Assays are also developed that capture the toxin on an immuno-affinity 
column, prior to an endopeptidase assay (Wictome and Shone, 1998). Further 
information about endopeptidase assays is given in section 16.4. 
 
17.2.2.3. Detection of neurotoxin genes using the polymerase chain 
reaction (PCR) and gene probes  
Probes have been constructed that enable PCR tests for the non-specific 
detection of genes for all botulinum toxin types (Campbell et al., 1993) and for the 
specific detection of genes for each of the toxins produced by C. botulinum and other 
clostridia species (e.g. Fach et al., 1995; Ferreira and Hamdy, 1995; Franciosa et al., 
1994; Szabo et al., 1993; Alsallami and Kotlowski, 2001; Carlin et al., 2004; Fach et 
al., 2002; Wu et al., 2001). A multiplex PCR for simultaneous detection of type A, 
B, E and F toxin genes was described by Lindstrom and colleagues (Lindstrom et al., 
2001). Following a cultural enrichment these methods correlated well with tests for 
toxin using mice and, with the inclusion of an MPN series of dilutions in the cultural 
enrichment, have been used for quantitative detection of bacteria containing these 
genes in aquatic sediments, fish and other samples (Aranda et al., 1997; Hielm et al., 
1998; Hielm et al., 1996; Lindstrom et al., 2001; Carlin et al., 2004). The use of a 
cultural enrichment provides a relatively high number of target bacteria, improves 
sensitivity and minimises possible problems due to the presence of extracellular 
DNA or to dead bacteria. Further details of molecular techniques to detect neurotoxin 
genes are given in section 16.4. 
 
17.2.3. Procedures for sporulation 
It can be difficult to get a substantial number of spores of C. botulinum. For 
proteolytic C. botulinum, the Anellis broth appears suitable for most strains (Anellis 
et al., 1972; Del Torre et al., 2004). One difficulty encountered is that of spores 
retained within cell. Mild sonication may be useful here. A biphasic medium has 
been found to give good sporulation for many strains of non-proteolytic C. botulinum 
(Peck et al., 1992; Plowman and Peck, 2002). 
 
17.3. Methods for use with Clostridium perfringens 
17.3.1. Detection, isolation and quantification of C. perfringens 
In water there is usually too much oxygen for vegetative cells to survive so 
tests are generally made for spores. The presence of spores of C. perfringens in water 
is used as indicator of faecal contamination (Labbe, 2000), although it might be 
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argued that soil and sediments may contaminate water as well. In foods it is 
important not to add oxygen by mixing or stirring the sample prior to testing. 
Frequently only the core of a food sample contains viable C. perfringens cells, 
especially if the food has been sampled long before analysis. Sometimes the cells can 
be visualised in the microscope even if no growth occurs after enrichment from the 
food samples, and it might be possible to culture C. perfringens from such samples. 
Freezing and thawing of food samples containing C. perfringens is not 
recommendable since the cells tolerate freezing poorly. Diluting food samples should 
preferably be carried out in freshly boiled solutions with as little oxygen as possible, 
although even vegetative cells tolerate oxygen for a short while. Once seeded the agar 
plates should be incubated anaerobically as quickly as possible.  
Several media have been described for detection and quantification of C. 
perfringens. The most commonly used medium is the Tryptose-Sulfite-Cycloserine 
(TSC) agar (commercially available) where black colonies will be visible after 24 
hours. A top layer of the same agar after seeding will result in faster and more 
reliable detection. Without the top layer the sulphite reduction and development of 
black colonies may take more the 24 hours. If the samples are seeded on blood agar 
plated (bovine) at the same time typical round and slightly opaque and shiny colonies 
on the surface of agar plates are observed. Colonies usually show a double-zone of 
haemolysis on blood agar plates with a clear inner θ toxin zone and a hazy outer zone 
caused by α toxin production (Brynestad and Granum, 2002). C. perfringens can 
grow between 15°C and 52°C with an optimum of about 45°C for most strains. The 
incubation temperature used is 37ºC. 
Confirmation of foodborne outbreaks does not generally involve isolation of 
the organism, instead it involves detection of the enterotoxin gene or enterotoxin, 
either by PCR or immunological methods (see below). Enterotoxin negative cells 
will not cause food poisoning (Brynestad and Granum, 2002). 
For water samples (and now also for food samples) a relatively new 
medium, mCP-agar, is frequently used (EU, 1998; NMKL, 2003) The medium is 
commercially available and consists of: tryptose (30g/l), yeast extract (20g), sucrose 
(5.0g/l), L-cysteine hydrochloride (1.0g/l), MgSO4⋅7H2O (0.1g/l), Bromocresol 
purple (40mg/l) and agar (15g/l), plus a supplement of D-cycloserine (400mg/l), 
indoxyl-β-D-glucoside (60mg/l), phenolphtalein diphosphate (20ml/l) and 4.5% 
FeCl3⋅6 H2O (2.0ml/l). The plates are incubated anaerobically for 24±3h at 
37.0±1.0°C. Colonies of C. perfringens are yellow to grey on mCP-agar, 3-6mm in 
diameter, and produce a yellow colour in the agar around the colonies. An acid 
phosphatase test is done with ammonia, and a positive reaction is visualised as a red 
colour (Schallehn and Brandis, 1973). 
 
17.3.2. Procedures for sporulation, and detection and quantification of 
enterotoxin and enterotoxin genes 
Since the enterotoxin from C. perfringens (Cpe) is produced only during 
sporulation, the strains have to grow on specific sporulation media prior to testing for 
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duringenterotoxin activity. Not all strains will sporulate in the described sporulation 
media in normal open laboratories (probably due to small amounts of oxygen). 
However stools after foodborne outbreaks always contain free spores and enterotoxin 
that can be detected directly by immunological methods. Alternatively PCR methods 
may be used to determine if the strains harbour the cpe gene (see below). Although 
rare, possible silent genes are then also detected. Several sporulation media for C. 
perfringens have been published (Meyer and Tholozan, 1999; de Jong, 2002) but we 
here describe one that we are commonly using. This is the Duncan and Strong (DS) 
medium (Duncan and Strong 1968), and is improved by the addition of raffinose 
(Labbe and Rey, 1979). Detection of the relative amount of C. perfringens 
enterotoxin in a crude “sporulated extract” is easily carried out using a commercially 
available RPLA test (Oxoid). Although this kit also reacts with a protein that is 
produced during vegetative growth (Brynestad and Granum, 2002) it does not matter 
if using extracts from sporulating cells, because it contains so much enterotoxin. 
However, if the extract is only positive after 2-8 fold dilution the result might be a 
false positive. Usually, enterotoxin containing cell extracts from sporulating cells are 
positive after dilution from 64 to over 1000-fold by this kit.  
 
17.3.2.1. Method for sporulation and detection of the enterotoxin 
A C. perfringens strain is transferred from an agar culture into 10ml of 
freshly boiled Robertsons cooked medium (RCM) and incubated at 37°C until 
sporulation (usually 2-7 days). The sporulated C. perfringens strain is then heat 
shocked at 77°C ± 2°C for 20 min. One ml of this medium is then inoculated into 
10ml of FTG (Fluid Thioglycollate) medium, and incubated at 37°C ± 2°C for about 
16 hours. A 1ml aliquot from the overnight FTG culture of C. perfringens is then 
transferred into 100ml DS-medium (preferably containing 0.4% raffinose). The DS-
medium should be freshly autoclaved and rapidly cooled to 37°C before inoculation. 
The flasks of DS-medium are then incubated at 37°C for 7-8 hours. Providing that at 
least 1% of the cells have sporulated (as judged by phase contrast microscopy), then 
the culture is suitable for testing for enterotoxin. If sporulation has been successful, 
the flasks should then be held at 4°C for about 16 hours in order to lyse sporulated 
cells. The culture is then centrifuged at about 10,000g for 25 min, and the supernatant 
used for enterotoxin detection using the Oxoid RPLA kit, according to the 
manufacturer’s instructions. 
 
17.3.2.2. Method for purification and detection of enterotoxin 
Once samples of sporulated C. perfringens cells have been produced it is 
relatively easy to detect the enterotoxin. Either the cells can be allowed to lyse (as 
described above) or the sporulated cells can be disrupted by sonication, French press 
or by other physical tools. It is not necessary to purify the enterotoxin, since it is 
usually produced in huge quantities by food poisoning strains during sporulation 
(Labbe, 2000). Because of the high hydrophobicity of the enterotoxin (319 amino 
acids, MW of 35 kDa), the protein is also easy to purify to at least 95% purity using a 
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double ammonium sulphate precipitation (Granum and Whitaker, 1980). Cell extracts 
after sporulation and sonication are centrifuged at about 10,000g for about 20 min, 
and the supernatant containing the enterotoxin (up to 10-20% of the protein) is 
precipitated with 40% ammonium sulphate. The precipitated protein can be harvested 
by another centrifugation step (as above). The precipitate (pellet) is then dissolved in 
10% of the volume used the first time and subjected to 15% ammonium sulphate 
precipitation. After a further centrifugation, the pellet is dissolved in buffer with a pH 
above 6.8. The enteroroxin is now close to purity. Further purification is possible, by 
passing a sample down a column that separates on the basis of molecular weight (i.e. 
G-100 column). The purified protein should be stored below 1 mg/ml to avoid 
aggregation. The crude or pure enterotoxin can be tested for biological activity by a 
variety of methods, but the most common involves tissue culture, like Vero cells that 
are relatively easy to grow and maintain (Granum, 1982). 
 
17.3.2.3. Method for detection of C. perfringens enterotoxin using 
Vero cell tissue culture 
The growth medium for Vero cells comprises; MEM (500 ml), foetal calf 
serum (50 ml), and penicillin-streptomycin solution (5 ml). In order to culture the 
Vero cells, a single flask with growing Vero cells is taken, and the growth medium 
removed. The cells are then removed using a cell scraper, and resuspended in 15 ml 
of fresh growth medium. A 5 ml aliquot of the cell suspension is then transferred to 
each of three new 250 ml flasks, and 15 ml of fresh growth medium added. The 
flasks are incubated under 5% CO2 at 37°C. 
The Vero cells are then used in a cytotoxicity test. The cells are loosened 
from one 250 ml flask with a cell scraper and added to 20 ml of fresh growth 
medium. After mixing, a further 30 ml of fresh growth medium is added. This 
suspension contains enough Vero cells for a single 24 well plate. An aliquot of 1 ml 
of cell suspension is transferred to each of the wells in the multi-well plate and 
incubated under 5% CO2 at 37°C for two days. Before the start of the toxicity test, it 
should be checked that the wells are completely covered with Vero cells. The growth 
medium is then removed from the wells, and each well is washed once with MEM (1 
ml). An addition of 1 ml of pre-warmed (37°C) MEM without leucine is made to 
each well, and 50 µl of enterotoxin solution is added immediately. The Vero cells are 
incubated with the enterotoxin at 37°C for 2 hours. The medium is then removed, and 
the cells washed once with 1 ml of pre-warmed (37°C) MEM without leucine.  An 
addition of 16 µl 14C-leucine is then made to 8 ml of MEM without leucine (this is 
enough for one 24 well plate), and 300 µl of this solution is added to each well. The 
plates are incubated at 37°C without CO2 for 1 hour, and then the medium is 
removed, and 1 ml 5% TCA is added to each well. After incubation at room 
temperature for 10 min, the TCA is removed and each well washed twice with 1 ml 
5% TCA. An addition of 300µl 0.1M KOH is then made to each well, and incubated 
at room temperature for a further 10 min. All of the solutions from each well are 
transferred into individual scintillation tubes, and 2 ml of scintillation liquid added. 
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After shaking, counts are made in a scintillation counter for 1 min. For a positive 
control, cells incubated with 50 µl supernatant from a positive C. perfringens strain 
are used (see enterotoxin preparation). For calculation, the average of two samples of 
the same enterotoxin test sample is used. The calculation of percentage inhibition of 
14C-leucine uptake is made by; (i) subtraction of the value for background counts 
(which is usually 30-60 cpm [counts per minute]); (ii) [cpm for Vero cells without 
toxin added – cpm test sample] x 100/ cpm for Vero cells without toxin added. 
 
17.3.2.4. Method for detection of C. perfringens enterotoxin gene 
(cpe) 
The sequence of gene transcribing the enterotoxin has been known for many 
years, and since it has little homology with other known genes, it is easy to detect by 
PCR. The high AT content of the gene is the only small problem. The presence of the 
enterotoxin gene (cpe) in the C. perfringens genome can be shown by PCR according 
to the following protocol (From: Norwegian Reference Laboratory for Spore-forming 
Food Pathogens): 
1. DNA is isolated from one colony on blood agar (or a selective medium). The DNA 
is extracted from the cells by using ADVAMAX Beads from AGTC 
(Advanced Genetic Technologies Corp.) according to the protocol from the 
suppliers. The DNA-pellet is suspended in 50 µl 10 mM Tris-HCl pH 7.5-8.5. 
2. The following primers are used: 
Forward:  CAAGTCAAATTCTTAATCCT 
Reverse:  CATCACCTAAGGACTGTTCT 
3. A master mix is made for x number of samples (including a positive and negative 
control) + 1 extra = n number of samples of 50 µl: 
10x PCR buffer    5 µl x n 
dNTP-mix (10 mM each)  1 µl x n 
primer 1 (10 pmol/µl)  1 µl x n 
primer 2 (10 pmol/µl)  1 µl x n 
DNA polymerase (2U/µl)  1 µl x n 
dH2O     40 µl x n 
4. The following PCR program is used: First 92°C for 3 min, followed by 30 cycles 
of 92°C for 1 min, 50°C for 1 min and 72°C for 1 min, end by 72°C for 7 min.  
5. The product size is 700 bp. Run the PCR products in a 1% agarose gel containing 
1 µg/ml ethidium bromide, at 70 V for 30 min. Visualise under UV light. Use 
known size markers on the gel, and always run a cpe-positive C. perfringens 
on the gel. 
 
17.3.3. Methods for detection of the C. perfringens  toxin 
The description of the methods in use for detection of the  toxin 
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